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SUMMARY 
Lynch syndrome is the most common inherited cause of colorectal cancer (CRC). 
It is an autosomal dominant condition, caused by a germline mutation in one of 
the mismatch repair (MMR) genes hMLH1, hMSH2, hMSH6 and hPMS2. 
Affected individuals are known to carry an increased risk of CRC as well as 
extracolonic malignancies, although the magnitude of that risk has been variably 
reported. 
Paper I documents the age- specific risk of CRC and other malignancies in a 
cohort of 200 subjects who are germline carriers of a single mutation in the 
hMLH1 gene. This mutation (C1528T (Exon 13) mutation in the hMLH1 gene) 
has been identified in 23 families in South Africa and is not known to occur 
elsewhere in the world. It was found that carriers of this mutation developed CRC 
at a median age of 44 years, and that their risk of developing CRC by age 65 was 
92%. Their risk of extracolonic cancers (most notably endometrial) was found to 
be relatively low however.  
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Paper II is a prospective study of the efficacy of colonoscopic surveillance in the 
cohort of subjects with Lynch syndrome who were the subject of PAPER I. It is the 
only study to have included only subjects who all carry the same MMR gene 
mutation. Of the 200 known carriers of the C1528T (Exon 13) mutation in the 
hMLH1 gene, 178 were identified before they had developed CRC and they were 
all offered colonoscopic surveillance. Of these 178 subjects, 129 underwent at 
least one surveillance colonoscopy, and 49 declined. After a median follow up of 
5 years, colorectal cancer was diagnosed in 14/129 (11%) of subjects in the 
surveillance group, and 13/49 (27%) in the non- surveillance group (p=0.019). 
Cancers in the surveillance group were detected at an earlier stage than in the 
non- surveillance group (P=0.032). Death from colorectal cancer occurred in 
3/129 (2%) of subjects in the surveillance group, and 6/49 (12%) in the non- 
surveillance group (p=0.021). The Kaplan- Meyer estimates for median survival 
from birth were 78 years in the surveillance group, and 55 years in the non- 
surveillance group (p=0.024). The Kaplan- Meyer estimates for median colorectal 
cancer free survival from birth were 73 years in the surveillance group and 47 
years in the non- surveillance group (p=0.0089).  
PAPER III addresses the choice of operation for colorectal cancer in Lynch 
syndrome. The high reported risk of metachronous colon cancer in Lynch 
syndrome has led some authors to recommend total colectomy as the preferred 
operation for primary colon cancer in this patient group, but this remains 
controversial. Paper III is prospective cohort study of 60 patients with proven 
MMR gene mutations who underwent surgical resection for adenocarcinoma of 
the colon with curative intent. Of these 60 patients, 39 had a total colectomy as 
their initial surgery and 21 had a segmental colonic resection. After a median 
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follow up of six years, metachronous colon cancer occurred in eight (21%) 
patients after segmental colectomy and in none of the total colectomy patients. 
This study confirms the significant risk of metachronous colon cancer after 
segmental colectomy in Lynch syndrome. This risk is eliminated by performing a 
total colectomy as the primary operation for colonic cancer. 
PAPER IV is a study of genetic anticipation in Lynch syndrome. Genetic 
anticipation occurs when the age of onset of a disorder decreases in successive 
generations. This is a well known phenomenon in a number of inherited 
conditions, but it is controversial whether this occurs in Lynch syndrome. Paper 
IV reports on the age of onset of CRC in 92 members of a single family over five 
generations who all carry the same C1528T (Exon 13) mutation in the hMLH1 
gene. Evidence of genetic anticipation (determined by age of onset of first CRC) 
was sought in two ways: Firstly, subjects were grouped as parent-child pairs and 
individuals were compared with their own offspring; secondly they were grouped 
by generation within the family tree. The appearance of genetic anticipation was 
found to be due to follow up bias. Once this bias was corrected for there was no 
evidence that genetic anticipation occurred. 
Another form of bias that can potentially create the false appearance of genetic 
anticipation is fecundity bias, which occurs if the disease adversely affects 
fertility.  PAPER V is the first publication to test whether this can occur in Lynch 
syndrome (or in any other inherited condition). This is a study of 1088 patients 
with CRC from families with Lynch syndrome identified from the Australasian 
Colorectal Cancer Family Registry (ACCFR). In this cohort, early onset of CRC 
was associated with lower lifetime fertility. The observed ages of onset of CRC 
xand lifetime fertility were used to construct a computer model that simulated a 
large number of parent- child pairs. The model demonstrated that fecundity bias 
can create the false appearance of genetic anticipation, and accurately predicted 
the appearance of genetic anticipation in the ACCFR cohort. 
PAPER VI is a study of age- specific fertility rates among Lynch syndrome 
patients who have survived colorectal cancer. Potential infertility is a significant 
concern for young colorectal cancer (CRC) survivors, but this risk is not well 
quantified. It was not known whether the reduction in lifetime fertility associated 
with early onset CRC documented in PAPER V was due to the effect of CRC on 
fertility, or if it was simply due to decreased survival. In PAPER VI, age- specific 
fertility rates for subjects with or without a CRC diagnosis were determined for 
1068 subjects with proven MMR mutations who were identified from the 
ACCFR. Total fertility rate was decreased in women who had been diagnosed 
with CRC compared to who had not, but age- specific fertility was only reduced 
in the 20-24 year age group. Subjects of both genders who survived into their late 
twenties and beyond had no detectable reduction in age- specific fertility, which 
may be reassuring to colon cancer survivors who hope to have children. 
In summary, this thesis: 
Documents the CRC and extracolonic cancer risk for a large cohort of subjects 
who carry the C1528T (Exon 13) mutation in the hMLH1 gene.  
Confirms that colonoscopic surveillance of subjects with Lynch syndrome 
reduces the incidence of CRC, leads to earlier detection of CRC, and thus 
improves cancer- specific and overall survival in these subjects.  
xi
Confirms the high rate of metachronous CRC after segmental colonic resection 
for CRC. 
Demonstrates that follow up bias and fecundity bias can falsely create the 
appearance of genetic anticipation. 
Demonstrates that age- specific fertility is largely unaffected by early- onset CRC 
in Lynch syndrome, except in women in the 20 to 25 year age group. 
xii
CONTENTS 
ACKNOWLEDGEMENTS ......................................................................................... III
PUBLISHED PAPERS INCLUDED IN THIS THESIS ............................................ V
SUMMARY ................................................................................................................. VII
LIST OF TABLES ..................................................................................................... XVI
LIST OF FIGURES ................................................................................................... XIX
LIST OF ABBREVIATIONS AND ACRONYMS ............................................. XXIII
1 BACKGROUND ..................................................................................................... 25
1.1 LYNCH SYNDROME: GENERAL INTRODUCTION .................................................... 26
1.1.1 Historical perspective ....................................................................... 26
1.1.2 Microsatellite instability ................................................................... 31
1.1.3 Mismatch repair genes ...................................................................... 32
1.1.4 Microsatellite instability in sporadic CRC ....................................... 35
1.1.5 Diagnosis of Lynch syndrome ........................................................... 36
1.2 THE ‘KLEINZEE’ MUTATION ................................................................................ 43
1.2.1 Introduction and history ................................................................... 43
1.2.2 Colonoscopic surveillance ................................................................ 47
1.2.3 Colorectal cancer in the Northern Cape Province of South Africa .. 48
2 AIMS OF THE THESIS ......................................................................................... 50
3 PUBLISHED PAPERS ........................................................................................... 51
3.1 PAPER I: CANCER RISK IN CARRIERS OF THE C1528T (EXON 13) MUTATION
IN THE HMLH1 GENE [1] .............................................................................................. 52
3.1.1 Abstract ............................................................................................. 52
3.1.2 Introduction ....................................................................................... 54
xiii 
3.1.3 Aim .................................................................................................... 66
3.1.4 Methods ............................................................................................. 66
3.1.5 Results ............................................................................................... 69
3.1.6 Discussion ......................................................................................... 75
3.2 PAPER II: SURVEILLANCE COLONOSCOPY IMPROVES SURVIVAL IN LYNCH
SYNDROME:  A STUDY OF SUBJECTS CARRYING A SINGLE MISMATCH REPAIR GENE
MUTATION [2] .............................................................................................................. 80
3.2.1 Abstract ............................................................................................. 80
3.2.2 Introduction ....................................................................................... 82
3.2.3 Aim .................................................................................................... 92
3.2.4 Methods ............................................................................................. 93
3.2.5 Results ............................................................................................... 95
3.2.6 Discussion ....................................................................................... 100
3.3 PAPER III: SURGERY FOR COLON CANCER IN LYNCH SYNDROME: TOTAL VS.
SEGMENTAL COLECTOMY [3] ...................................................................................... 107
3.3.1 Abstract ........................................................................................... 107
3.3.2 Introduction ..................................................................................... 109
3.3.3 Aim .................................................................................................. 116
3.3.4 Methods ........................................................................................... 116
3.3.5 Results ............................................................................................. 117
3.3.6 Discussion ....................................................................................... 122
3.4 PAPER IV: DOES GENETIC ANTICIPATION OCCUR IN LYNCH SYNDROME?[4] ..... 126
3.4.1 Abstract ........................................................................................... 126
3.4.2 Introduction ..................................................................................... 128
3.4.3 Aim .................................................................................................. 133
xiv 
3.4.4 Methods ........................................................................................... 133
3.4.5 Results ............................................................................................. 136
3.4.6 Discussion ....................................................................................... 143
3.5 PAPER V: FERTILITY AND APPARENT GENETIC ANTICIPATION IN LYNCH
SYNDROME [5] ........................................................................................................... 146
3.5.1 Abstract ........................................................................................... 146
3.5.2 Introduction ..................................................................................... 148
3.5.3 Method ............................................................................................ 148
3.5.4 Results ............................................................................................. 152
3.5.5 Discussion ....................................................................................... 154
3.6 PAPER VI: FERTILITY AFTER YOUNG- ONSET COLORECTAL CANCER IN
LYNCH SYNDROME [6]. .............................................................................................. 157
3.6.1 Abstract ........................................................................................... 157
3.6.2 Introduction ..................................................................................... 159
3.6.3 Aim .................................................................................................. 161
3.6.4 Methods ........................................................................................... 161
3.6.5 Results ............................................................................................. 178
3.6.6 Discussion ....................................................................................... 188
4 CONCLUSION ...................................................................................................... 192
5 APPENDICES ....................................................................................................... 195
5.1 APPENDIX I: ORIGINAL PUBLISHED PAPERS ....................................................... 196
5.1.1 PAPER I ............................................................................................ 196
5.1.2 PAPER II ........................................................................................... 201
5.1.3 PAPER III ......................................................................................... 206
5.1.4 PAPER IV .......................................................................................... 211
  
xv 
5.1.5 PAPER V ........................................................................................... 217
5.1.6 PAPER VI .......................................................................................... 223
5.2 APPENDIX II: STATEMENTS OF AUTHORSHIP ..................................................... 241
5.2.1 PAPER I ............................................................................................ 241
5.2.2 PAPER II ........................................................................................... 242
5.2.3 PAPER III ......................................................................................... 243
5.2.4 PAPER IV .......................................................................................... 244
5.2.5 PAPER V ........................................................................................... 245
5.2.6 PAPER VI .......................................................................................... 246
5.3 APPENDIX III: CODE (VISUAL BASIC FOR APPLICATIONS) OF THE MODEL 
USED FOR SIMULATING LYNCH SYNDROME PARENT- CHILD PAIRS WITH CRC ............ 247
5.4 APPENDIX IV: CITATIONS ................................................................................. 251
5.4.1 Paper I ............................................................................................ 251
5.4.2 Paper II ........................................................................................... 252
5.4.3 Paper III .......................................................................................... 254
5.4.4 Paper IV .......................................................................................... 255
6 REFERENCES ...................................................................................................... 256
  
xvi 
LIST OF TABLES 
TABLE 1 TUMOUR SITES IN AFFECTED MEMBERS OF FAMILY “G” (FROM LYNCH AND
KRUSH (1971)) .............................................................................................. 30
TABLE 2 NUMBER OF UNIQUE MMR VARIANTS REPORTED TO THE INSIGHT
DATABASE (DECEMBER 2014)[26] ................................................................. 34
TABLE 3 THE AMSTERDAM CRITERIA FOR THE DIAGNOSIS OF HNPCC[37] ........... 38
TABLE 4 THE AMSTERDAM CRITERIA II FOR THE DIAGNOSIS OF HNPCC[39] ........ 38
TABLE 5 THE REVISED BETHESDA GUIDELINES FOR INVESTIGATION OF TUMOURS
FOR LYNCH SYNDROME. ................................................................................. 39
TABLE 6 LIFETIME RISK OF EXTRACOLONIC CANCERS IN SUBJECTS WITH LYNCH
SYNDROME ..................................................................................................... 64
TABLE 7 SITES OF COLORECTAL CANCERS. ............................................................ 72
TABLE 8 STAGE DISTRIBUTION OF COLORECTAL CANCERS. .................................... 72
TABLE 9 SITES OF EXTRACOLONIC MALIGNANCIES ................................................ 74
xvii
TABLE 10 AMERICAN JOINT COMMITTEE ON CANCER (AJCC)/ UNION
INTERNATIONALE CONTRE LE CANCER (UICC) TNM STAGING
DEFINITIONS[94] ............................................................................................ 83
TABLE 11 AJCC/UICC AND DUKES’ STAGE GROUPINGS ....................................... 84
TABLE 12 STAGE DISTRIBUTION OF CANCERS FROM SCREENED OR CONTROL GROUPS
(JARVINEN ET AL 2000 [104]) ........................................................................ 89
TABLE 13 STAGE DISTRIBUTION OF CRC ............................................................... 96
TABLE 14 CAUSES OF DEATH ................................................................................. 97
TABLE 15 CRC INCIDENCE IN SCREENED VS. UNSCREENED POPULATIONS ........... 104
TABLE 16 CRC- RELATED MORTALITY IN SCREENED VS. UNSCREENED
POPULATIONS ............................................................................................... 104
TABLE 17 MISMATCH REPAIR GENE MUTATIONS IDENTIFIED ............................... 118
TABLE 18 DUKES’ STAGE OF THE CANCER(S) RESECTED AT THE FIRST OPERATION.
 ..................................................................................................................... 119
TABLE 19 CAUSES OF DEATH ............................................................................... 122
TABLE 20 PREVIOUS STUDIES OF GENETIC ANTICIPATION IN LYNCH SYNDROME . 132
TABLE 21 AGE OF FIRST COLORECTAL CANCER (CRC) BY GENERATION. ............. 141
TABLE 22 AGE- SPECIFIC FERTILITY RATES FOR WOMEN FROM THE ENTIRE STUDY
GROUP AND FROM THE AUSTRALIAN GENERAL POPULATION. ....................... 179
TABLE 23 AGE- SPECIFIC FERTILITY RATES FOR WOMEN WITH OR WITHOUT A CRC
DIAGNOSIS. ................................................................................................... 182
xviii
TABLE 24 AGE- SPECIFIC FERTILITY RATES FOR MEN WITH OR WITHOUT A CRC
DIAGNOSIS. ................................................................................................... 183
TABLE 25 AGE- SPECIFIC FERTILITY RATES FOR SUBJECTS AFTER A CRC DIAGNOSIS,
GROUPED BY SITE OF TUMOR (COLON VS. RECTUM). ..................................... 187
xix 
LIST OF FIGURES 
FIGURE 1 GENOGRAM OF FAMILY “G”. FROM WARTHIN 1925 [12] ....................... 28
FIGURE 2 ‘SLIPPAGE’ DURING DNA REPLICATION. ADAPTED FROM CHUNG AND
RUSTGI 2003[33] ........................................................................................... 34
FIGURE 3 MAP OF SOUTH AFRICA SHOWING THE GEOGRAPHICAL DISTRIBUTION OF
KNOWN NPC-1 FAMILY MEMBERS AND THE NEAREST PUBLIC HEALTH SECTOR
COLONOSCOPY SERVICES. .............................................................................. 44
FIGURE 4 PEDIGREE OF THE KLEINZEE (NPC-1) FAMILY AS INITIALLY REPORTED IN
1990. .............................................................................................................. 45
FIGURE 5 CUMULATIVE CRC RISK FOR HMLH1 MUTATION CARRIERS .................. 65
FIGURE 6 HISTOGRAM SHOWING THE AGE IN YEARS OF ONSET OF CRC IN SUBJECTS
WHO DID NOT UNDERGO SURVEILLANCE. ....................................................... 69
FIGURE 7 KAPLAN- MEIER ESTIMATES OF AGE OF DIAGNOSIS OF CRC .................. 70
xx 
FIGURE 8 KAPLAN- MEIER ESTIMATES OF AGE OF DIAGNOSIS OF CRC INCLUDING
ONLY THOSE PATIENTS WHO HAD NO CRC DIAGNOSIS PRIOR TO GENETIC
TESTING. ........................................................................................................ 73
FIGURE 9 CUMULATIVE RISK OF CRC FOR CARRIERS OF THE C1528T (EXON 13)
MUTATION IN THE HMLH1 GENE (IN BOLD RED) COMPARED WITH OTHER
REPORTS OF CRC RISK IN HMLH1 MUTATION CARRIERS. .............................. 76
FIGURE 10 SURVIVAL AFTER SURGERY FOR CRC GROUPED BY DUKES’ STAGE AT
DIAGNOSIS. ..................................................................................................... 82
FIGURE 11 FLOWCHART SHOWING INCLUSIONS AND OUTCOMES OF THE STUDY
GROUPS. ......................................................................................................... 95
FIGURE 12 COLORECTAL CANCER- FREE SURVIVAL (FROM BIRTH). ........................ 98
FIGURE 13 OVERALL SURVIVAL (FROM BIRTH). ..................................................... 99
FIGURE 14 FOREST PLOT OF STUDIES COMPARING CRC INCIDENCE BETWEEN
SCREENED AND UNSCREENED POPULATIONS (EXCLUDING STUDIES WITH
REPETITION OF THE STUDY GROUPS .............................................................. 105
FIGURE 15 FOREST PLOT OF STUDIES COMPARING CRC- RELATED MORTALITY
BETWEEN SCREENED AND UNSCREENED POPULATIONS (EXCLUDING STUDIES
WITH REPETITION OF THE STUDY GROUPS). .................................................. 106
FIGURE 16 METACHRONOUS CRC RISK AFTER SEGMENTAL RESECTION OF A COLON
CANCER. ....................................................................................................... 120
FIGURE 17 COLORECTAL CANCER SPECIFIC SURVIVAL AFTER TOTAL OR SEGMENTAL
COLECTOMY FOR THEIR FIRST COLON CANCER. ............................................ 121
xxi 
FIGURE 18 YEAR OF BIRTH VS. AGE OF ONSET OF FIRST CRC (ALL C1528 (EXON 13)
HMLH MUTATION CARRIERS) ....................................................................... 128
FIGURE 19 YEAR OF BIRTH VS. AGE OF FIRST CRC DIAGNOSIS (NPC-1 FAMILY) . 137
FIGURE 20 AGE OF ONSET OF FIRST CRC IN THE NPC-1 FAMILY, GROUPED BY
BIRTH COHORT ............................................................................................. 138
FIGURE 21 KAPLAN- MEIER PLOT OF AGE OF ONSET OF FIRST CRC GROUPED BY
BIRTH COHORT. ............................................................................................ 138
FIGURE 22 AGE OF ONSET (IN YEARS) OF FIRST CRC FOR PARENT- CHILD PAIRS. . 140
FIGURE 23 KAPLAN- MEIER PLOT OF AGE OF ONSET OF FIRST CRC (IN YEARS) FOR
PARENT- CHILD PAIRS. .................................................................................. 140
FIGURE 24 AGE OF ONSET (IN YEARS) OF FIRST CRC GROUPED BY GENERATION . 142
FIGURE 25 AGE OF ONSET OF FIRST CRC (IN YEARS) BY GENERATION (KAPLAN- 
MEIER) ......................................................................................................... 142
FIGURE 26 HISTOGRAM OF AGE (IN YEARS) OF FIRST CRC DIAGNOSIS IN SUBJECTS
FROM THE ACCFR. ...................................................................................... 152
FIGURE 27 COHORT (LIFETIME) FERTILITY RATES VS. AGE (IN YEARS) OF DIAGNOSIS
OF CRC ........................................................................................................ 153
FIGURE 28 AGE DISTRIBUTION OF SUBJECTS WITH OR WITHOUT A CRC DIAGNOSIS.
 ..................................................................................................................... 167
FIGURE 29 AGE- SPECIFIC FERTILITY RATES FOR WOMEN FROM THE STUDY COHORT
VS. THE AUSTRALIAN GENERAL POPULATION. .............................................. 180
xxii
FIGURE 30 AGE- SPECIFIC FERTILITY RATES FOR WOMEN FROM THE STUDY COHORT
WITH OR WITHOUT A CRC DIAGNOSIS. ......................................................... 184
FIGURE 31 AGE- SPECIFIC FERTILITY RATES FOR MEN WITH OR WITHOUT A CRC
DIAGNOSIS. ................................................................................................... 185
xxiii
LIST OF ABBREVIATIONS 
AND ACRONYMS 
ACCFR Australasian Colorectal Cancer Family Registry 
AJCC American Joint Committee on Cancer 
APC Adenometous polyposis coli 
ASCO American Society of Clinical Oncologists 
ASFR Age- specific fertility rate 
ASR Age standardised rate 
C.I. Confidence interval 
CRC Colorectal cancer 
DSR Directly standardised rate 
FAP Familial adenomatous polyposis 
GIT Gastrointestinal tract 
xxiv
HNPCC Hereditary non- polyposis colorectal cancer 
IHC Immunohistochemisty 
InSiGHT International Society for Gastrointestinal Hereditary Tumours 
ISR Indirectly standardised rate 
MMR Mismatch repair 
MSI Microsatellite instability 
NPC-1 Non- polyposis colorectal cancer family 1 
PCR Polymerase chain reaction 
SBR Standardised birthrate 
SC/ISA Subtotal colectomy and ileo- sigmoid anastomosis 
SMR Standardised mortality rate 
TC/IRA Total colectomy and ileo- rectal anastomosis 
TFR Total fertility rate 
TNM Tumour/Node/Metastasis 
UICC Union Internationale Contre le Cancer 
WHO World Health Organisation 
25 
1 BACKGROUND 
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1.1 Lynch syndrome: General introduction 
Lynch syndrome is the most common known inherited form of bowel cancer. 
It accounts for about 3% of colorectal cancers (CRC). This autosomal 
dominant condition is caused by germline mutations in the mismatch repair 
(MMR) genes (hMLH1, hMSH2, hMSH6 or hPMS2) [7].  These mismatch 
repair gene mutations are associated with young onset CRC. In addition, 
carriers are at risk for extracolonic malignancies such as endometrial ovarian, 
small bowel, hepatobiliary, urinary tract and brain tumours. Throughout this 
thesis, the term Lynch syndrome is applied only to individuals or families 
who carry a proven germline MMR mutation, while HNPCC is used when the 
diagnosis is made on clinical and family history criteria in keeping with 
current nomenclature [8,9] (This nomenclature is not, however, used 
consistently in the original forms of the papers included in this thesis, as these 
conventions have evolved over recent years. 
1.1.1 Historical perspective 
In 1913, Aldred Warthin published the first report of a family with what is 
now referred to as Lynch syndrome. This was part of an extraordinary study 
on the ‘influence of heredity on cancer’[10] in which he reviewed 1600 cases 
of carcinoma diagnosed at the University of Michigan pathology laboratory, 
and obtained 1000 ‘fairly good’ family histories from affected patients. In 
four of these families, he noted that ‘the incidence of cancer in these families 
is so striking that it can be interpreted as showing an inherited susceptibility’ 
to cancer. In one of these families, designated family “G”, 17 of 48 
27 
descendants of the ‘cancerous grandfather’ had been diagnosed with uterine 
or gastrointestinal (GIT) cancers. An interesting personal note to this history 
is that one of the members of this family was Warthin’s seamstress, who had 
expressed her concerns about her family’s predisposition to cancer, and who 
later died of endometrial cancer herself[11]. 
In 1925, Warthin published a more extensive description of family “G”[12]. 
The genogram presented in this paper is illustrated below (Figure 1). In this 
paper he concluded that the family carried an inherited susceptibility to 
cancers of the gastrointestinal tract in men and of the reproductive organs in 
women.  He further noted the unusually young age on onset of cancer (mean 
38 years) in this family. In this paper, Warthin complained that his findings 
had ‘met with little favour among surgical writers and particularly among 
those interested in propaganda for the prevention of cancer’. This remained 
the case for many years. 
In 1936, five years after Warthin’s death, Hauser and Weller published ‘a 
further report on the cancer family of Warthin’ [13]. The family tree had been 
extended to include 305 individuals over six generations. A total of 43 
cancers had been diagnosed in 41 individuals. All but two of these tumours 
occurred in the GIT or uterus, and the authors made the point that the 
‘anatomical location (was) more significant than total incidence’ of cancers in 
this family.  They concluded that ‘this family provides very strong 
presumptive evidence for an inheritable organ-specific predisposition to 
carcinoma’ although they could not come to any conclusions regarding the 
pattern of Mendelian inheritance. 
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In 1962, Henry T. Lynch (who was a second year medical resident at the 
time) met a patient who was recovering from delirium tremens. The patient 
believed that he was going to die of CRC, which was prevalent in his family, 
and that this was the reason for his heavy drinking. Sadly, like Warthin’s 
seamstress, he was correct and later died of bowel cancer[14]. The initial 
presumptive diagnosis of familial adenomatous polyposis (FAP), which at the 
time was the only known inherited form of bowel cancer, was found to be 
incorrect as there was no evidence of colonic polyposis in this family. Lynch 
et al reported on this family’s (designated family “N” for Nebraska) cancer 
risk along with another pedigree (family “M” from Michigan) which had been 
identified by Marjorie Shaw[15]. The authors noted an unusually high number 
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of cancers diagnosed (predominantly colon and uterus, but also in a number 
of other sites) in these families, and recognised an autosomal pattern of 
inheritance.Lynch then gained access to Warthin’s genograms and pathology 
specimens relating to family “G” and in 1971 Lynch and Krush [16] reported 
on this family. By this time, the family tree included over 650 individuals, of 
whom 95 had been diagnosed with malignant neoplasms. The sites of the 
tumours that were identified are summarised in Table 1. 
The authors also elucidated the pattern of inheritance in this family, which 
was ‘consistent with an autosomal dominant inheritance pattern’.  
Lynch used the term ‘cancer family syndrome’ to describe the families he had 
reported, and listed its characteristics as follows:  
“1. Increased occurrences of adenocarcinomas, primarily of colon and 
endometrium; 
2. Increased incidence of multiple primary malignant neoplasms;
3. Autosomal dominant inheritance;
4. Early age of onset of cancer”[16]
 30 
Table 1 Tumour sites in affected members of family “G” (from Lynch 
and Krush (1971)) 
Tumour site Number 
Colon 52 
Endometrium 18 
Stomach 8 
Breast 4 
Skin 6 
Urothelium 2 
Prostate 2 
Liver 2 
Ovary 1 
Thyroid 1 
Lung 2 
Pituitary 1 
Pancreas 2 
Soft tissue sarcomas 5 
Lymphocytic leukaemia 2 
Plasmacytoma of sternum 1 
Brain 2 
Site unknown 2 
Total 113 
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 1.1.2 Microsatellite instability 
By 1990, a multistep molecular pathway for CRC tumorigenesis had been 
hypothesised[17]. In this model, a series of mutations in suppressor genes 
including the APC, p53, and DCC genes as well as oncogenes such as K-ras 
occur sequentially. This leads to the development first of a benign adenoma 
and later carcinoma. This has become known as the “Vogelstein”, “canonical” 
or “suppressor” pathway, and is now known to account for about 80% of 
sporadic CRC (as well as being the pathway through which CRC develops in 
familial adenomatous polyposis (FAP))[18].  
In 1993, three groups almost simultaneously published reports of what is now 
referred to as microsatellite instability (MSI) in colorectal cancers [19-21] and 
recognised this as a novel pathway for CRC tumorigensis. They amplified the 
DNA of tumour cells and of surrounding normal tissue by polymerase chain 
reaction (PCR), and the PCR products were separated by gel electrophoresis. 
The tumour DNA showed small differences in the lengths of some DNA 
fragments containing repetitive sequences of base pairs when compared with 
normal tissue. It was noted that this only occurred in a subset of CRC, but in 
those tumours there was a dramatic (100 to 1000 fold) increase in the rates of 
these mutations compared to normal cell lines. Thibodeau et al [19] noted that 
microsatellite instability was more frequently observed in proximal CRC and 
was associated with a better prognosis. It was also inversely associated with 
chromosomal abnormalities typical of tumorigenesis via the Vogelstein 
pathway. Aaltonen et al [20] observed these changes (referred to as 
replication error (RER+)in this paper) in 13% of sporadic tumours and in the 
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majority of familial cancers and concluded that this was “a mechanism for 
familial tumorigenesis different from that mediated by classic tumor 
suppressor genes”.  Ionov et al [21] hypothesised that the occurrence of these 
numerous small mutations was likely due to a mutation in a gene coding for 
“a factor essential for the replication fidelity (or repair) of these simple 
repeated sequences”. They also noted that these changes occurred in a 
distinctive phenotypic subset of CRC (right sided, metachronous, poorly 
differentiated tumours in young patients), and postulated that they may be the 
“molecular genomic manifestations of … hereditary non- polyposis colorectal 
cancer”. It is now well recognised that there is a distinctive histological 
phenotype, characterised by tumor infiltrating lymphocytes, Crohn’s like 
inflammatory reaction, mucinous and/or signet ring differentiation and a 
medullary growth pattern, which is strongly associated with microsatellite 
unstable tumours [22]. 
 1.1.3 Mismatch repair genes 
At the time that MSI was first described in human CRC, the human mismatch 
repair genes were unknown. In bacteria and fungi, however, well defined 
DNA mismatch repair (MMR) pathways had already been elucidated, and it 
had been observed that mutations in the genes coding for MMR proteins led 
to instability in the replication of repetitive dinucleotide repeat sequences. 
Fishel et al [23] recognised that this was analogous to MSI that had been 
reported in some CRC and later in 1993 (the same year that MSI was first 
described in CRC) they reported that they had identified the first human 
MMR protein. Specifically, they had cloned the human homolog of the 
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bacterial MutS and Saccharomyces cerevisiae MSH proteins (named 
hMSH2). They also identified a germline mutation in the gene that codes for 
this protein in affected members of two HNPCC kindreds, and concluded that 
hMSH2 was the HNPCC gene. 
There are now known to be at least seven genes involved in the MMR system: 
hMLH1, hMLH3, hMSH2, hMSH3, hMSH6, hPMS1 and hPMS2[18]. The 
MMR complex identifies DNA mismatches (defined as non- Watson- Crick 
base pairs or small loops of nucleotides that form from the two strands of 
DNA slipping relative to each other), excises the aberrant base pair(s), and 
repairs the error. Deficiencies in any of the MMR proteins can lead to 
malfunction of this system, causing widespread mutations. Repetitive 
sequences of mononucleotide or dinucleotide pairs are particularly prone to 
replication errors by DNA polymerase due to slippage, causing insertion or 
deletion errors and changes in the length of these repetitive segments, which 
manifests as microsatellite instability (MSI) [18, 24, 25]. This is illustrated in 
Figure 2.  
Mutations in the hMLH1 and hMSH2 genes account for about three quarters 
of the mutations that have been reported to the  International Society for 
Gastrointestinal Hereditary Tumours (InSiGHT) database[26], which is the 
major international repository for gene variant information for Lynch 
syndrome[27]. The frequencies of reported variants are listed below (Table 2). 
In Lynch syndrome, there is a somatic mutation in one of the MMR genes. Of 
the seven known MMR genes, the following are known to cause Lynch 
syndrome: hMLH1[28]; hMSH2[23, 29]; hMSH6[30]; hPMS2[31] (Warthin’s 
family “G” is now known to carry a mutation in the hMSH2 gene[32]). 
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Table 2 Number of unique MMR variants reported to the InSiGHT 
database (December 2014)[26] 
MMR gene Number of unique variants 
hMLH1 1184 (40%) 
hMSH2 1003 (34%) 
hMSH6 533 (18%) 
hPMS2 234 (8%) 
Total 2954 
 
 
 
 
 
 
 
Figure 2 ‘Slippage’ during DNA replication. Adapted from Chung and 
Rustgi 2003[33] 
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Affected individuals carry one wildtype and one mutated copy of the gene. 
Failure of the MMR proteins to function normally requires somatic 
inactivation of the wildtype allele. In subjects who do not carry a germline 
MMR mutation, abnormal MMR function occurs when both copies of the 
MMR gene become inactivated. This provides an example of Knudson’s 
two hit” model of oncogenesis that explains the variable penetrance of 
inherited tumour suppressor gene abnormalities, and also the occurrence of 
tumours typical of those inherited conditions in subjects who do not carry the 
germline mutation [34]. Because somatic inactivation of MMR genes is 
common, Lynch syndrome manifests phenotypicalOy as an autosomal 
dominant condition.  
1.1.4 Microsatellite instability in sporadic CRC 
Approximately 95% of all tumours in Lynch syndrome show MSI [24]), 
making this a cardinal feature of Lynch syndrome. MSI also occurs in some 
sporadic (i.e. not inherited) CRC. This usually occurs as a result of abnormal 
somatic hypermethylation of the promoter region of the hMLH1 gene[35]. 
Unlike Lynch syndrome, where there is a germline mutation in the mutated 
copy of the gene, acquired somatic epimutations of both copies of the hMLH1 
gene occur. In a 2001 study of CRC, in specimens which were not selected for 
family history, Cunningham et al [36] found that approximately 20% of CRC 
had evidence of MSI, the great majority of which were due to inactivation of 
hMLH1. Only ten per cent of tumours that exhibited MSI (or two per cent of 
all CRC) had a definite germline MMR mutation (i.e. had Lynch syndrome). 
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In summary, almost all Lynch syndrome tumours demonstrate MSI, but only 
a small minority of microsatellite unstable CRC are due to Lynch syndrome. 
 1.1.5 Diagnosis of Lynch syndrome 
 1.1.5.1 Clinical diagnosis- the Amsterdam criteria 
Prior to the availability of genetic testing for Lynch syndrome, the diagnosis 
of HNPCC was defined by clinical criteria.  The newly formed International 
Collaborative Group on Hereditary Non- Polyposis Colorectal Cancer met in 
Amsterdam in 1990, and produced the Amsterdam criteria for the diagnosis of 
hereditary non- polyposis colorectal cancer (HNPCC)[37], which had become 
the favoured term for the ‘family cancer syndrome’ by that time[38]. The 
criteria are listed below (Table 3). They were later broadened to include 
families in whom extracolonic tumours were prevalent (referred to as the 
Amsterdam II criteria[39], (Table 4)). The Amsterdam criteria are neither 
sensitive nor specific in diagnosing Lynch syndrome (i.e. germline MMR 
mutation carriers). Up to three quarters of patients with CRC and genetically 
proven Lynch syndrome come from families that do not fulfil the Amsterdam 
II criteria [40]. Almost half the families that fulfil the Amsterdam I criteria do 
not carry MMR mutations [41]. These families, described as “familial CRC 
type X” appear to carry a CRC risk which is higher than the general 
population, but lower than families with Lynch syndrome. Lindor et al, who 
first documented the cancer risk in his group, hypothesised that these familes 
represented a “heterogeneous group comprised of (1) some cancer 
aggregation occurring by chance alone, (2) some aggregation related to shared 
lifestyle factors, and (3) some yet-to-be-defined genetic syndromes” [41]. 
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 1.1.5.2 Bethesda guidelines 
In response to the recognised lack of sensitivity of the Amsterdam criteria in 
detecting families with Lynch syndrome, the Bethesda guidelines for selecting 
tumours for MSI testing (in order to screen for Lynch syndrome)were 
formulated in 1997 [42], and revised in 2004 [43]. The revised guidelines are 
listed below (Table 5). Pinol et al in 2005 [44] reported on a large series of 
1978 consecutively diagnosed CRC, all of which underwent MSI testing as 
well as immunohistochemical (IHC) staining for MMR proteins. All patients 
with MSI tumours and/ or tumours with absent MMR protein on IHC had 
germline mutation testing for Lynch syndrome. The family history, 
demographics and histological features of the tumours were also documented.  
The Revised Bethesda criteria were positive in 10/11 (91%) of patients with 
Lynch syndrome, and in 227/1211 (23%) patients who did not have Lynch 
syndrome, so the criteria perform well as a screening test. It is a widely 
accepted recommendation that these criteria are used to screen CRC for 
further testing for Lynch syndrome [9], although some authors advocate using 
less stringent [45](and therefore more sensitive but less specific) criteria  to 
guide testing, or even routine testing of all CRC  [46].  The optimum strategy, 
taking into account cost- effectiveness and resource availability is an area of 
on- going debate. 
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Table 3 The Amsterdam criteria for the diagnosis of HNPCC[37] 
Families must fulfil all criteria 
1. There should be at least three relatives with colorectal 
cancer 
2. One should be a first-degree relative to the other two 
3. At least two successive generations should be affected 
4. At least one should be diagnosed before age 50 
5. Familial adenomatous polyposis (FAP) should be excluded 
6. Tumours should be verified by pathological examination 
 
 
 
Table 4 The Amsterdam criteria II for the diagnosis of HNPCC[39] 
Families must fulfil all criteria 
1. There should be at least three relatives with an HNPCC-
associated cancer (colorectal, endometrium, small bowel, 
ureter or renal pelvis) 
2. One should be a first-degree relative to the other two 
3. At least two successive generations should be affected 
4. At least one should be diagnosed before age 50 
5. Familial adenomatous polyposis (FAP) should be excluded 
in the CRC cases (if any) 
6. Tumours should be verified by pathological examination 
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Table 5 The Revised Bethesda guidelines for investigation of tumours for 
Lynch syndrome.  
(Guideline 5 has been reworded for clarity after Lindor et al [9]) 
Individuals meeting any one of the following should undergo 
microsatellite instability (MSI) testing: 
1. Colorectal cancer (CRC) diagnosed in an individual under
age 50 years.
2. Presence of synchronous, metachronous colorectal, or
other Lynch syndrome- associated tumours*, regardless of
age.
3. CRC with histological features suggestive of a high degree
of microsatellite instability ** in a patient <60 years of age.
4. CRC in 1 or more first-degree relatives with a Lynch
syndrome- associated tumour*, with 1 of the cancers being
diagnosed under age 50 years.
5. CRC or Lynch syndrome- associated tumour diagnosed at
any age in 2 or more first- or second-degree relatives.
* Endometrial, ovarian, gastric, small bowel, pancreas, hepatobiliary tract,
renal tract and brain tumours, sebaceous gland adenomas and 
keratoacanthomas. 
**Presence of tumour-infiltrating lymphocytes, Crohn’s like lymphocytic 
reaction, mucinous or signet-ring differentiation, or medullary growth pattern. 
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 1.1.5.3 Evidence of MMR dysfunction- MSI or IHC testing 
MSI testing of CRC tissue has a sensitivity of around 85% for detecting 
Lynch syndrome [47]. Immunohistochemical staining for MMR proteins has 
similar sensitivity [47], and the results of MMR IHC and MSI testing are 
almost perfectly concordant [48, 49].  IHC more readily available to general 
pathology laboratories [50] and also has the advantage of directing germline 
MMR genetic testing (as only the MMR gene whose protein is deficient needs 
to be tested). However, the accuracy of IHC is variable and operator 
dependent [46]. The choice of MMR or IHC for screening tumours for Lynch 
syndrome should therefore be based on the availability of local skills and 
resources. 
Sporadic microsatellite unstable tumours that are hMLH1 deficient can 
usually be differentiated from Lynch syndrome tumours by testing for hMLH1 
promoter hypermethylation [24] or by testing for a specific mutation 
(designated V600E; c.1799>A) in the BRAF oncogene which occurs in about 
half of all sporadic microsatellite unstable CRC, but is almost never 
detectable in Lynch syndrome- associated tumours[24, 51]. 
 1.1.5.4 Germline mutation testing 
The molecular diagnosis of Lynch syndrome requires germline mutation 
testing. This should be offered to all individuals with CRC who show 
evidence of MMR deficiency (without evidence of hMLH1 promoter 
methylation) [9, 24, 46].   
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The strategy for testing is more complex in the setting of an individual who 
has a family history suggestive of Lynch syndrome but who has not had a 
cancer. In this setting, the most effective approach is to perform genetic 
testing on a (living) relative who has previously developed a Lynch 
syndrome- associated cancer.  If tissue from the tumour is available, it can be 
tested as above, and germline testing performed on the affected individual if 
the tumour has features suggestive of Lynch syndrome as above. If the 
affected relative is found to have a germline MMR mutation, targeted testing 
(for that specific family mutation, which is considerably cheaper and easier 
than screening the entire MMR gene(s)) may be undertaken for other family 
members. If no tissue is available, germline genetic testing on an affected 
individual may be performed, and the diagnosis of Lynch syndrome may be 
confirmed [9, 24, 46, 52]. 
In the absence of a living (or available) affected relative, one may proceed 
directly to germline mutation testing in individuals with a strong family 
history. If a known pathological mutation is found, the diagnosis of Lynch 
syndrome can be made. Commonly, however, the results of testing in this 
setting may be inconclusive, as not all mutations are necessarily pathological. 
In this case, further testing of the family will not be helpful [9, 46]. 
In summary, Lynch syndrome should be suspected in subjects with a strong 
family history of CRC or other associated tumours, or in patients with 
tumours that display the typical histological features associated with the MSI 
phenotype. Testing for MSI or absent MMR proteins by IHC can help to 
screen tumours for Lynch syndrome, but the definitive (molecular) diagnosis 
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of Lynch syndrome requires germline genetic testing demonstrating a 
pathological germline MMR mutation. 
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 1.2 The ‘Kleinzee’ mutation 
 1.2.1 Introduction and history 
In 1987, the general practitioner working at the mine hospital in Kleinzee (a 
remote town of about 2000 people in the Northern Cape province of South 
Africa, (Figure 3)) referred a thirty year old man to Groote Schuur Hospital in 
Cape Town for possible colonoscopic surveillance. The patient (J.C.) had 
undergone a sigmoid colectomy for cancer at age 19, his brother had 
developed colon cancer at age 23, and his father and three paternal uncles had 
all died of abdominal cancers. A description of this family was first published 
in 1990 by Goldblatt et al [53]. The authors documented a pedigree of 47 
individuals over four generations of whom 16 men (and notably no women) in 
three successive generations had bowel cancers. This pedigree is illustrated 
below (Figure 4). The family therefore fulfilled the Amsterdam criteria[37, 
39] for the diagnosis of HNPCC. The authors described the pattern of
inheritance as ‘autosomal dominant with male predominance’. An amendment 
was added to the paper after it had been accepted for publication in which the 
authors noted that they had also identified two female family members who 
had died of suspected bowel cancer. Over time, as the family tree was 
expanded, it became clear that the apparent absence of women was 
artefactual, at least partly due to the pattern of migration in that community 
(the men tended to stay and work in the mine but women were more likely to 
leave the area, so information about them was often incomplete).  
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Figure 3 Map of South Africa showing the geographical distribution of 
known NPC-1 family members and the nearest public health sector 
colonoscopy services.  
The shaded ovals cover the sites where affected individuals are known to 
live; the colonoscopes illustrate the three nearest colonoscopy services. 
The arrow shows the site of Kleinzee, where the family was first 
identified. Note the distance of approximately 700 km from Kleinzee to 
the nearest colonoscopy service. 
45 
Figure 4 Pedigree of the Kleinzee (NPC-1) family as initially reported in 
1990.  
Note the ‘male specificity’ and the scarcity of female family members. 
From Goldblatt et al [53]. 
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Colonoscopic surveillance was offered to members of this family based on 
empiric risk, and an active program of identifying further individuals at risk 
of HNPCC (on the basis of early age of onset or family history of CRC) was 
instituted by the Colorectal Surgery Unit and Division of Human Genetics at 
the University of Cape Town. In 1998, Goldberg et al [52] reported that the 
pathological mutation in this family had been identified, so a molecular 
diagnosis of Lynch syndrome was made and mutational analysis with genetic 
counselling could be offered to family members. The mutation was a C to T 
transversion at nucleotide 1528 in exon 13 of the hMLH1 gene 
(“NP_000240.1:p.Gln510*/NP_000240.1:p.Gln510Ter” using the Human 
genome Variation Society standard nomenclature [54]).This mutation was 
not identified in any population- matched controls, and has not been identified 
in any Lynch syndrome families outside South Africa. It is not known 
whether this is due to a founder effect or if it is an indigenous African 
mutation. By the time that the mutation was identified, the family tree had 
expanded to the extent that 160 family members had undergone germline 
mutational analysis, 37 of whom were mutation positive[52].  
 Throughout this thesis, this mutation is referred to as the “C1528T (Exon 13) mutation 
in the hMLH1 gene” rather than by the Human Genome Variome Society nomenclature for 
ease of reading and for consistency with the previously published papers on which the 
thesis is based. 
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By the year 2000, this number had increased to 140 mutation- positive in 
individuals in a family of 500 [55], and in this report two metachronous colon 
cancers were documented, as well as one extracolonic tumour (a breast cancer 
in a woman). This family is referred to as the “NPC-1” (non- polyposis 
colorectal- 1) family in this thesis. 
Currently, there are seventeen families known to carry the C1528T mutation 
in exon 13 of the MLH1 gene. Although they are presumed to have a common 
ancestor, this is currently unproven. The “NPC-1” family is the largest of 
these, with 714 known family members. 
 1.2.2 Colonoscopic surveillance 
By 2007, ongoing identification of individuals at risk of familial cancers had 
led to the detection of 30 Lynch syndrome families carrying 12 different 
mismatch repair gene mutations. This presented a formidable challenge to the 
resources available for colonoscopic surveillance in South Africa, where 
colonoscopic services are restricted to major centres. Not only were the 
majority of family members living in remote areas with no easy access to 
these services (Figure 3), but the number of individuals in whom surveillance 
was indicated on the basis of family history would have overwhelmed the 
colonoscopy services at the nearest centres. This was one of the major 
motivations behind offering genetic testing to family members. Mutational 
analysis allowed subjects who were found not to carry the mutation (and who 
were therefore at population risk for CRC) to avoid lifelong surveillance. This 
spared them the risk and discomfort of multiple colonoscopies. It also reduced 
the number of patients who needed to undergo colonoscopy, which is of 
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particular importance in a resource- poor country such as South Africa.[52, 
55] 
Aside from the difficulty of delivering a colonoscopic service to large 
numbers of people in a small number of centres, the distance that the subjects 
needed to travel is a major obstacle in itself. Many of the subjects at risk are 
from impoverished areas, with little or no available transport, and the costs of 
travel and accommodation in order to have a colonoscopy are often 
unaffordable to them.  
In order to provide surveillance colonoscopy to individuals at risk who could 
not travel to a dedicated endoscopic unit, a mobile colonoscopic service was 
developed. This is an annual service, in which a group of endoscopists, nurses 
and technicians travel by road (with all the required equipment) to a number 
of small rural clinics along the West coast of South Africa over a one week 
period. Subjects who are identified as requiring colonoscopy (on the basis of 
genetic testing) are offered the service and provided with bowel preparation in 
advance. Anderson et al [56] have audited this mobile colonoscopy service, 
and found the service to be of a similarly high quality to the established 
colonoscopy units in Cape Town and Johannesburg (and in keeping with 
international norms) in terms of colonoscopy completion and pathological 
lesion detection rates.  
 1.2.3 Colorectal cancer in the Northern Cape Province of South 
Africa 
The incidence of CRC is variable around the world, with a higher incidence 
reported in the ‘developed’ compared with the ‘developing world’. Ferlay et 
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al [57] calculated an annual age standardised rate (ASR) of 38/100,000 
(males) and 24/100,000 (females) in ‘more developed regions’ vs. 12/100,000 
(males) and 9/100,000 (females) in ‘less developed regions’. CRC has been 
reported to have a low but increasing incidence in South Africa [58, 59]. The 
first estimate of the incidence of CRC in the Northern Cape Province was 
published in 2010[60].  In this study, the pathology reports of CRC from the 
laboratories serving that area between 2007 and 2009 were reviewed. During 
that time, 113 patients were diagnosed with CRC, in a population of 1.1 
million. The annual incidence was calculated as 3.5/100,000 for men, and 
3.9/100,000 for women (using the World Standard Population, an ASR of 
4.2/100,000 was calculated (this was similar for men and women).  
In summary, the Northern Cape Province of South Africa is an extremely low 
incidence area for CRC overall, but a large number of subjects with Lynch 
syndrome have been identified in this area. This provides a unique 
opportunity to study a large cohort of subject with Lynch syndrome who all 
carry the same mutation, in an environment with a low background incidence 
of sporadic CRC. 
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2 AIMS OF THE THESIS 
This thesis aims to increase the body of knowledge of the natural history of 
Lynch syndrome, and add to the body of evidence regarding the efficacy of 
colonoscopic surveillance in this population, under the following headings: 
To determine the lifetime cancer risk for carriers of the C1528T (Exon 13) 
mutation in the hMLH1 gene. 
To determine whether surveillance colonoscopy prevents CRC and improves 
survival in carriers of the C1528T (Exon 13) mutation in the hMLH1 gene . 
To determine the risk of metachronous CRC after segmental colectomy for 
colon cancer in Lynch syndrome. 
To determine whether genetic anticipation occurs in a Lynch syndrome.  
To determine the effect of young onset CRC on fertility in Lynch syndrome. 
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3 PUBLISHED PAPERS 
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 3.1 PAPER I: Cancer risk in carriers of the C1528T (Exon 
13) mutation in the hMLH1 gene [1] 
 3.1.1 Abstract 
 3.1.1.1 Introduction  
There is marked variability in the reported cancer risk in Lynch syndrome. 
The purpose of this study is to document the cancer risk for subjects who 
carry the C1528T (Exon 13) mutation in the hMLH1 gene. 
 3.1.1.2 Patients and methods 
This is a prospective cohort study of 200 subjects who carry this mutation. 
The risk of developing colorectal cancer was calculated only in those subjects 
who had not undergone surveillance colonoscopy. The incidence of 
extracolonic cancers (for which surveillance was not offered) was determined 
for the entire cohort. 
 3.1.1.3 Results 
Among the 71 subjects who did not undergo surveillance colonoscopy, 
colorectal cancers occurred in 36 (51%). They occurred at a median age of 44 
years (range 17-73). Using Kaplan- Meier estimates, the risk of developing a 
colorectal cancer by age 65 years was 92%. Eighteen subjects in the cohort of 
200 were diagnosed with extracolonic tumours. The most common 
extracolonic malignancies were breast (6/98 women) and endometrial (3/98 
women). 
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 3.1.1.4 Conclusion 
This mutation has a high penetrance for colorectal cancer. Although 
extracolonic cancers were common overall, no individual extracolonic 
malignancy occurred commonly. 
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 3.1.2 Introduction 
Accurate genetic counselling and a rational approach to screening require 
knowledge of the natural history and penetrance of the disease in question. 
This is especially important in the South African setting where there are 
limited resources available for screening.  
Reported estimates of cancer risk in Lynch syndrome are highly variable, 
depending on the methodology used as well as the patient groups that have 
been studied. 
Vasen et al in 1996 [61] reported on the cancer risk in19 families with proven 
hMLH1 (12 families) and hMSH2 (seven families) mutations from the Dutch 
HNPCC registry. They identified 210 mutation carriers out of 382 family 
members. Using standard survival (Kaplan- Meier) analysis techniques to 
correct for variable follow up, they reported a cumulative risk of CRC of 92% 
for men and 83% for women by the age of 75 years. The lifetime risk for 
endometrial cancer was approximately 50% for the two groups combined (and 
no difference was detected in cancer risk between the two mutations). They 
also observed an increased risk of small bowel cancers. Gastric and ovarian 
cancers were not significantly increased among mutation carriers compared 
with the general population.  
Aarnio et al [62] in 1999 reported on a large cohort of 50 Finnish families in 
which an hMLH1 (47 families) or hMSH2 (3 families) mutation had been 
detected. Out of a total of 1763 family members, they identified 265 mutation 
carriers. Their cumulative risk of CRC by age 70 years was 100% in men and 
54% in women. Women had a 60% lifetime risk for endometrial cancer, and 
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there was a high incidence of gastric (13%), ovarian (12%) as well as other 
extracolonic neoplasms.  
 3.1.2.1 The problem of ascertainment bias  
Ascertainment bias (also referred to as detection bias) is a form of selection 
bias in which the method of detecting or diagnosing a condition leads to a 
systematic deviation from the true frequency of that condition[63].  
Dunlop et al [64] in 1997 noted that most reported mutations in mismatch 
repair genes had been identified in HNPCC families which had been selected 
because of a notably high number of cancer cases, and that therefore 
‘ascertainment bias is an inherent problem with cancer risk estimates derived 
from such families’. They therefore used a different strategy to determine 
CRC risk in Lynch syndrome. They performed targeted genetic testing on 
individuals with young onset CRC with microsatellite instability and thus 
identified six probands (one with mutations in hMLH1 and five with hMSH2 
mutations) unselected for family history. They then traced the respective 
pedigrees of these mutation- positive probands, and identified 156 family 
members, of whom 67 were mutation carriers. In order to include clinical 
information for family members with an unknown mutation status (mainly 
family members who had died before commencement of the study) they 
assigned a probability that the untested individual carried the mutation using a 
model taking into account the known (autosomal dominant) inheritance as 
well as the known population risk for sporadic CRC. They estimated the 
cumulative CRC risk by age 70 years at 74% in men and 30% in women, 
which were only slightly lower than the estimates from HNPCC registries 
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mentioned earlier.  In women, the risk of endometrial cancer was 42% by age 
70 years. 
Carayol et al [65] in 2002 more formally addressed the issue of ascertainment 
bias, criticising the methodology used to estimate penetrance in Lynch 
syndrome in previous studies. They made the observation that “the use of 
these very restrictive (Amsterdam) criteria[37] is bound to cause an 
ascertainment towards multiple case families” as families with fewer than 
three known cases of CRC would not meet these selection criteria, and 
families with multiple and young onset CRC are more likely to be included. 
This would be expected to lead to an overestimation of CRC risk in families 
carrying mutations in MMR genes.  It would also be expected to lead to an 
under- estimation of the prevalence of extra- colonic tumours, as these did not 
form part of the original Amsterdam criteria [37] (although they do for part of 
the broader Amsterdam II criteria [39]). In order to determine the extent to 
which ascertainment bias could affect estimation of CRC risk in Lynch 
syndrome, the authors constructed a series of simulations of families carrying 
MMR mutations. They used French demographic data to determine family 
sizes, and applied standard Mendelian (autosomal dominant) risk to determine 
which offspring carried the mutation, and applied arbitrarily defined “high” 
and “low” age- specific CRC risks to affected family members. In this 
simulation, only four per cent of “low risk” families, and ten per cent of “high 
risk” families fulfilled the Amsterdam criteria. The estimated risk for 
members of those simulated families who fulfilled the Amsterdam criteria 
was consistently higher than the simulated risk for the entire cohort (the over- 
estimation ranged from 17% to 130% depending on risk and age group). The 
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authors concluded that any estimate of CRC risk in HNPCC where inclusion 
in the study cohort is based on family history should correct for ascertainment 
bias, and that “colorectal cancer risks are largely overestimated in HNPCC, at 
about double the actual levels”.   
This model can be criticised as CRC mortality and decreased fertility after 
CRC were not considered. The authors note that “…people dying from cancer 
at a young age would not have the opportunity to have descendants, which 
would reduce the number of carriers in the following generation” which could 
cause an underestimation of CRC risk (as young patients who died of cancer 
would not generate enough offspring for their family to be noted to be at risk). 
They state, however, that “since the average age at diagnosis is about 45 
years, most people would have already had their children before the 
occurrence of their disease…therefore an allowance for mortality would not 
have modified the cancer risk estimates.” Chapter 3.5 addresses the effect of 
age of onset of CRC on lifetime fertility in Lynch syndrome. 
 3.1.2.2 Correction for ascertainment bias leads to lower estimates of CRC 
risk 
In order to completely eliminate ascertainment bias in determining 
penetrance, one would need to perform mutational analysis on unselected 
members of the general population, and compare cancer risk between 
mutation carriers and non- carriers. This approach would not be practical in 
Lynch syndrome however, as the population frequency of the mutation is 
extremely low (three per ten thousand population as calculated by Dunlop et 
al[66]).  
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One simple method of reducing ascertainment bias is to exclude probands (the 
first family member identified as having a MMR mutation who, by definition, 
have a 100% lifetime risk of CRC). Hampel et al [67] used this approach in a 
study of 70 families known to carry hMLH1 (65 families) or hMSH2 (5 
families) mutations from Finland. They identified 88 probands and 373 
mutation- positive family members. They excluded the probands from the 
analysis and used the Kaplan- Meier survival method to determine cancer risk 
in all other family members who were proven mutation carriers.  They 
calculated a lifetime cancer risk of 69% for men and 52% for women. The 
median age of onset of CRC was 54 years for men and 70 years for women. 
In contrast, the median age of onset of CRC among the probands was 44 years 
for both men and women.  
Quehenberger et al in 2005 [68] reported on 84 families from the Dutch 
HNPCC Cancer Registry in which an hMLH1 (39 families) or hMSH2 (45 
families) mutation had been identified. The study included 1088 subjects from 
MLH1 families, and 1304 from hMSH2 families. Genotyping was performed 
on approximately 20% of affected subjects (with CRC, endometrial or other 
Lynch syndrome cancers) and 35% of unaffected family members. They 
found that 98% (hMLH1) and 94% (hMSH2) of genotyped affected 
individuals were mutation carriers, and 49% (hMLH1) and 41% (hMSH2) of 
unaffected subjects were mutation carriers. They used the technique of 
ascertainment- corrected maximum likelihood estimation to determine the 
age- specific relative cancer risk. This methodology is based on the principle 
that the proportion of mutation carriers to non- carriers among phenotypically 
normal relatives (index cases are excluded from the analysis) should decrease 
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with age (because the mutation carriers will develop cancer), although the 
number of subjects who do not carry the mutation but develop the disease (i.e. 
who have sporadic, population risk cancers) will increase with age (but at a 
lower rate). They reported a 29% cumulative risk of CRC by the age of 80 
years for men, and 24% for women, with a 46% (men) and 59% (women) 
cumulative risk for extracolonic cancers. Note that these estimates or CRC 
risk are about one third of those published by Vasen et al [61]studying a 
smaller number of cases from the same registry (but not correcting for 
ascertainment bias) . 
Jenkins et al in 2006 [69] identified 17 MMR mutation carriers (8 hMLH1, 4 
hMSH2, 4 hMSH6, 1 hPMS2) from 131 individuals with young (under 45 
years) onset CRC, unselected for family history. They determined the 
mutation carrier status and cancer history for first and second degree relatives 
of these probands, and used a modified segregation analysis method to correct 
for ascertainment bias. They reported a cumulative CRC risk to age 70 years 
for MMR mutation carriers (all mutations) of 45% for men, and 22% for 
women. For hMLH1 or hMSH2 mutation carriers only, these risks were 60% 
for men, and 56% for women.  
Choi et al in 2009 [70] studied 32 North American families who carried 
hMLH1 or hMSH2 mutations, recruited from the Ontario Familial Colorectal 
Cancer Registry. They used two different methods to determine penetrance of 
these mutations for CRC (they did not report on extracolonic tumours). 
Firstly, they applied standard (Kaplan- Meier) survival analysis to the 
mutation positive first-and-second degree relatives of the probands. They then 
used a modified segregation- based approach to allow the entire cohort 
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(including probands and those with a negative or unknown mutation status) to 
be included in a model designed to correct for ascertainment bias. The two 
methods gave similar results. As assessed by Kaplan- Meier estimates, 67% 
of men and 51% of women had developed CRC by the age of 70 years. Using 
segregation analysis, the corresponding figures were 60% and 47%. A 
weakness of this study was the small numbers of proven mutation positive 
subjects who were not probands in their study group (25 hMLH1 and 35 
hMSH2 carriers in total), but this paper is unique in demonstrating the 
equivalence of these two methods of calculating cancer risk in Lynch 
syndrome. 
Stoffel et al in 2009[71] reported on 147 families from the USA with 
mutations in MMR genes (55 hMLH1, 81 hMSH2, 11 hMSH6). They used a 
similar method of modified segregation analysis to Quehenberger et al 
[68]and Jenkins et al [69]. In their cohort, the cumulative risk of CRC in 
hMLH1 mutation carriers was 97% in men and 53% in women and the 
cumulative risk of extracolonic cancers was 33% for women by the age of 70 
years. In hMSH2 mutation carriers, there was a cumulative risk of CRC of 
52% in men and 39% in women and the cumulative risk for extracolonic 
cancers in women was 45%  by the age of 70 years.  
Plashke et al [72]compared the oncological manifestations of hMSH6 mutation 
carriers with hMLH1 and hMSH2 mutation carriers recruited from the German 
HNPCC registry. They did not attempt to correct for ascertainment in any 
way, and included probands in their analysis. They found the median age of 
onset of CRC to be ten years higher in hMSH6 mutation carriers than in 
carriers of mutations in the two other genes (54 vs. 44 years) but there was no 
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difference in cumulative risk by age for extracolonic tumours between these 
two groups. 
Barrow et al in 2008 [73] studied 121 families with proven MMR mutations 
(51 hMLH1, 59 hMSH2 and 11 hMSH6) from the North West of England. 
They assumed that any first degree relatives of mutation carriers who 
developed an HNPCC- related cancer was mutation positive (which they 
reasonably justified by noting that only 3/185 first degree relatives with such 
cancers who were tested were found not to be mutation carriers). They 
attempted to reduce the impact of ascertainment bias by including families 
who underwent genetic testing after being selected by the Bethesda criteria 
[43] (which are more sensitive and less specific for detecting Lynch
syndrome) as well as Amsterdam II criteria [39]. They also randomly 
assigned an assumed carrier status to unaffected relatives (based on the 
proportion of unaffected individuals (stratified by age) who underwent 
genetic testing and were found to be mutation negative). They did, however, 
include probands in their analysis. They reported a cumulative risk of CRC to 
age 70 years of 54% for men and 46% for women (all mutations combined). 
For hMLH1 mutation carriers the cumulative risk for CRC at age 70 years was 
58% for men and 49% for women. For hMSH2 mutation carriers this risk was 
56% for men and 51% for women. 
Bonadona et al in 2011 [74] studied families with Lynch syndrome recruited 
from 40 French cancer genetics clinics. They identified 537 families with 
MMR gene mutations (248 hMLH1, 256 hMSH2 and 33 hMSH6). They applied 
the genotype- restricted likelihood method (described by Alarcon et al [75], 
this is based on similar principles to the maximum likelihood method used by 
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Quehenberger et al [68]) to correct for ascertainment). They reported a similar 
cumulative risk of CRC by age 70 years for hMLH1 and hMLH2 carriers (59% 
and 57% respectively), but a significantly lower risk for hMSH6 carriers 
(25% by age 70 years). They found no difference in risk between men and 
women. The cumulative risk for women by age 70 years of developing 
endometrial cancer was 54% for hMLH1 mutation carriers, 21% for hMSH2 
mutation carriers, and 16% for hMSH6 carriers. Ovarian cancer cumulative 
risks to age 70 years were 20% and 24% for hMLH1 and hMSH2 mutation 
carriers respectively, and 1% for hMSH6 mutation carriers.  
Dowty et al in 2013[76] studied almost 18000 members of 166 hMLH1 and 
224 hMSH2 mutation- carrying families from the Colon Cancer Family 
Registry (which recruits subjects from Australasia, Canada and the USA) 
using modified segregation analysis to correct for ascertainment bias. They 
reported a cumulative risk of CRC by age 70 years in hMLH1 mutation 
carriers of 34% for men and 36% for women. For hMSH2 mutation carriers 
these risks were 47% and 37% respectively. They also demonstrated a high 
level of CRC risk heterogeneity. It is not known whether this is due to 
environmental or genetic factors, but did not appear to be related to 
geographic distribution, type of mutation (protein truncating vs. others) or 
method of ascertainment (family vs. population). The authors noted that a 
weakness in their estimate of penetrance, which is shared by other studies, is 
that the effect of surveillance colonoscopy and polypectomy on CRC risk is 
not well known. 
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 3.1.2.3 Cancer risk in Lynch syndrome: summary 
It is apparent from the above studies that there is marked variability of 
reported cancer risk in Lynch syndrome, but the following observations are 
generally consistent within the current literature[77]: hMLH1 and hMSH2 
mutations carry a similar risk for CRC, and this risk is higher than for hMSH6 
mutations; Men with Lynch syndrome appear to carry a higher CRC risk than 
women for all mutations; Endometrial cancers are the commonest 
extracolonic malignancies (Table 6 summarises the reported lifetime risks for 
extracolonic malignancies in Lynch syndrome). 
 Even if only hMLH1 mutation carriers are considered, and the CRC risk of 
men and women calculated separately, there is still significant variability in 
the reported CRC risk. Figure 5 below illustrates the seven previous reports 
that have documented cumulative CRC risk for hMLH1 mutation carriers at 
more than one age [61, 68, 70, 71, 73, 74, 76] (rather than a single statement 
of lifetime risk).  This variability can at least be partly accounted for by 
differences in statistical methods used, but note that Stoffel et al [71] reported 
a considerably higher CRC risk than Quehenberger et al [68] and Jenkins et al 
[69] despite using a similar methodology. This suggests that there are real
differences in risk between groups of subjects with Lunch syndrome, even if 
they carry mutations in the same gene.  
Those studies that have not corrected for ascertainment bias have generally 
reported a higher penetrance for hMLH1 mutations than those that have not, 
and it is often assumed that the lower estimates are more accurate. It is 
possible, however, that CRC risk may truly be higher in individuals from 
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families that are ascertained due to multiple CRC cases if their mutations are 
inherently more pathogenic, or because of other genetic or environmental 
factors specific to those families [69]. Methods that reduce ascertainment bias 
by correcting for these (currently unknown) factors may underestimate cancer 
risk in members of the high risk families that present to family cancer clinics 
and are included in registries [77].  
At a practical level, patients undergoing genetic counselling may be more 
usefully informed by knowing the cancer risk specific to their own family than 
by knowing the statistically more complex estimate of penetrance for Lynch 
syndrome overall. 
 
Table 6 Lifetime risk of extracolonic cancers in subjects with Lynch 
syndrome 
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Figure 5 Cumulative CRC risk for hMLH1 mutation carriers 
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 3.1.3 Aim 
The purpose of this study was to document the cancer risk of subjects who 
carry the C1528T (Exon 13) mutation in the hMLH1 gene in order to give 
accurate genetic counselling to members of the affected families, and to 
assess whether screening for extracolonic malignancies should be undertaken 
(in addition to CRC surveillance, which is already offered to these subjects). 
 3.1.4 Methods 
Between 1997 and 2007, genetic testing was performed on 590 members of 
17 families known to carry the C1528T (Exon 13) mutation in the hMLH1 
gene. Of these, 200 subjects were found to be germline mutation carriers. All 
of these 200 mutation carriers were offered surveillance colonoscopy every 2 
years until age 30, and annually thereafter, in keeping with current guidelines 
[9, 46] 
Subjects who were known to carry the mutation and were diagnosed with 
resectable colon cancers or adenomas with high grade dysplasia were offered 
a subtotal colectomy and ileorectal anastomosis. Subjects with curable rectal 
cancers were offered rectal resections after radiotherapy as indicated. Those 
subjects who had undergone segmental colonic resections prior to being 
recognized as having Lynch syndrome were all offered surveillance of their 
remaining colon. 
Surveillance colonoscopy has been shown to delay the onset of colorectal 
cancer. In order to calculate the risk of developing colorectal cancers in 
subjects who carry this mutation, therefore, we included only those subjects 
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who had developed colorectal cancers before they were offered surveillance 
colonoscopy (21 cases) and those who had declined surveillance (50 cases) in 
this analysis.   
Screening for cancers other than colorectal (specifically endometrial, cervical, 
ovarian and breast cancer) was not routinely offered, so the incidence of 
extracolonic tumours was determined for the entire cohort of 200 subjects. 
Subjects were followed up prospectively from the time of genetic testing until 
December 2008. Patients were followed up twice annually. At follow up a  
clinical history was taken, with particular attention to symptoms of colorectal 
and endometrial carcinoma, a clinical examination was performed, and the 
subjects were investigated as indicated if there was any clinical suspicion of 
malignancy. If the subjects declined the offer of attending for the clinical 
examination, he history was taken telephonically. All cancer diagnoses were 
made histologically from biopsies or operative specimens.  
 3.1.4.1 Statistics 
Colorectal cancer risk was calculated using the Kaplan- Meier technique, and 
comparison between groups was done using the log rank method.  In order to 
avoid introducing lead- time bias into these analyses, colorectal cancer risk 
was calculated from birth rather than from diagnosis or enrolment in the 
study. Categorical data were compared using the chi- square test. Statistical 
analysis was done using Statistica® (Mariakerke, Belgium) software. 
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 3.1.4.2 Ethics 
All subjects were counselled and gave informed consent for genetic testing. 
The patients who declined surveillance were offered it again whenever they 
were contacted. The Health Sciences Faculty Research Ethics Committee of 
the University of Cape Town approved the study. 
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 3.1.5 Results 
 3.1.5.1 Colorectal malignancies 
Of the 200 mutation- positive subjects, 71 (45 men and 26 women) did not 
undergo colonoscopic surveillance. They were followed up for a mean of 4 
years (range 0 to 18 years) after genetic counselling. They were a mean age of 
43 years (range 17 to 83 years) at their most recent follow up or death.  
Thirty- six of these 71 subjects (51%) developed colorectal cancers. The 
youngest was 17 years old, and the oldest was 73 years old at the time of first 
CRC diagnosis. The ages of diagnosis are illustrated below (Figure 6). No 
adenomas were diagnosed in these subjects.  
 Figure 6 Histogram showing the age in years of onset of CRC in subjects 
who did not undergo surveillance. 
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Among the subjects who did not undergo surveillance, Kaplan- Meier 
estimate of median age of first CRC diagnosis was 44 years (42 years for 
men; 48 years for women. There was no significant difference in age of CRC 
diagnosis between men and women (p=0.096)). The risk of developing a 
colorectal cancer by age 65 years was 92% (standard error 7%). The oldest 
mutation- positive subject not to develop CRC died at the age of 83years. The 
Kaplan- Meier estimates for colorectal cancer risk are illustrated below 
(Figure 7).  
 
Figure 7 Kaplan- Meier estimates of age of diagnosis of CRC  
 
Three of the subjects had synchronous colorectal cancers (one of whom had 
three cancers at his first operation), and four developed metachronous 
tumours (one of these developed a metachronous transverse colon tumour, 
underwent a total colectomy, and later developed a rectal cancer), so a total of 
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45 colorectal cancers were diagnosed in this group of 71 subjects.  The sites 
and stages of the colorectal cancers are presented below (Table 7 and Table 
8). In one case, the patient’s operation notes could not be obtained, and the 
site of his tumour could not be identified. Of the colonic cancers whose site 
was recorded, 29/44 (66%) were situated proximal to the splenic flexure and 
15/44 (34%) were found at the splenic flexure or more distally (p=0.05).  
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Table 7 Sites of colorectal cancers. 
Site of tumour Number 
Caecum 9 (20.0%) 
Ascending 7 (15.6%) 
Hepatic flexure 5 (11.1%) 
Transverse 7 (15.5%) 
Splenic flexure 3 (6.7%) 
Descending 5 (11.1%) 
Sigmoid 2 (4.4%) 
Rectosigmoid 1 (2.2%) 
Rectum 5 (11.1%) 
Unknown 1 (2.5%) 
Total 45  
 
 
 
Table 8 Stage distribution of colorectal cancers. 
Patients with synchronous tumours at presentation have been staged 
according to the most advanced tumour only. 
Duke’s Stage Number 
A 5   (12%)  
B 13 (31%) 
C 12 (29%) 
D 7   (17%) 
Unknown 4   (10%) 
Total  41 
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 3.1.5.2 Correcting for possible ascertainment bias 
In order to determine whether the estimated CRC was falsely high due to 
ascertainment bias (where subjects with young onset CRC are more likely to 
undergo genetic testing than those who are diagnosed with the disease later 
(or who are never diagnosed with CRC in their lifetime)) this analysis was 
repeated including only those subjects who had not been diagnosed with CRC 
prior to being offered genetic testing (i.e. those who were identified as being 
at risk purely on the basis of family history and not phenotype). In this subset 
of 50 subjects (28 men and 22 women), the Kaplan- Meier estimate of median 
age of first CRC diagnosis was 47 years (44 for men and 47 for women; there 
was no significant difference in age of CRC diagnosis between men and 
women (P = 0.44)). The Kaplan- Meier estimates of CRC risk in this 
subgroup are illustrated in below (Figure 8) 
Figure 8 Kaplan- Meier estimates of age of diagnosis of CRC including 
only those patients who had no CRC diagnosis prior to genetic testing. 
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 3.1.5.3 Extracolonic malignancies 
Of the entire cohort of 200 subjects, 102 were men and 98 were women. Their 
mean age was 41 years at death or last follow up (range 18 to 83), and they 
were followed up for a mean of five years (range 0-18). Nineteen extracolonic 
malignancies were diagnosed in 18 of these 200 subjects (9%). The 
commonest were breast (in 6/98 (6%) of women) and endometrial (in 3/98 
(3%) of women). The extracolonic malignancies are listed below (Table 9). 
 
 
Table 9 Sites of extracolonic malignancies 
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 3.1.6 Discussion 
A reasonably large cohort of subjects with Lynch syndrome who all carry the 
same predisposing mutation is a rarity, and provides an important vehicle for 
research aimed at understanding the role of genes and environment in cancer 
risk in order to improve surveillance strategies. This is the first study to 
prospectively record the cancer risk of a cohort of subjects carrying a single 
hMLH1 mutation.  
The subjects developed colorectal cancer at a young age (median 44 years), 
and frequently developed synchronous or metachronous colorectal tumours. 
This mutation has a high penetrance, with 92% of subjects developing a 
colorectal cancer by age 65 years. Cumulative CRC risk for carriers of the 
C1528T (Exon 13) mutation in the hMLH1 gene compared with previous 
reports of age- specific CRC risk in hMLH1 mutation carriers is illustrated in 
Figure 9. There was no difference in the frequency or age of onset of 
colorectal cancers between men and women in contrast to previous reports, 
which have generally found the penetrance to be higher in men.  
Ascertainment bias may lead to an overestimation of CRC risk in Lynch 
syndrome. Those families with the highest numbers of cancers are the most 
likely to be studied, and if one relies on clinical criteria to diagnose HNPCC, 
those subjects who do not develop tumours (or who develop them later in life) 
may be excluded from the analysis. In this study, an attempt was made to 
identify the entire cohort of mutation positive members of the families 
studied, regardless of whether they have developed cancers, and to follow 
them up prospectively. This approach does not eliminate ascertainment bias, 
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but should reduce it. In order to further reduce ascertainment bias, a subgroup 
analysis was done which included only subjects who had not been diagnosed 
with CRC prior to genetic testing (i.e. who were suspected of having Lynch 
syndrome purely from family history and not phenotype). The results for this 
subgroup were similar to those for the larger cohort. 
 
Figure 9 Cumulative risk of CRC for carriers of the C1528T (Exon 13) 
mutation in the hMLH1 gene (in bold red) compared with other reports 
of CRC risk in hMLH1 mutation carriers.  
Note the high penetrance of the C1528 (exon 13) mutation. Age is given in 
years. 
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The results of studies of cancer risk in Lynch syndrome may be influenced by 
interventions aimed at preventing the development of cancers.  In order to 
avoid this, all subjects who had undergone surveillance colonoscopy were 
excluded from the estimation of colorectal cancer risk. The drawback of this 
approach, however, is that these cancers were only diagnosed once they 
become clinically apparent, with a variable lead time from the development of 
premalignant adenomas and early asymptomatic cancers.  
Endometrial carcinoma is the commonest extracolonic cancer among women 
with Lynch syndrome, with a reported lifetime risk of up to 30% in carriers of 
hMLH1 mutations (and higher in hMSH2 and hMSH6 mutations (Table 9)). 
Current guidelines advocate screening for endometrial cancer in women with 
Lynch syndrome [9, 46] despite there being no evidence that it confers a 
survival benefit [86-88]. It is even argued that prophylactic hysterectomy with 
or without oophorectomy should be offered to women with Lynch syndrome 
who have completed their families [9, 46]. The best evidence to support this is 
from Schmeler et al[89], who performed a large retrospective study of 315 
women with Lynch syndrome, some of whom had undergone prophylactic 
gynaecological surgery. Endometrial cancer occurred in 33% and ovarian 
cancer in 5% of the control group (who had not undergone surgery), and this 
risk was eliminated by prophylactic surgery.  In women who carry the 
C1528T (Exon 13) mutation in the hMLH1 gene, only 3 of 98 (3%) women 
developed endometrial carcinoma. There were also no cases of ovarian cancer 
in this cohort of women, so screening for endometrial or ovarian cancers is 
not clearly indicated in women who carry this particular mutation, and 
prophylactic gynaecological surgery does not appear warranted. It should be 
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noted, however, that these tumours were diagnosed only once they were 
clinically apparent (as no screening was performed), and so early cancers may 
have been missed. 
Breast cancer was the commonest extracolonic malignancy in this cohort, 
affecting 6 of 98 (6%) women. This is unusual, as other studies of 
extracolonic cancer risk in hMLH1 mutation carriers [62, 64, 67, 68, 71, 84, 
85] have not reported an increased risk of breast cancer (see Table 9 above). 
Immunohistochemical evidence of mismatch repair gene inactivity has been 
documented in some cases of breast cancer in these families [90] so breast 
cancer can be regarded as a manifestation of Lynch syndrome in carriers of 
this mutation.  
Recent guidelines recommend screening for urothelial cancers in Lynch 
syndrome patients by urinalysis for microscopic haematuria[9] and/ or urine 
cytology [9, 46] although there is no evidence for the efficacy of either 
screening test in this setting [9, 46, 91]. The only large study of screening for 
urothelial cancers in HNPCC by urine cytology found that the test performed 
extremely poorly- sensitivity was 29%, approximately 1000 tests needed to be 
performed to detect one cancer, and false positive tests were ten times as 
common as true positives. Among carriers of the C1528T (Exon 13) mutation 
in the hMLH1 gene, no urothelial cancers were diagnosed. This justifies the 
current policy of not offering screening for these cancers in members of this 
family.  
Five subjects developed cancers of the duodenum, small bowel and bile duct, 
so the risk of developing any one of these tumours was low, in keeping with 
reports of other Lynch syndrome families.   
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In conclusion, subjects who carry the C1528T (Exon 13) mutation in the 
hMLH1 gene carry a high lifetime risk of colorectal cancer, regardless of their 
gender, but have a relatively low incidence of extracolonic tumours, most 
notably endometrial carcinomas. This information allows accurate genetic 
counselling to members of this family, and justifies the current policy of not 
offering routine gynaecological screening or prophylactic gynaecological 
surgery to women who carry this mutation.  
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 3.2 PAPER II: Surveillance colonoscopy improves 
survival in Lynch syndrome:  A study of subjects 
carrying a single mismatch repair gene mutation [2] 
 3.2.1 Abstract 
 3.2.1.1 Introduction 
Previous studies have shown a benefit for surveillance colonoscopy in 
heterogeneous groups of subjects with suspected or proven Lynch syndrome. 
The aim of this study is to investigate whether surveillance colonoscopy 
improves survival in subjects who all carry a single mismatch repair gene 
defect. 
 3.2.1.2 Methods 
This is a prospective cohort study of 178 subjects who carry a mutation of the 
C1528T (Exon 13) mutation in the hMLH1 gene. They were offered 
surveillance colonoscopy between 1988 and 2006, and were followed up until 
September 2007. 
 3.2.1.3 Results 
129 subjects underwent surveillance colonoscopy, and 49 declined. After a 
median follow up of 5 years, colorectal cancer was diagnosed in 14/129 
(11%) of subjects in the surveillance group, and 13/49(27%) in the non- 
surveillance group (p=0.019). Cancers in the surveillance group were detected 
at an earlier stage than in the non- surveillance group (P=0.032)  
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Death from colorectal cancer occurred in 3/129 (2%) of subjects in the 
surveillance group, and 6/49 (12%) in the non- surveillance group (p=0.021).  
The Kaplan- Meyer estimates for median survival from birth were 78 years in 
the surveillance group, and 55 years in the non- surveillance group (p=0.024) 
The Kaplan- Meyer estimates for median colorectal cancer free survival from 
birth were 73 years in the surveillance group and 47 years in the non- 
surveillance group (p=0.0089).  
 3.2.1.4 Conclusion 
 Surveillance colonoscopy was associated with improved overall and 
colorectal cancer- specific survival. 
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 3.2.2 Introduction 
There is strong evidence (from observational and randomised trials) that 
endoscopic screening of the general population (whether by flexible 
sigmoidoscopy or complete colonoscopy) can prevent bowel cancers by 
removing premalignant adenomas[92]. It can also lead to the detection of 
earlier stage tumours and thereby reduce cancer- related mortality (CRC stage 
at diagnosis strongly predicts survival as illustrated below (Figure 10). The 
commonly used staging systems for CRC are summarised below (Table 10 & 
Table 11). The survival benefit of population screening for CRC by 
colonoscopy has been confirmed in a recent meta- analysis [93]. A number of 
other studies have explored the utility of surveillance for CRC in the setting 
of Lynch syndrome 
 
Figure 10 Survival after surgery for CRC grouped by Dukes’ stage at 
diagnosis.  
Median survival for Dukes’ A,B,C and D tumours were 112, 108, 56 and 
11 months respectively; P<0.0001. (The author’s own analysis of 
unpublished data from the Geelong Hospital colorectal database). 
 83 
Table 10 American Joint Committee on Cancer (AJCC)/ Union 
Internationale Contre le Cancer (UICC) TNM staging definitions[94] 
Category Definition 
Primary tumor (T) TX Primary tumor cannot be assessed 
  TO No evidence of primary tumor 
  Tis Carcinoma in situ  
  T1 Tumor invades the submucosa 
  T2 Tumor invades the muscularis 
propria 
  T3 Tumor invades through the 
muscularis propria into the 
subserosa or into the 
nonperitonealized pericolic or 
perirectal tissues* 
  T4 Tumor directly invades other 
organs or structures or perforates 
the visceral peritoneum* 
Regional lymph 
nodes (N) 
NX Regional lymph nodes cannot be 
assessed 
  N0 No regional lymph nodes 
metastasis 
  N1 Metastasis in one to three lymph 
nodes 
  N2 Metastasis in four or more lymph 
nodes 
Distant metastasis 
(M) 
MX Presence of distant metastasis 
cannot be assessed 
  M0 No distant metastasis 
  M1 Distant metastasis 
* For simplicity, the subdivisions of T3 and T4 have not been included. 
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Table 11 AJCC/UICC and Dukes’ stage groupings 
 
*Dukes did not include stage D in his original classification, this was added in 
1976[96], and has become part of the standard nomenclature[97]. 
  
AJCC/UICC Stage Groupings[94] Dukes’ 
stage[95] 
Stage 0 Tis N0 M0 N/A 
     
Stage I T1 N0 M0 A 
  T2 N0 M0 A 
     
Stage 
IIA 
T3 N0 M0 B 
Stage 
IIB 
T4 N0 M0 B 
     
Stage 
IIIA 
T1, T2 N1 M0 C 
Stage 
IIIB 
T3, T4 N1 M0 C 
Stage 
IIIC 
Any T N2 M0 C 
     
Stage IV Any T Any N M1 D* 
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 3.2.2.1 Surveillance for CRC in Lynch syndrome 
In 1987, Mecklin et al [98] reported on the results of a single episode of 
screening for colonic neoplasms in members of 22 Finnish families with 
‘cancer family syndrome’ (which they defined as families with at least three 
first- degree relatives with CRC). This study included only asymptomatic 
family members who had not previously been diagnosed with CRC. They 
identified 236 subjects, of whom 137 attended for a single screening 
investigation (colonoscopy in 58 and double- contrast enema plus flexible 
sigmoidoscopy in 79). Thirteen adenomas were found in ten subjects. Two 
subjects were diagnosed with potentially curable (Dukes’ A and B stage) 
colon cancers, underwent surgery and were alive at 18 and 30 months’ follow 
up. An inconsistency in this report is that although it is stated that only 
asymptomatic subjects were included, the man with the Dukes’ B tumour 
‘already had diffuse abdominal symptoms at the time of the examination’ so 
his diagnostic examination cannot strictly be considered a screening test. The 
authors noted that the number of neoplasms detected was approximately ten 
times the average yield for screening of the general population. Two subjects 
in the group who declined surveillance developed CRC during the three year 
study period, so the incidence of CRC was similar between the groups, but the 
tumours in the unscreened group were more advanced (although the paper 
was underpowered to detect any difference in tumour stage, it has been cited 
as demonstrating that screening can detect tumours at an early stage[99]).  
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Vasen et al in 1989 [100] studied members of 22 HNPCC families from the 
Netherlands. In this paper, they compared subjects who had colorectal 
neoplasms detected by screening (20 patients) with those who had developed 
clinical signs or symptoms (87 patients). Fourteen adenomas were detected by 
screening, and none were detected in the symptomatic group. There were six 
invasive CRC detected by screening, and 87 in the symptomatic group. The 
stages of the cancers in the two groups were as follows: Symptomatic group: 
6 Dukes’ A; 37 Dukes’ B; 21 Dukes’ C; 10 Dukes’ D vs. 2 Dukes’ A and 4 
Dukes’ B in the screened group. The authors concluded that ‘screening leads 
to the early detection of colorectal carcinomas…’ although there is no 
statement of statistical significance in the paper, and if one applies the chi- 
square test to their data, there is no significant difference in stage of cancer 
between the groups (P=0.10). 
In 1995, both the Finnish and Dutch groups published long- term follow up 
results of their surveillance programmes, which by this time were well 
established. Jarvinen et al [101] offered 3- yearly surveillance by colonoscopy 
or barium enema plus sigmoidoscopy to the 22 Finish families described 
above. A total of 133 subjects underwent screening, and a control group of 
118 did not. They observed a significant reduction in CRC incidence in the 
screened group (6 vs. 14, P=0.03) presumably due to the much higher 
number of adenomas detected (22 vs. 2, P=0.0002). There was a trend 
towards reduced mortality in the screened group, but this did not reach 
statistical significance (6 vs. 12 deaths, P=0.08). There were no deaths 
directly due to CRC in the screened group, compared to five in the control 
group, but again this did not reach statistical significance.  The stages of the 
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CRC diagnosed in the two groups were as follows: Control group: 3 Dukes’ 
A; 4 Dukes’ B; 1 Dukes’C, 6 Dukes’ D compared with 2 Dukes’ A and 4 
Dukes’ B in the screened group. The authors state that the stage distribution 
of carcinomas was more favourable in the screened group, but no mention is 
made of statistical significance, and if one applies the chi- square test to their 
data, no significant difference can be detected (P= 0.19).  
Vasen et al [102] reported on the results of a similar surveillance programme 
(colonoscopy or barium enema plus sigmoidoscopy every two to three years) 
for members of 50 Dutch families who met the Amsterdam criteria for 
diagnosis of HNPCC[37]. They compared the stage distribution of CRC that 
were detected by screening with those that were not. These results were as 
follows: Control group: 10 Dukes’ A; 75 Dukes’ B; 51 Dukes’ C; 25 Dukes’ 
D vs. 2 Dukes’ A and 4 Dukes’ B in the screened group. The authors 
concluded that ‘periodic examination… allows the detection of cancer at an 
earlier stage…’ although, as in the above studies, the authors did not make 
any statement about statistical significance, and if one analyses their data, the 
two groups are not significantly different (P=0.47, Chi- square test). They also 
reported a difference in 5- year survival between the two groups (87% in the 
screened group vs. 63% in the control group), but with no statement of 
statistical significance. This group also published another report in 1995 [103] 
in which they noted an unexpectedly high number of interval cancers which 
occurred between 2 and 5 years after a normal colonoscopy (and before the 
next planned surveillance endoscopy). They concluded that this supported the 
hypothesis that the progression from adenoma to carcinoma was accelerated 
in HNPCC, and that surveillance intervals should be reduced to 1- 2 years. 
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This recommendation was strengthened in a publication by the same group in 
2002, in which they reported the incidence of CRC in 887 members of 114 
HNPCC families who had been enrolled in their surveillance programme. 
They calculated that there was a 10.5% cumulative risk of developing CRC 
by ten years’ follow up (so surveillance did not totally prevent the 
development of CRC), but that all but one of the subjects who developed 
CRC within two years of a screening investigation had Dukes’ A or Dukes’ B 
(i.e. potentially curable by surgery alone) cancers, whereas six Dukes’ C 
cancers were detected after a longer interval. The authors reasonably argued 
that this provided a strong case against prophylactic colectomy to prevent 
CRC as long as appropriate (1-2 yearly) surveillance occurred. 
By the year 2000, the Finnish group could report on 15 years of CRC 
screening in HNPCC, and published a landmark paper on the subject [104]. 
By this time, mutational analysis for MMR mutations was available, and 
mutations in the hMLH1 gene (19 families) and hMSH2 gene (one family) had 
been identified in 20 of the 22 families on which they had previously 
reported. Three- yearly colonoscopies had been performed on 133 members 
of these 22 families, and 119 control subjects had declined screening. They 
reported a significant reduction in the incidence of CRC (6% vs. 16% 
P=0.014). Of this cohort, 44 subjects in the surveillance group, and 46 in the 
control group were proven carriers of MMR gene mutations. The results were 
even more dramatic when this subset was studied separately. Among MMR 
mutation carriers, there was a reduction in CRC from 41% (19 of 46) in the 
control group to 18% (8 of 44) in the surveillance group (P=0.02). This was 
attributable to the removal of adenomas from 13 mutation carriers who 
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underwent surveillance. They further reported that the stage distribution of 
cancers was more favourable in the surveillance group, illustrated below 
(Table 12). There were now sufficient numbers to reach statistical 
significance (P=0.03).  
Most notably, surveillance was associated with a decrease in overall mortality 
among mutation carriers (4 vs. 12 deaths, P=0.05) and in the overall cohort 
(10 vs. 26 deaths, P=0.003). 
Table 12 Stage distribution of cancers from screened or control groups 
(Jarvinen et al 2000 [104]) 
Dukes’ stage Control group Screened group 
A 2 3 
B 4 4 
C 1 0 
D 6 0 
In the same year, Renkonen- Sinisalo et al [105] published a retrospective 
review of 150 CRC cases diagnosed in 57 Finnish HNPCC families. They 
found a more favourable stage distribution in the cancers diagnosed at 
screening (P<0.001) and improved CRC- specific survival in the screened 
group (although no difference in overall survival could be detected). The 
authors concluded that surveillance enables early detection of CRC in 
HNPCC, and reduces CRC mortality. However, they noted that both lead- 
time bias (in which early detection of the disease leads to longer survival from 
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the time of diagnosis, without necessarily conferring improved survival from 
the unknown time at which the disease first develops) and selection bias could 
falsely favour the surveillance group in a study of this design.  
Also in 2005, Dove- Edwin et al [106] reported on the results of the 
colonoscopic surveillance program for the St Mark’s Hospital family cancer 
registry in the U.K. They included families with HNPCC (as defined by the 
Amsterdam I or II criteria) and genetically proven Lynch syndrome as well as 
other families with lesser CRC risks. Among the 554 subjects from 290 
HNPCC or Lynch syndrome families they detected eight CRC on surveillance 
colonoscopy (after the initial surveillance endoscopy), which they calculated 
to be 43% of the expected number based on their estimated risk in an 
unscreened population. Note that there were no unscreened controls in this 
study that could allow direct comparison.  
In 2005, Arrigoni et al [107] reported on an Italian cohort of 22 families with 
HNPCC who were enrolled in a two- yearly colonoscopic surveillance 
programme. Their diagnosis was made using the Amsterdam criteria and not 
by genetic testing, which was not offered to these families.  Of the 331 
individuals identified as being at risk, 199 underwent surveillance. After a 
mean follow up of two years, 11 subjects were found to have adenomas on 
screening. Seven CRC were diagnosed in the surveillance group, and five in 
the non- surveillance group (not significantly different). The CRC diagnosed 
at screening were at an earlier stage, with a higher proportion being Dukes’ A 
tumors (P<0.02), but it is interesting to note that in both groups all CRC were 
staged as Dukes’ A or B. 
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De Jong et al, in 2006 [108] reported on the cancer- related mortality rates of 
subjects from Lynch syndrome families from the Dutch HNPCC Registry. A 
family was included if at least one member of the family was a proven MMR 
mutation carrier. They identified almost 3000 subjects from 140 families, and 
documented their standardised mortality rates (SMR) over three time periods 
(1960-1975, 1975-1990 and 1990-2004). They observed a decrease in SMR 
for CRC over time (P<0.001) as well as when comparing patients who did or 
did not undergo surveillance (SMR 6.5 vs. 23.9, P<0.001). They did not 
observe any such decrease for other cancers. They attributed the improvement 
in SMR to the introduction of a surveillance program in the late 1980’s. 
However, the authors did not discuss the possible effect that changes in 
cancer therapy over this time period may have had on mortality rates, but it is 
likely that this may also have influenced their results. This highlights the 
challenge in interpreting studies that include historical controls. 
In 2007, the Finnish group [109] published long term results of their 
colonoscopic surveillance programme for 420 subjects who carried a MMR 
mutation, and who had not had been diagnosed with CRC before 
commencement of screening. They calculated the cumulative risk by age 60 
years of developing an adenoma to be 68% in men and 48% in women, and 
the risk of CRC by age 60 to be 35% in men and 22% in women. Only five 
patients died of CRC in this cohort during a median follow up time of seven 
years.  
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 3.2.2.2 Surveillance colonoscopy is offered for Lynch syndrome by the 
University of Cape Town 
Since 1988, the University of Cape Town has offered surveillance 
colonoscopy to individuals with suspected HNPCC based on family history. 
Mutational analysis was introduced in 1997.  This has led to the detection of 
thirteen mutations in the hMLH1 and hMSH2 genes in 33 families, the 
commonest being the C1528T (Exon 13) mutation in the hMLH1 gene. At the 
time of publication of this study, 200 proven germline mutation carriers had 
been identified in 17 families, all of whom were offered surveillance. 
 3.2.2.3 Introduction- summary 
Previous studies have demonstrated the efficacy of surveillance colonoscopy 
in HNPCC and Lynch syndrome. These studies have included heterogeneous 
groups of subjects with multiple different mutations, and (in some studies) 
also subjects without proven mutations. A large cohort of subjects who all 
carry the same MMR mutation provides a unique opportunity to test the 
efficacy of surveillance colonoscopy in a genetically homogenous group of 
subjects.  
 3.2.3 Aim 
The aim of this study was to investigate whether surveillance colonoscopy 
improves survival in subjects who carry a single MMR germline mutation 
(the C1528T (Exon 13) mutation in the hMLH1 gene). 
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 3.2.4 Methods 
Two hundred subjects who with a proven germline C1528T (exon 13) 
mutation in the hMLH1 gene were identified. Twenty- one of them had been 
treated for colorectal cancer before they were offered genetic testing or 
colonoscopic surveillance and they were excluded from this study. A further 
patient underwent positive genetic testing at age 83 years, and died before 
being offered surveillance, and so was also not included. The remaining 178 
subjects were all offered surveillance colonoscopy between 1988 and 2006, 
and were studied prospectively.   
These 178 subjects were included in this analysis regardless of whether their 
genetic testing was done before or after they were offered screening 
colonoscopy. None had symptoms suggestive of colorectal cancer when they 
were first offered surveillance.  Surveillance colonoscopy was offered from 
the age of 18 years, or 10 years before the age of onset of disease of the 
youngest relative with cancer (whichever age was the older). If the subject 
was only identified as being at risk when already older than this, surveillance 
was offered to commence at the earliest opportunity. Colonoscopy was 
offered every 2 years until age 30 years, and annually thereafter.  
Colonoscopies were performed either in the endoscopy unit at Groote Schuur 
Hospital in Cape Town, or by a mobile endoscopic unit which visited rural 
hospitals annually. Subjects were considered to have undergone surveillance 
if they underwent at least one colonoscopy before developing symptoms 
suggestive of colorectal cancer.  
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Patients with colorectal cancers or adenomas with high grade dysplasia were 
offered a subtotal colectomy and ileorectal anastomosis. 
Subjects were followed up by physical or telephonic contact from the time 
they were first offered surveillance colonoscopy until September 2007. 
Records were kept of colonoscopic findings, and of the histopathology of any 
abnormalities found. The cause of death was determined from medical 
records and death certificates. Where necessary, records from other 
institutions were obtained. 
 3.2.4.1 Statistics 
The Kaplan- Meyer and log rank techniques were used to calculate overall 
and colorectal cancer- free survival. Categorical data were compared using 
the chi- squared test. Continuous data were compared using the Student’s t- 
test. Statistical analysis was performed using Medcalc® (Mariakerke, 
Belgium) software. 
 3.2.4.2 Ethics 
Subjects were counselled and gave informed consent for genetic testing, and 
for all procedures performed. Patients who declined surveillance were offered 
it again whenever they were contacted. Ethics committee approval for the 
study was given by the Health Sciences Faculty Research Ethics Committee 
of the University of Cape Town  
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 3.2.5 Results 
Of the 178 subjects, 129 chose to undergo surveillance colonoscopy, and 49 
declined. The two groups were similar in age when they were first offered 
surveillance (mean 33 years (standard deviation 12.2) in the surveillance 
group, and 35 years (standard deviation 13.0) in the non- surveillance group 
(P=0.41)). The male: female ratio was 58:71 (45% men) in the surveillance 
group, and 26:23 (53% men) in the non- surveillance group (P=0.42). The 
subjects were followed up for a median of 5 years (range 0 to 18). Seven 
subjects (5%) in the surveillance group and 6 (12%) in the non- surveillance 
group were lost to follow up, so the follow up rates in the two groups were 
similar (p=0.22).  During this period, the surveillance group underwent a 
median of 3 colonoscopies (range 1 to 12). A flowchart summarising these 
pathways is illustrated below (Figure 11). 
Figure 11 Flowchart showing inclusions and outcomes of the study 
groups. 
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In all, 35 adenomatous polyps (all asymptomatic) were removed 
endoscopically from 29 patients in the surveillance group. Eleven subjects 
had adenomas with high grade dysplasia and underwent subtotal colectomy 
and ileorectal anastomosis.  
Colorectal cancer was diagnosed in 14/129 (11%) of subjects in the 
surveillance group, and 13/49(27%) in the non- surveillance group (p=0.019, 
relative risk 0.42, 95% confidence interval 0.21-0.82). Cancers in the 
surveillance group were at an earlier stage than in the non- surveillance group 
(P=0.032) (Table 13) 
Table 13 Stage distribution of CRC 
Dukes’ stage Surveillance group 
(n=129) 
Non- surveillance 
group 
(n=129) 
A 7 1 
B 1 2 
C 6 6 
D 0 4 
Total CRC 14 13 
 
Death from colorectal cancer occurred in 3/129 (2%) of subjects in the 
surveillance group, and 6/49 (12%) in the non- surveillance group (p=0.021, 
relative risk 0.19 (95% confidence interval 0.026-0.61). Death from all causes 
occurred in 11/129(9%) of subjects in the surveillance group and 12/49 (25%) 
in the non- surveillance group (p=0.0097, relative risk of death 0.35 (95% 
confidence interval 0.16- 0.74). Their causes of death are summarized below ( 
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Table 14). Death rates from causes other than colorectal cancer during the 
study period were similar in the two groups (8/129 (6%) in the surveillance 
group vs. 6/49 (12%) in the non- surveillance group (p=0.30)). 
Table 14 Causes of death 
Cause of death Surveillance 
group (n=129) 
Non- surveillance 
group (n=49) 
Colorectal 
cancer 
3 (2%) 6 (12%) P=0.021 
Breast cancer 1 1 
Renal cell 
cancer 
1 
Neuroendocrine 
tumor 
1 
AIDS 1 1 
Tuberculosis 1 
Cardiac 2 
Upper GIT 
bleed 
1 
Pneumonia 1 
Unknown 3 
Total deaths 11 (9%) 12 (25%) P=0.0097 
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The Kaplan- Meyer estimates for median colorectal cancer free survival from 
birth was 73 years in the surveillance group and 47 years in the non- 
surveillance group (p=0.0089). This is illustrated below (Figure 12). 
 
 
Figure 12 Colorectal cancer- free survival (from birth).  
Age is in years.  
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The Kaplan- Meyer estimates for median overall survival from birth were 78 
years in the surveillance group, and 55 years in the non- surveillance group 
(p=0.024). Their survival curves are presented below (Figure 13). 
Figure 13 Overall survival (from birth). 
Age is in years. 
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 3.2.6 Discussion 
In this study of patients who all carry the same mismatch repair gene 
mutation, surveillance colonoscopy was found to improve survival, and delay 
the onset of colorectal cancers. Those subjects who declined surveillance 
colonoscopy had a median colorectal cancer- free survival from birth of 47 
years. This was extended by 26 years to 73 years in those who chose to 
undergo surveillance. Overall life expectancy was similarly lengthened by 23 
years (from 55 to 78 years) in the subjects who underwent colonoscopies.   
The reduction in colorectal cancers in the surveillance group can be ascribed 
to the removal of 35 adenomatous polyps from 29 subjects who underwent 
surveillance. Surveillance colonoscopy was associated with earlier detection 
of colorectal cancers-in the surveillance group, half the cancers were staged as 
Duke’s A, and none had detectable metastatic disease at the time of diagnosis. 
In contrast, only one patient in the non- surveillance group had a Duke’s A 
cancer at diagnosis, and 4 of 13 of them had metastases at diagnosis.  
It is concerning that 6 subjects in the surveillance group had Duke’s C cancers 
at diagnosis. In 5 of these cases the tumors were detected at their first 
colonoscopy. The other subject had a normal colonoscopy in 1988, and then 
defaulted on his planned surveillance until 1994, when this cancer was 
detected. These tumors cannot, therefore, be regarded as interval cancers. 
They would not have been prevented by decreasing the surveillance interval, 
and do not represent tumors that had been missed at colonoscopy.    
Subjects with the mutation who had cancers were routinely offered subtotal 
colectomy and ileorectal anastomosis rather than segmental colonic resections 
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because of concerns about the high rate of metachronous tumors in this group 
of patients. More controversially, subtotal colectomy was offered to patients 
who had adenomas with high grade dysplasia, even if these had been 
completely excised (as judged endoscopically and histologically). All of these 
patients were diagnosed by colonoscopic surveillance, and some of the 
reduction in colorectal cancers in the surveillance group may be due to this 
policy.  
Good follow up was achieved, despite the logistical difficulties of reaching 
many of the subjects. This is largely because the process of genetic 
counselling allowed on- going contact with many members of the affected 
families, who helped to maintain contact with their relatives. 
Self- selection bias is a potential cause for bias in a study of this kind. Those 
subjects who elected to undergo surveillance may have had generally better 
health, or been more likely to seek primary or preventative health care earlier. 
This is unlikely to explain the results of this study however, as there was no 
difference in mortality due to causes other than colorectal cancer between the 
two groups.  
In order to avoid introducing lead- time bias into the survival analysis, all 
survival and cancer- free survival calculations were done from birth rather 
than from diagnosis or enrolment in the study.  
It was not considered ethical to conduct a randomized trial of surveillance 
colonoscopy in this group of patients, and it is unlikely that such a trial would 
ever be performed.   
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 The variable compliance with screening in this study population reflects the 
socioeconomic and logistic difficulties faced by these communities (see 
chapter 1.2.2). It is encouraging that surveillance colonoscopy appears to 
achieve significant improvement in survival to subjects with Lynch syndrome, 
even in this setting. 
 3.2.6.1 Further evidence of the efficacy of surveillance colonoscopy in 
Lynch syndrome  
Since the publication of this study (Paper II) in 2009 [2], further studies have 
strengthened the evidence for the efficacy of surveillance colonoscopy in 
Lynch syndrome.  In 2010, the German Consortium for HNPCC published the 
results of their screening programme, which had begun in 1999 [110]. This 
was a prospective cohort study of 1126 subjects who were offered annual 
surveillance. This study included a heterogeneous group of families, some 
with proven MMR mutation carriers, some who fulfilled the Amsterdam II 
criteria and some with individuals who fulfilled the Bethesda guidelines[43]. 
They were offered annual colonoscopic surveillance, and 3474 colonoscopies 
were performed, at which 245 adenomas were detected. They diagnosed 28 
CRC at initial surveillance colonoscopy and 43 at subsequent surveillance 
colonoscopies. Seventeen patients developed symptomatic CRC. The CRC 
detected at follow up colonoscopy were detected at an earlier stage than the 
other groups (P<0.001), and 41 of 43 (95%) of the CRC detected at follow up 
colonoscopies were UICC stage I or II (i.e. locally resectable disease, 
equivalent to Dukes’ stage A or B). They reported a 23% cumulative risk of 
CRC by age 60 years. 
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In the same year, Vasen et al reported the Dutch group’s [111] (extremely 
impressive) results of surveillance in 745 mutation carriers from 205 Lynch 
syndrome families (75 hMLH1, 87 hMSH2 and 43 hMSH6). Their screening 
interval was 2- yearly for proven mutation carriers. They reported only a 6% 
cumulative risk of developing CRC at ten years’ follow up. In the patients 
who developed CRC while on the screening programme, 90% were Dukes’ A 
or B cancers, and there were no deaths due to CRC. 
Stuckless et al in 2012 [112] reported on the results of surveillance in a cohort 
of MSH2 mutation carriers (this included proven carriers by mutation testing, 
obligate carriers and also subjects who had not had genetic testing but had 
developed CRC as ‘presumed mutation carriers’) in Newfoundland (Canada). 
This was a retrospective study that included historical probands.  They 
compared 152 subjects who had undergone surveillance with 170 who had 
not. They corrected for survivor bias by matching screened and control 
subjects by age and gender. They found that screening delayed the age of 
onset of CRC (58 vs. 47 years in the control group for men, and 79 vs. 57 
years for women (P<0.001 for both groups)) and improved survival (from 
birth, not from diagnosis) (66 vs. 62 years for men (P=0.034) and 80 vs. 63 
years for women.   
Overall, four studies (other than those presented in this thesis) have directly 
compared CRC incidence between screened and unscreened populations with 
HNPCC or Lynch syndrome, summarised below (Table 15).  
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Table 15 CRC incidence in screened vs. unscreened populations 
CRC incidence 
Reference Year Screened Unscreened P- value
Jarvinen et al [101] 1995 6/135 (4%) 
14 of 118 
(12%) 
0.03 
Jarvinen et al [104] 2000 8/133 (6%) 19/119 (16%) 0.014 
Arrigoni et al [107] 2005 7/199 (4%) 5/132 (4%) N.S. 
Stuckless et al 
[112] 
2012 28/152 (18%) 
116/170 
(68%) 
<0.0001 
Three studies (other than those presented in this thesis) have directly 
compared CRC- related mortality between screened and unscreened 
populations with HNPCC or Lynch syndrome, summarised below (Table 16).  
Table 16 CRC- related mortality in screened vs. unscreened populations 
CRC- related mortality 
Reference Year Screened Unscreened P- value
Jarvinen et al 
[101] 
1995 0/135 5/118 (4%) 0.08 
Jarvinen et al 
[104] 
2000 0/133 9/119 (8%) <0.001 
Arrigoni et al 
[107] 
2005 0/199 1/132 (0.8%) N.S.
Barrow et al [113] published a meta- analysis of these studies, which also 
included the results of PAPER I and PAPER II of this thesis, which showed a 
benefit for screening in reducing both CRC incidence and CRC- related 
105
mortality. The methodology of this meta- analysis can be criticised, however, 
as there is significant repetition in the patient groups presented in Jarvinen et 
al (1995)[101] and Jarvinen et al (2000)[104], as well as in PAPER I and 
PAPER II included in this thesis. If one repeats the meta- analysis without 
repetition of study groups, the main results remain essentially unchanged: The 
incidence of CRC is reduced by screening (odds ratio 0.30 (95% C.I. 0.12 to 
0.74)), as is CRC- related mortality (odds ratio 0.11 (95% C.I 0.04 to 0.46)). 
The Forest plots are illustrated below (Figure 14 and Figure 15). 
Figure 14 Forest plot of studies comparing CRC incidence between 
screened and unscreened populations (excluding studies with repetition 
of the study groups 
CRC incidence
0.01 0.1 1 10
Odds ratio
Jarvinen et al 2000
Arrigoni et al 2005
Paper II 2009
Stuckless et al 2012
Total (fixed effects)
Total (random effects)
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Figure 15 Forest plot of studies comparing CRC- related mortality 
between screened and unscreened populations (excluding studies with 
repetition of the study groups). 
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 3.3 PAPER III: Surgery for colon cancer in Lynch 
syndrome: Total vs. segmental colectomy [3] 
 3.3.1 Abstract 
 3.3.1.1 Introduction 
The high reported risk of metachronous colon cancer in Lynch syndrome has 
led some authors to recommend total colectomy as the preferred operation for 
primary colon cancer in this patient group, but this remains controversial. The 
purpose of this study was to determine the risk of developing metachronous 
colorectal cancer after segmental or total colectomy in Lynch syndrome 
patients, and to compare their long- term survival. 
 3.3.1.2 Method 
This is a prospective cohort study of all patients referred to Groote Schuur 
Hospital (Cape Town, South Africa) between 1995 and 2009 with a proven 
germline mismatch repair gene defect, who had undergone a resection for 
adenocarcinoma of the colon with curative intent. All patients were offered 
annual endoscopic surveillance. 
 3.3.1.3 Results 
Of 60 patients in the study, 39 had a total colectomy as their initial surgery 
and 21 had a segmental colonic resection. After six years’ follow up, 
metachronous colon cancer occurred in eight (21%) patients after segmental 
colectomy and in none of the total colectomy patients. The risk of developing 
metachronous colon cancer after segmental colectomy was 20% at five years.  
 108
 
 3.3.1.4 Conclusion 
Patients with Lynch syndrome have a significant risk of metachronous colon 
cancer after segmental colectomy. This risk is eliminated by performing a 
total colectomy as the primary operation for colonic cancer. 
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 3.3.2 Introduction 
Several studies have documented a high risk of developing metachronous 
colorectal cancer (CRC) after segmental colonic resection for primary CRC. 
Fitzgibbons et al, in 1987 [114], and Lynch et al in 1988 [115] reporting on a 
similar cohort of 116 members of 10 American families with HNPCC, 
calculated the risk of developing metachronous colorectal CRC to be 40% by 
10 years. Lanspa et al [116] in a later study from the same institution, 
identified 225 patients with HNPCC who underwent surgery for colorectal 
cancer. Of these, 17 (8%) developed a second CRC within five years.  
In their 2002 study describing the impact of surveillance on 114 Dutch 
families with HNPCC, de Vos tot Nederveen Cappel et al [117] also noted a 
high incidence of metachronous CRC in subjects who had previously 
undergone a partial colectomy for colon cancer. After a mean follow up of 6.8 
years after their initial surgery, 13 of 110 (12%) patients had developed a 
metachronous CRC, one of which was in the rectum.  
Shen et al [118] reported on 98 patients from 28 Chinese HNPCC families 
who had undergone colorectal cancer resections, of whom 20% developed 
metachronous colon cancer within 10 years. 
Newton et al [119] performed a retrospective study of patients who had been 
diagnosed with CRC, recruited from the Manchester Colorectal Cancer 
Registry in the UK. They included 528 subjects with Lynch syndrome (this 
included MMR mutation carriers and obligate carriers, but also first degree 
relatives with CRC and individuals with cancers that were MMR-deficient on 
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immunohistochemistry and who fulfilled the Amsterdam II [39]criteria for 
HNPCC). They calculated a cumulative risk of metachronous CRC of 3% at 
10 years and 14% at 20 years. They also included a control cohort of subjects 
who were judged to be at population risk for CRC based on family history. In 
this group, the risk of metachronous CRC was considerably lower (0.6% at 10 
years and 2% at 20 years, P<0.001). This is the only study to directly compare 
the risk of metachronous CRC in Lynch syndrome with the risk of 
metachronous CRC after sporadic CRC. 
 3.3.2.1 More extensive colonic resections reduce the risk of metachronous 
CRC 
The high incidence of metachronous CRC observed by de Vos tot Nederveen 
Cappel et al [117] led the authors to conclude that ‘when a member of an 
HNPCC family develops colon cancer, we, as most authors, would 
recommend total colectomy…rather than partial colectomy’ in order to 
prevent later colon cancers, while acknowledging the potential deleterious 
effect on quality of life after a total colectomy. 
Van Dalen et al in 2003 [120] retrospectively studied a cohort of 93 patients 
who had undergone surgical resection for colon cancer and whose families 
fulfilled the Amsterdam criteria [37] for HNPCC. Seventy patients had 
undergone a segmental colectomy, and 15 of these developed metachronous 
CRC after a median of 14 years follow up, whereas none of 23 patients 
developed metachronous CRC after total colectomy. The authors concluded 
that ‘there is a high risk of metachronous colorectal cancer if an index cancer 
in an HNPCC patient…is treated by partial colectomy. However, this risk can 
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be lowered, either by performing a total colectomy at the time of index 
surgery or possibly by effective postoperative surveillance’.  
Natarajan et al [121] retrospectively studied 106 proven MMR mutation 
carriers (66 hMLH1, 40 hMSH2) who had undergone previous colorectal 
resections. Of these, 69 had undergone limited colonic resections, and 37 had 
undergone extended colectomies (this included total and subtotal colectomy, 
extended right hemicolectomy and (in four cases) proctocolectomy). Fifteen 
of 69 in the limited resection group, and eight of 37 in the extended 
colectomy group had undergone surgery for (unspecified) diagnoses other 
than cancer. They found that the rate of subsequent CRC was significantly 
reduced in the extended colectomy group (7% vs. 12% at five years, P= 
0.006).  
Parry et al in 2011 [122] published a large retrospective cohort study of 382 
MMR mutation carriers (172 hMLH1, 167 hMSH2, 23 hMSH6, 20 PMS2) 
from the Colon Cancer Family Registry (recruited from Australia, New 
Zealand, USA and Canada) who had undergone surgery for CRC. Fifty of 
these subjects had undergone an ‘extensive colon resection’ (defined as a total 
or subtotal colectomy), and none of these developed a metachronous CRC 
after a mean of 8 years’ follow up. Of the 332 who had segmental 
colectomies, 74 (22%) were diagnosed with CRC after a mean of 9 years’ 
follow up (P<0.001).  The cumulative risk of metachronous CRC after 
segmental colectomy was 16% at ten years and 62% at 30 years. Ten (18%) 
of the metachronous CRC were AJCC stage III (nodal metastases present, 
equivalent to Dukes’ C) at diagnosis. This is despite active surveillance 
(subjects were undergoing on average one surveillance endoscopy every 20 
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months after segmental colectomy, and the large majority (78%) of patients 
who developed metachronous CRC were undergoing at least 2- yearly 
surveillance colonoscopies).  
 3.3.2.2 Extent of surgery for CRC and long- term survival 
Despite showing a significant reduction in metachronous CRC after more 
extensive colectomy compared with segmental colonic resections in the 
setting of HNPCC [120] or Lynch syndrome [121, 122], none of these studies 
reported any difference in survival between the two groups [120-122]. 
De Vos tot Neederveen Cappel et al [123] presented a decision analysis 
(Markov) model for predicting the benefits of different surgical options for 
primary CRC in Lynch syndrome in preventing metachronous CRC. They 
predicted an improvement in life expectancy after subtotal colectomy as 
compared with segmental colectomy, with the greatest benefit in young 
patients with early stage tumors. Overall they calculated an expected life 
expectancy gain of 2.3, 1 and 0.3 years for subjects undergoing surgery at 
ages 27, 47 and 67 years.  They also predicted even greater improvements in 
life- expectancy (3.2, 1.3 and 0.3 years for subjects undergoing surgery at 27, 
47 and 67 years of age) if the primary operation was a proctocolectomy and 
ileo- anal anastomosis. On this basis they recommended subtotal colectomy as 
the preferred surgical treatment of primary CRC in Lynch syndrome.  
Maeda et al [124] also performed a Markov analysis of this question, and 
calculated only a very small (median 43 vs. 42 year) survival benefit for total 
colectomy. 
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 3.3.2.3 Choice of operation and quality of life 
Subtotal or total colectomy leads to significant disruption of normal bowel 
function, with the potential to have a greater adverse effect on quality of life 
than segmental colectomy.   
Studies of long- term bowel function after total colectomy and ileo-rectal 
anastomosis (TC/IRA) for various indications have found that about 20% of 
patients experience significant faecal incontinence in the long term, and that 
stool frequency is increased (a mean three to seven stools per day is reported) 
[125-128]. Church et al [125], reporting specifically on subjects who had 
undergone a prophylactic TC/IRA for FAP found overall quality of life to be 
well maintained, despite an incontinence rate of 20% and a median stool 
frequency of four stools per day. Duclos et al [128], in a study of patients who 
had undergone bowel resections for a number of different indications, 
reported rates of incontinence and stool frequency after TC/IRA that were 
similar to Church et al[125], and also described quality of life and functional 
outcomes as ‘satisfactory’ . Lim and Ho [127] also noted a 20% incontinence 
rate, but a slightly lower stool frequency (three stools per day) after TC/IRA, 
but noted that fear of faecal leakage adversely affected the lifestyle of 20% of 
the patients even with perfect continence. They concluded that TC/IRA “leads 
to an appreciable incidence of incontinence and loss in quality of life”. This 
highlights the multifactorial and subjective nature of quality of life studies, 
and the variability in what different authors (and patients) will regard as an 
acceptable functional outcome. 
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You et al [129] published a large retrospective study comparing long- term 
outcomes between patients who had undergone segmental, subtotal or total 
colectomies for a number of different indications. In this cohort, median daily 
stool frequency was five after TC/IRA, compared with four after subtotal 
colectomy and ileosigmoid anastomosis (STC/ISA) and two after segmental 
colectomy. Incontinence was also more common in patients who had 
undergone a TC/IRA and STC/ISA than those who had a segmental 
colectomy.  This was despite significant dietary modifications in 56% of 
patients and medication use (20%) to reduce stool frequency in the TC/IRA 
group. This was associated with significant restrictions in social and 
recreational activities, housework and travel. Overall, disease- specific quality 
of life (assessed using the Irritable Bowel Syndrome- Quality of Life 
Measure) was most adversely affected after TC/IRA, then STC/ISA and least 
affected after segmental colectomy. 
In a multicentre randomized trial comparing subtotal with segmental 
colectomy for obstructing left sided colon cancers, the SCOTIA group[130] 
found that there was more stool frequency after STC/IRA compared with 
segmental colectomy, but no detectable difference in quality of life. It should 
be noted, however, that stool frequency and quality of life were assessed after 
a short (four month) follow up time in this study. 
One study has specifically documented quality of life after surgery for colon 
cancer in Lynch syndrome. Haanstra et al [131] in 2012 performed a cross 
sectional study of patients who had undergone colectomy for Lynch syndrome 
in the Netherlands. They received responses to questionnaires from 51 
patients who had undergone a segmental colectomy, and 53 who had 
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undergone a TC/IRA or STC/ISA a mean of 12 years previously. Bowel 
function (stool frequency and the social impact of disordered bowel function) 
were worse in the group who had undergone TC/IRA or STC/ISA than those 
who had a segmental colectomy, but there was no difference in overall quality 
of life as assessed by the Short Form-36 (SF-36) (a generic health survey tool) 
as well as the European Organization for Research and Treatment of Cancer 
Colorectal Cancer- specific Quality of Life Questionnaire Module (EORTC 
QLQ CR-38). 
 3.3.2.4 Introduction- summary 
The risk to patients with Lynch syndrome of developing metachronous colon 
cancer after segmental colectomy for colon cancer is high, with reported rates 
of around 4% per year. The risk of developing metachronous CRC has led 
some authors to recommend total colectomy as the preferred operation for 
colonic cancer in Lynch syndrome, but this remains controversial.  Most 
previous estimates of metachronous CRC risk in Lynch syndrome have come 
from retrospective studies which included patients diagnosed by clinical 
criteria as well as by proven germline mutations, and no previous studies have 
compared long- term survival after total or segmental colectomy in Lynch 
syndrome 
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 3.3.3 Aim 
The aim of this study was to determine the risk of developing metachronous 
CRC in patients with genetically proven Lynch syndrome after total or 
segmental colectomy for cancer and to compare their long- term survival. 
 3.3.4 Methods 
All patients referred to the colorectal unit at Groote Schuur Hospital (a 
tertiary referral center, linked to the University of Cape Town, in Cape Town, 
South Africa) between 1995 and 2009 with a proven germline MMR gene 
defect who had undergone a resection for adenocarcinoma of the colon with 
curative intent were included in this study. Patients were followed 
prospectively from the time of genetic testing for Lynch syndrome until 
January 2009. They were included in the study regardless of whether they 
underwent surgery before or after they underwent genetic testing and 
regardless of whether the initial surgery had been performed at Groote Schuur 
Hospital or elsewhere. All patients who had undergone segmental colonic 
resection or total colectomy were offered annual surveillance by colonoscopy 
or flexible sigmoidoscopy respectively. 
Patients were offered a completion colectomy if a resectable metachronous 
CRC or a high grade dysplastic adenoma was identified. Patients who 
developed rectal cancer were offered resection, with neoadjuvant radiotherapy 
if appropriate. They were considered to have developed a metachronous CRC 
only if the tumor was diagnosed more than two years after the initial surgery. 
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 3.3.4.1  Statistical Analysis 
The Kaplan- Meier technique was used to calculate survival and the risk of 
developing metachronous CRC, and groups were compared using the log rank 
technique. Categorical data were compared using the chi square test, and 
continuous data using Student’s t- test. Statistical analysis was performed 
using Medcalc ® (Mariakerke, Belgium) software. 
 3.3.4.2 Ethical approval 
All subjects were counseled by a trained genetic counselor and gave informed 
consent for genetic testing, and for all procedures performed. Ethical approval 
for the study was granted by the Research Ethics Committee of the University 
of Cape Town. 
 3.3.5 Results 
 3.3.5.1 Patient characteristics 
Between 1995 and 2009, mutational analysis was performed on 856 
individuals, and 280 germline mismatch repair gene mutation carriers were 
identified. Sixty- two of these underwent a colonic resection for 
adenocarcinoma between 1975 and 2007, of whom two had incurable 
metastatic disease at the time of surgery and were excluded from further 
analysis. The mismatch repair gene mutations of the remaining 60 patients, 
who came from 17 different families, are listed below (Table 17). The 
majority of patients in both groups carried the C1528T (Exon 13) mutation. 
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Thirty- nine patients underwent segmental colectomy as their initial operation 
and 21 had a total colectomy and ileo- rectal anastomosis (TC/IRA). The two 
groups were similar in age at the time of their first diagnosis of colonic cancer 
(mean 44 (+/-11.0) years in the segmental colectomy group and 41 (+/- 7.9) 
years in the total colectomy group (p=0.19)). The ratio of males to females 
was similar in the two groups (21 (54%) males in the segmental colectomy 
group; 13 (62%) males in the total colectomy group (p=0.74)). There was no 
significant difference in the prevalence of the various mismatch repair gene 
defects between the two groups. All total colectomy patients and 9/39 (23%) 
segmental colectomy patients were identified to be at risk for Lynch 
syndrome prior to surgery (p<0.0001). Patients undergoing total colectomy 
were more likely to have a Dukes’ A tumors (p=0.0003; Table 4.2). Thirty 
day mortality was zero in both groups. 
Table 17 Mismatch repair gene mutations identified 
Germline mutations identified. Segmental colectomy  
(n=39) 
Total colectomy  
(n=21) 
hMLH1 C 1528T (Exon13)   23 17 
hMLH1 Exon13 ins T at 1521 0 1 
hMSH1 2-16 del 1 0 
hMSH2 Exon 1-16 1 0 
hMSH2 Exon 15 4 0 
hMSH2 Exon 1-5 del 1 0 
hMSH2 Exon 1-6 del 1 0 
hMSH2 Exon 3 1 0 
hMSH2 Exon 8 3 0 
hMSH2 Exon 3 del TC at 387  0 1 
hMSH2 Exon7 del CT at 1220 4 2 
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Table 18 Dukes’ stage of the cancer(s) resected at the first operation. 
In four cases, the initial surgery was done at another institution, and 
complete pathological staging was incomplete. 
Duke’s stage of first colon 
cancer 
Segmental 
colectomy  
(n=40) 
Total 
colectomy  
(n=22) 
P-value 
A 1 (2.5%) 8 (36.4%) 0.0003 
B 15 (37.5%) 4 (18.2%) 0.11 
C 19 (47.5%) 9 (40.9%) 0.62 
D 1 (2.5%) 1 (4.5%) 0.66 
Unknown 4 (10%) 0 (0%) 0.13 
 
 3.3.5.2 Follow up and surveillance 
After the initial operation, patients were followed to a median of six (range 1-
30) years after surgery in the total colectomy and eight (range 0 – 34) years 
after surgery in the segmental colectomy group (p=0.60). Five (13%) 
segmental colectomy patients and 1 (5%) total colectomy patients were lost to 
follow up (p=0.58). 
During the study period, 22 (56%) segmental colectomy patients underwent a 
mean of three (S.D. 2.2) surveillance colonoscopies and 15 (71%) total 
colectomy patients a mean of five (S.D. 3.2) flexible sigmoidoscopies. The 
groups were equally likely to present for at least one surveillance endoscopy 
(p=0.39), but the total colectomy patients attended more often (p=0.015). 
Thirteen adenomatous polyps were identified and removed endoscopically in 
seven segmental colectomy patients. Three contained high grade dysplasia 
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and these patients underwent a completion colectomy and ileorectal 
anastomosis. One low grade rectal adenomatous polyp was identified and 
endoscopically removed from the rectum of a total colectomy patient. 
3.3.5.3 Metachronous cancers
Figure 16 Metachronous CRC risk after segmental resection of a colon 
cancer. 
 
A metachronous colon cancer occurred in eight (21%) segmental colectomy 
patients and none of the total colectomy patients. The risk of developing 
metachronous colon cancer after segmental colectomy was 20% at 5 years 
and 41% at 15 years (Figure 16). Two metachronous colon cancers were 
interval cancers, in patients who developed symptoms less than one year after 
a normal surveillance colonoscopy and six occurred in patients who had 
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defaulted surveillance colonoscopy for at least two years. Two (10%) total 
colectomy patients developed a rectal cancer, at 15 and 23 years after colonic 
resection. There were no rectal cancers diagnosed in the segmental colectomy 
group. One rectal cancer was diagnosed one year after a normal surveillance 
sigmoidoscopy, and the second patient had defaulted surveillance 
sigmoidoscopy for four years. Overall there were eight metachronous 
colorectal cancers in the segmental colectomy group (all in the colon) and two 
in the total colectomy group (both in the rectum). 
 3.3.5.4 . Mortality 
Figure 17 Colorectal cancer specific survival after total or segmental 
colectomy for their first colon cancer. 
During the follow up period, fifteen (38%) patients in the segmental 
colectomy group, and five patients (24%) in the total colectomy group died. 
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Death due to colorectal cancer occurred in 13 (33%) and 2 (10%) patients in 
the segmental and total colectomy groups respectively. Causes of death are 
summarized below (Table 19). Colorectal cancer- specific survival was 
significantly better in total colectomy patients (p=0.048, Figure 17), but 
overall survival of the two groups was similar (p=0.29). 
Table 19 Causes of death 
 Segmental colectomy 
(n = 39) 
Total colectomy 
(n = 21) 
Metastatic CRC 13 2 
Cholangiocarcinoma 0 1 
Small bowel cancer 1 0 
Breast cancer 0 1 
Asthma 1 0 
Upper gastrointestinal 
bleed 
0 1 
 
 
 3.3.6  Discussion 
Patients with genetically proven Lynch syndrome who underwent a segmental 
colectomy for primary colon cancer have a significant lifetime risk of 
developing metachronous colon cancer. This risk is eliminated by performing 
a total colectomy as the primary operation for colon cancer.  
Most previous reports of metachronous CRC risk in Lynch syndrome have 
been from retrospective studies which have included patients in whom the 
diagnosis was made on clinical grounds and family history as well as with 
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proven MMR mutations. This may result in an overestimation of risk due to 
selection bias as Lynch syndrome is more likely to be suspected in patients 
with multiple tumors (both the Bethesda [42]and Japanese [132] criteria list 
metachronous CRC as a clinical criterion for HNPCC). This study confirms 
the results of previous studies which included only proven MMR mutation 
carriers [121] [122]3.  
Fourteen asymptomatic adenomas were detected and removed endoscopically, 
but this did not eliminate the risk of metachronous CRC after segmental 
colectomy. All patients were offered surveillance endoscopy, but compliance 
was poor in this cohort, especially after segmental colectomy. Seven of the 
ten patients who developed metachronous CRC had defaulted surveillance. 
The poor surveillance attendance is surprising in a cohort of patients who 
have already developed CRC and who have family members with the disease. 
The reasons for non-compliance in these patients are unknown and are 
currently under investigation, but poor socio-economic conditions and low 
education standards, which are all prevalent in this community, are likely to 
be contributory. 
The low number of surveillance colonoscopies affects the results of this study 
as surveillance colonoscopy may prevent metachronous CRC by removing 
adenomas.  
3 In the original published version of this chapter (PAPER III), it was erroneously stated that 
this was the first published report on metachronous CRC to include only proven MMR 
mutation carriers. 
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Two patients developed an interval cancer within a year of normal 
colonoscopy. Rapid development of cancer from adenoma occurs in Lynch 
syndrome [103] but an oversight during surveillance cannot be excluded.  
Rectal cancers were infrequent and all occurred more than 15 years after the 
initial surgery. This long interval justifies avoiding the increased morbidity 
associated with proctocolectomy as the primary operation for colon cancer in 
Lynch syndrome, but lifelong endoscopic surveillance of the rectum should 
be offered to patients who undergo a total colectomy. 
There is evidence of selection bias in this study, where patients selected for 
total colectomy were more likely to have been diagnosed with Lynch 
syndrome pre-operatively and were more likely to have a Dukes’ A cancer 
than those who underwent segmental colectomy. This bias explains the 
apparent difference in CRC- specific survival between the two groups, and 
one cannot conclude from this study that the choice of surgery influenced this. 
For patients with Lynch syndrome who develop colon cancer, the standard 
recommendation for surgery is a total or subtotal colectomy (rather than a 
segmental) colectomy [9, 46, 133] in order to prevent metachronous colon 
cancers. This is despite there being no proven survival benefit to this 
approach when compared to segmental colonic resection followed by 
endoscopic surveillance of the residual colon. 
An interesting feature of the study by Parry et al [122] is that this occurred in 
only 13% of subjects (the rest had segmental colectomies). It is not known 
whether this was because of a lack of awareness of the guidelines by the 
treating surgeon, or a deliberate decision based on specific patient factors. 
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The authors note that ‘this may reflect the fact that surgery was performed in 
the emergency setting or that at the time surgery was planned the diagnosis of 
HNPCC or MMR gene mutation was unknown’. Van Dalen et al [120] also 
noted marked variability in surgical practice between centres in the USA that 
cared for these patients.  
In deciding between the surgical approaches of total (or subtotal) vs. 
segmental colectomy, the surgeon and patient need to weigh up the relative 
benefits of total colectomy in terms of preventing metachronous CRC and 
allowing less invasive surveillance endoscopy (surveillance of the rectum can 
be done with by flexible sigmoidoscopy, which does not require full oral 
bowel preparation and can be done without sedation, unlike a colonoscopy 
which is required after segmental resection) against the long- term adverse 
effects on bowel function.  
An awareness of the long term risk of metachronous CRC helps patients to 
make an informed choice of operation for primary colon cancer. This study 
confirms the results of other reports of metachronous CRC risk after 
segmental colectomy in Lynch syndrome. 
 126
 3.4 PAPER IV: Does genetic anticipation occur in Lynch 
syndrome?[4] 
 3.4.1 Abstract 
 3.4.1.1 Introduction 
Genetic anticipation occurs when the age of onset of a disorder decreases in 
successive generations. It is controversial whether this occurs in Lynch 
syndrome. Previous studies have included heterogeneous groups of subjects 
from multiple families, including subjects with a clinical diagnosis (based on 
family history) as well as those with proven germline mismatch repair gene 
mutations. The purpose of this study was to determine whether genetic 
anticipation occurs in mismatch repair gene carriers from a single Lynch 
syndrome family.  
 3.4.1.2 Method 
This study includes members of a single family known to carry an hMLH1 
gene mutation who are proven germline mutation carriers or obligate carriers 
(based on their offspring's mutation status). Evidence of genetic anticipation 
(determined by age of onset of first CRC) was sought in two ways: Firstly, 
subjects were grouped as parent-child pairs and individuals were compared 
with their own offspring; secondly they were grouped by generation within 
the family tree. The Kaplan- Meier technique was used to adjust for variable 
follow up times.  
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 3.4.1.3 Results 
The family tree consisted of 714 subjects. Ninety-two subjects over five 
generations were included in the study. There was no evidence of genetic 
anticipation over the generations. Similarly, in the 75 parent-child pairs 
identified, age of onset of CRC was similar for parents and children.  
 3.4.1.4 Conclusion 
There was no evidence of genetic anticipation in mutation carriers from a 
single family with Lynch syndrome. 
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 3.4.2  Introduction  
The age of onset of CRC in carriers of the C1528T (Exon 13) mutation in the 
hMLH1 gene was described in chapter 3.1. A trend was noted in which those 
subjects who were born more recently appeared to develop their first CRC at 
an earlier age. This is illustrated below (Figure 18). There was a strong 
negative association between year of birth and age of onset of first CRC 
(Pearson correlation coefficient r=-0.75; P<0.0001). This led to an exploration 
of possible genetic anticipation in carriers of this mutation.  
 
Figure 18 Year of birth vs. age of onset of first CRC (all C1528 (exon 13) 
hMLH mutation carriers) 
Genetic anticipation is the phenomenon in which the age of onset of an 
inherited disorder decreases in successive generations. When Warthin [12] 
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first described a family with Lynch syndrome (‘Family G’) in 1925, he made 
the observation that colorectal cancers occurred at a younger age in 
successive generations. Since then, a number of conflicting reports have 
documented the presence or absence of genetic anticipation in Lynch 
syndrome and it remains controversial whether it occurs in this disease.  
Genetic anticipation has been definitively shown to occur in several 
neurodegenerative disorders, including Huntington’s chorea [134] and 
spinocerebellar ataxia [135-137]. In these diseases, the observed generational 
expansion of trinucleotide repeats during meiosis and gametogenesis provides 
a molecular mechanism to explain the earlier onset and worse prognosis of 
affected individuals in successive generations, but there is no direct evidence 
that this occurs in Lynch syndrome[138]. Indeed, in a mouse model of 
Huntington disease, mismatch repair gene deficiency has been shown to 
prevent instability of trinucleotide repeats [139]. It has been proposed that 
germline mismatch repair gene defects may lead to an accumulation of small 
errors in DNA replication prior to loss of heterozygosity, and that this could 
be passed on over the generations, however there is little direct evidence that 
this occurs [140]. In Li- Fraumeni syndrome, anticipation has been found to 
be linked to decreasing telomere length over generations [141]. Bozzao et al 
[140] have recently described abnormalities in telomere length in carriers of
MSH2 mutations, but not MLH1 mutation carriers. This is an intriguing and 
developing area of research, but a definitive molecular mechanism for 
anticipation in Lynch syndrome has not yet been identified.  
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Previous studies of genetic anticipation in Lynch syndrome have variably 
reported the presence or absence and extent of this phenomenon. These are 
summarised below (Table 20).  
Tsai et al [142] and Westphalen et al [143] found no evidence of genetic 
anticipation, whereas other authors [12, 144-150] described an effect ranging 
from three [148, 150] to ten [150] years. A striking feature of this literature is 
the variability in reported anticipation, even when different authors have 
studied similar cohorts but using different methodologies.  Vasen et al [144] 
studied 74 patients with CRC from the Foundation for the Detection of 
Hereditary Tumors in the Netherlands, and reported an average anticipation of 
8.5 years. Voskuil et al [146] later analysed 1186 subjects from the same 
registry (but using a different methodology) and could not detect any 
evidence of anticipation. Larsen et al [148], Nilbert et al [149] and Boonstra 
et al [150] reported an anticipation effect in subjects from the Danish HNPCC 
Registry ranging between three and 9.8 years depending on the methodology 
used. A further confounder when attempting to interpret the available 
literature is that, apart from Warthin’s initial paper, all previous studies 
describing anticipation in Lynch syndrome have included heterogeneous 
groups of subjects from multiple families with different mutations and in most 
cases have included subjects with a clinical diagnosis of HNPCC as well as 
those with proven germline mismatch repair gene mutations. 
A well- recognized form of bias that can falsely create the appearance of 
genetic anticipation is follow- up bias. This occurs when older subjects, who 
have passed through more of their period of risk, are compared with younger 
ones who have not. Subjects who have not yet manifest the disease, but may 
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have developed it later, are excluded from the analysis. There are more such 
subjects in the later generations, and so the average age of onset appears 
(falsely) lower in the more recent cohort [151]. This bias can be corrected for 
by including only subjects who were born sufficiently long ago that they have 
completed their period at risk. Differences in follow up time can be corrected 
for using survival analysis techniques, in which subjects with incomplete 
follow up are censored. 
Genetic anticipation may also be falsely detected due to differential 
ascertainment of families. The chance of detecting HNPCC families with 
predominantly younger patients in later generations is higher than that of 
finding families with predominantly older patients in later generations. This is 
because individuals in later generations have not lived long enough to detect 
cancers that may develop later in their lives [146]. Correcting for variable 
ascertainment when subjects from multiple families are studied requires 
complex statistical methods (reviewed by Boonstra et al [150]).  
The largest single family known to carry the C1528T mutation in exon 13 of 
the hMLH1 gene (referred to as the NPC-1 family) consists of over 700 
known individuals. This affords a unique opportunity to study genetic 
anticipation in a single family tree over multiple generations, and avoiding the 
confounding effect of variable ascertainment of multiple families. 
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Table 20 Previous studies of genetic anticipation in Lynch syndrome 
Paper Patient set Numbers Average 
anticipation (years) 
Survival 
analysis  
Warthin 1925 “Famliy G” 28 patients with 
CRC over 4 
generations 
8  No 
Vasen et al 
1994 
Foundation for the 
Detection of 
Hereditary Tumors 
(Netherlands) 
74 patients with 
CRC over three 
generations 
8.5  No 
Rodriguez- 
Bigas 1996 
Roswell Park Cancer 
Institute HNPCC 
Registry 
193 patients with 
CRC 
5.5  No 
Tsai et al 1997 Johns Hopkins 
Hereditary 
Colorectal Cancer 
Registry 
67 parent- child 
pairs with CRC* 
0 No 
Voskuil et al 
1997 
Foundation for the 
Detection of 
Hereditary Tumors 
(Netherlands) 
1186 subjects  0 Yes 
Westphalen et 
al 2005 
University of Basel 
and Institut Central 
des Hopitaux 
Valaisans registrees 
55 parent-child 
pairs with CRC 
8  No 
Stella et al 2007 Five Italian families 24 parent-child 
pairs with CRC 
11  No 
Larsen et al 
2009 
Danish HNPCC 
Registry 
824 subjects  3  Yes 
Nilbert et al 
2009 
Danish HNPCC 
Registry 
290 parent-child 
pairs with CRC 
5.5 – 9.8 ** No 
Boonstra et al 
2010 (a) 
Danish HNPCC 
Registry 
290 parent- child 
pairs with CRC 
8.7  No 
Boonstra et al 
2010 (b) 
University of 
Michigan Cancer 
Genetics Clinic 
136 parent- child 
pairs with CRC 
9.9 No 
Boonstra et al 
2010 (c) 
Danish HNPCC 
Registry 
816 subjects  3 *** Yes 
 
*The full paper included 475 parent- child pairs with CRC, but only 67 of these had HNPCC 
** Different estimates of anticipation were calculated depending on the method of analysis 
*** Boonstra et al analyzed different datasets in a number of different ways. These analyses have been 
listed separately although they are from the same paper. Larsen et al and Boonstra (c) used a similar 
dataset. 
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 3.4.3 Aim 
The aim of this study was to determine whether genetic anticipation occurred 
within members of this single family. 
 3.4.4 Methods 
The C1528T mutation in exon 13 of the hMLH1 gene has been identified in 
23 families, the largest of which (referred to as the NPC-1 family) consists of 
714 known individuals.  This study included only members of the NPC-1 
family (a single large family tree, allowing multiple generations to be studied 
and to reduce the impact of ascertainment bias that occurs when multiple 
families are recruited). Only subjects who were proven germline mutation 
carriers or judged to be obligate mutation carriers based on the positive 
mutation status of their offspring were included. 
Information about age of onset of CRC was obtained by interviewing the 
subjects and their family members, and confirmed with hospital and 
pathology records wherever possible. Subjects who were found to be mutation 
carriers were followed up prospectively twice annually from the time of 
genetic testing until May 2010.  Follow up consisted of a clinical history 
(paying particular attention to symptoms of colorectal or endometrial cancer), 
physical examination and further investigations if indicated. All subjects were 
offered surveillance colonoscopy. Subjects who declined the offer of 
attending for clinical follow up were contacted and interviewed 
telephonically.  
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Evidence of genetic anticipation was sought in two ways: Firstly, subjects 
were grouped as parent- child pairs and individuals were compared with their 
own offspring; the second method was to group them by generation within the 
family tree. In both cases, analyses were done comparing only those subjects 
who had developed CRC, and then repeated using the entire cohort and 
applying standard survival analysis techniques to correct for differences in 
follow up time. In addition, the analyses were repeated including only those 
subjects born before 1960 (i.e. those with a potential follow up time of at least 
50 years).  
 3.4.4.1 Statistics  
Age of onset of CRC was not normally distributed, so non- parametric 
techniques were used to compare groups. Parent- child pairs with CRC were 
compared using the Wilcoxon (paired) test. Age of onset of CRC (in 
individuals with CRC) was compared between generations using the 
Kruskall- Wallis test. These analyses were repeated for the entire cohort 
(including those who had not yet developed CRC within the study period) 
using the Kaplan– Meier technique and comparison between groups was done 
using the log rank method. For the Kaplan- Meier analyses, subjects were 
censored if they had not developed CRC by the end of the follow up period, if 
they had died before developing the disease or (in one case) where the subject 
had undergone a prophylactic subtotal colectomy for an adenomatous polyp. 
In order to avoid introducing lead-time bias into these analyses, CRC risk was 
calculated from birth rather than from diagnosis or enrolment in the study. 
Numbers are stated as median (95% CI for the median) unless otherwise 
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stated. Statistical analysis was done using Medcalc® (Mariakerke, Belgium) 
software.  
 3.4.4.2 Ethics 
All subjects were counseled and gave informed consent for genetic testing. 
The Health Sciences Faculty Research Ethics Committee of the University of 
Cape Town approved the study. 
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 3.4.5 Results 
The family tree consisted of 714 subjects over five generations. Of these, 257 
have undergone germline mutational analysis. Eighty of these 257 subjects 
(31%) carried the C1528T (Exon 13) mutation in the hMLH1 gene, and 176 
(69%) were found not to be carriers.  Of the 457 who have not undergone 
genetic testing, 12 were determined to be obligate carriers as they had 
children proven to carry the mutation. The cohort for analysis therefore 
consisted of a total of 92 subjects (80 with a proven mutation, and 12 obligate 
carriers), of whom 50 were men and 42 women. These 92 subjects were born 
between 1913 and 1979, and have been followed up to a median age of 38 
years (range 19 to 80 years). Thirty- three of them have been diagnosed with a 
colorectal cancer, and 22 have died. The Kaplan- Meier estimate of the 
median age of first CRC was 49 years. 
 3.4.5.1 Age of onset of CRC grouped by birth cohort 
Similar to the findings of the larger cohort of all carriers of the C1528T (Exon 
13) mutation in the hMLH1 gene, there was an inverse relationship between 
the date of birth of the subjects and the age of onset of their first CRC 
(correlation coefficient r= -0.69, P<0.0001) as illustrated below (Figure 19). 
This relationship persisted, but was weaker, when only subjects born before 
1960 were included (correlation coefficient r=- 0.58, P=0.0028).  
When subjects who had developed CRC were divided into birth cohorts by 
quartiles, there was an apparent decrease in the age of onset of first CRC in 
the later birth cohorts (P=0.0022, Kruskall- Wallis test, Figure 20). This 
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apparent effect persisted when only those subjects born before 1960 were 
included (P=0.046, Kruskall- Wallis test). When those patients who had not 
yet developed CRC were included (using the Kaplan- Meier technique to 
estimate age of onset of CRC by censoring subjects who had not developed 
the disease at the end of the follow up period), this apparent effect 
disappeared regardless of whether subjects born after 1960 were included 
(P=0.19, Logrank test, or not (P=0.18, Logrank test, Figure 21). 
Figure 19 Year of birth vs. age of first CRC diagnosis (NPC-1 family) 
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Figure 20 Age of onset of first CRC in the NPC-1 family, grouped by 
birth cohort 
 
Figure 21 Kaplan- Meier plot of age of onset of first CRC grouped by 
birth cohort. 
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 3.4.5.2 Parent- child pairs 
Seventy- five parent- child pairs were identified from the 92 subjects in the 
study cohort. Of these, there were 22 parent- child pairs in whom both the 
parent and child had developed CRC. When analyzing only those pairs in 
which both parents and children had developed CRC, the median age of first 
CRC was 45 years (44.7 to 55.0) for the parents, and 36 years (30.8 to 44.0) 
for the children (P=0.0004, Wilcoxon test. Figure 22). This apparent effect 
persisted when we included only those parent- child pairs with CRC born 
before 1960 (45 years (33-52) for the parents vs.32 years (26-38) for the 
children (P=0.02).  When we analyzed the entire group of 75 parent child 
pairs (using the Kaplan- Meier technique and censoring those who had not 
developed CRC at the end of the follow up period), this apparent effect 
disappeared (P=0.51, Logrank test. Figure 23). 
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Figure 22 Age of onset (in years) of first CRC for parent- child pairs.  
The bars are median age, the error bars are 95% C.I. for the median. 
 
Figure 23 Kaplan- Meier plot of age of onset of first CRC (in years) for 
parent- child pairs. 
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 3.4.5.3 Age of onset of CRC grouped by generation 
The 92 subjects studied were born over five generations, summarized below 
(Table 21).  
Table 21 Age of first colorectal cancer (CRC) by generation. 
Age is stated as Median (95% C.I. for median). In generations 1 and 4 
there were insufficient numbers to calculate the confidence interval. 
Generation Number of subjects Number with 
CRC 
Age of first 
CRC (years) 
1 2 2 60 
2 13 8 46.5 (38.0-62.9) 
3 44 18 38.5 (30.4-45.0) 
4 32 5 35.5 
5 1 0 N/A 
Total 92 33 41.5 (35.2-45.0) 
When analyzing only those subjects who had developed CRC, there was an 
apparent decrease in the age of onset of first CRC over the generations 
(P=0.0091, Kruskall- Wallis test (Figure 24). This apparent effect persisted 
when only the 24 subjects with CRC who were born before 1960 were 
included (P=0.029, Kruskall- Wallis test). When the entire cohort was 
analyzed using the Kaplan- Meier technique, and censoring those without 
CRC by the end of the follow up period, no difference was detected (P=0.59, 
Logrank test, Figure 24). A similar result was obtained when generations one 
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and five (which had very small numbers) were excluded from the analysis 
(P=0.37, Logrank test). 
 
Figure 24 Age of onset (in years) of first CRC grouped by generation 
 
Figure 25 Age of onset of first CRC (in years) by generation (Kaplan- 
Meier) 
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 3.4.6 Discussion 
There was no evidence of genetic anticipation in this study of mutation 
carriers from an extended single family with Lynch syndrome. 
In this study, the appearance of genetic anticipation was falsely detected when 
only individuals who had developed CRC were included in the analysis. This 
is as a result of follow up bias being inadequately controlled for. This occurs 
when older subjects, who have passed through more of their period of risk, 
are compared with younger ones who have not. A subject who has not yet 
manifest the disease, but may develop it later, would not be included in the 
analysis. There are more such subjects in the later generations, and so the 
average age of onset appears (falsely) lower in the more recent cohort[151]. 
This bias can be corrected for by including only subjects who were born 
sufficiently long ago that they have completed their period at risk. The 
analyses were repeated including only subjects born before 1960, with a 
similar result. As the median age of onset of CRC in Lynch syndrome is 45 
years, and they continue to be at risk at least into their seventies, one would 
need to only include subjects born at least 80 years ago to fully correct for this 
type of bias. In previous studies, Nilbert et al [149] found that genetic 
anticipation could be detected even when only subjects with more than 80 
years of potential follow up were considered, whereas Tsai et al [142] found 
that the apparent difference in age of onset of CRC between parents and their 
children was no longer detectable when this birth cohort effect was taken into 
account. There were insufficient numbers of such old patients to test this, and 
indeed genetically proven Lynch syndrome carriers born more than 80 years 
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ago would be extremely rare in any cohort (as genetic testing only first 
became available in the 1990’s).  
After correction for follow up bias by including the entire cohort and by 
applying Kaplan- Meier survival techniques (censoring those who had not yet 
developed CRC), the apparent anticipation effect was no longer detected. In 
previous studies aimed at detecting genetic anticipation in Lynch syndrome 
(Table 20). There was a significant difference in reported anticipation 
between those studies in which survival type statistical analyses were 
performed on cohorts of subjects at risk (mean of two years) and those in 
which only individuals who had developed CRC were studied (mean 7.5 
years) (P=0.0073, Student- t test). 
Genetic anticipation may also be falsely detected due to ascertainment bias. 
By including only subjects from a single family, the risk of ascertainment bias 
that could occur studying multiple families was reduced, and allowed simpler 
statistical methods to be applied. This also allowed subjects to be accurately 
grouped according to their generation in the single pedigree.  
A possible confounder in this study of genetic anticipation in Lynch 
syndrome is the effect of surveillance, which has been shown to delay the 
onset of CRC in this population.  As the oldest subjects developed CRC 
before the surveillance program was instituted, this could cause a real 
anticipation effect to be falsely missed. The sample size in this study may also 
have been insufficient to detect the small anticipation effect (of three years) 
detected in previous studies of large population databases.  
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This study highlights the methodological difficulties in studying genetic 
anticipation in inherited cancers such as Lynch syndrome.   
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 3.5 PAPER V: Fertility and apparent genetic anticipation 
in Lynch syndrome [5] 
 3.5.1 Abstract 
 3.5.1.1 Introduction 
Genetic anticipation is the phenomenon in which age of onset of an inherited 
disorder decreases in successive generations. Inconsistent evidence as 
discussed in chapter 3.4 suggests that this may occur in Lynch syndrome. A 
possible cause for the false appearance of apparent anticipation is fecundity 
bias, which occurs if the disease adversely affects fertility. The purpose of this 
study was to determine the effect of age of diagnosis of colorectal cancer 
(CRC) on lifetime fertility in Lynch syndrome, and whether this can falsely 
create the appearance of genetic anticipation. 
 3.5.1.2 Method 
A computer model simulated age of diagnosis of CRC in hypothetical Lynch 
syndrome carriers and their offspring. The model assumed similar age 
distribution of CRC across generations (i.e. that there was no true 
anticipation).  Age distribution of CRC diagnosis, and lifetime fertility rates 
(grouped by age of diagnosis of CRC) were determined from the Australasian 
Colorectal Cancer Family Registry (ACCFR). Apparent anticipation was 
calculated by comparing ages of diagnosis of CRC in affected parent- child 
pairs. 
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 3.5.1.3 Results 
A total of 1088 patients with CRC were identified from the ACCFR. Total 
lifetime (cohort) fertility was related to age of diagnosis of CRC (correlation 
coefficient 0.13, P= 0.0001). In the simulation, apparent anticipation was 1.8 
± 0.54 years (P=0.0044). Observed apparent anticipation in the ACCFR 
cohort was 4.8 ±1.73 years (P = 0.0064). There was no difference in apparent 
anticipation between the simulated and observed parent- child pairs (P = 
0.89). 
 3.5.1.4 Conclusion 
The appearance of genetic anticipation in Lynch syndrome can be falsely 
created due to changes in fertility 
.  
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 3.5.2 Introduction 
In Chapter 3.4, it was shown that the appearance of genetic anticipation can 
be falsely caused by follow up bias, and that this artefact disappeared when 
survival analysis techniques were used to correct for incomplete follow up.  
Another potential cause of falsely apparent anticipation is referred to as 
fecundity bias. This occurs if the disease adversely affects fertility, so 
individuals who develop the disease at a younger age are likely to have fewer 
children than those who are diagnosed at an older age.  No previous studies of 
anticipation in Lynch syndrome (or in any inherited condition) have examined 
whether fecundity bias can mimic genetic anticipation, and therefore be the 
explanation for any apparent anticipation.  
The purpose of this study was (i) to determine the effect of age of onset of 
CRC on lifetime fertility in Lynch syndrome, (ii) to determine by computer 
simulation whether observed changes in fertility can falsely create the 
appearance of genetic anticipation, and to what extent, (iii) to compare the 
results of that simulation with the observed appearance of genetic anticipation 
in a large series of families with Lynch syndrome. 
 3.5.3 Method  
The Australasian Colorectal Cancer Family Registry (ACCFR) is a registry of 
more than 11500 people from 1800 families in Australia and New Zealand 
[152]. This registry contains CRC families recruited through the Victorian 
Cancer Registry (960 population-based case-families) and from family cancer 
clinics throughout Australia and New Zealand (580 clinic-based case-
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families), as well as families of people without CRC recruited through the 
Victorian electoral roll (270 control-families). For all family members, 
personal and family history of cancer, reproductive history, and other lifestyle 
and personal characteristics were collected by questionnaire.  Attempts were 
made to verify all reports of CRC diagnoses by medical records, pathology 
reports, death certificates and linkage to national cancer registry and death 
registry databases.  
Individuals who had developed CRC, and who were members of families 
known to carry MMR gene mutations (Lynch syndrome families) were 
categorised by age of diagnosis of CRC.  Cohort fertility (the mean number of 
children born to each individual by the end of their reproductive life- defined 
as over the age of 50 years) was calculated for each age group of CRC 
diagnosis (for both men and women). We only included subjects born before 
1963 in this analysis in order to include only those who had completed their 
period of potential fertility. 
 3.5.3.1 Model design 
A computer model was designed to simulate the age of diagnosis of CRC in 
large numbers of hypothetical MMR gene mutation carrying men and women 
(first generation) and their offspring (second generation). The model assumed 
complete follow-up over the lifetime for all individuals, and assumed the age 
distribution of CRC diagnoses to be the same across generations (i.e. that 
there was no genetic anticipation). In this setting any apparent genetic 
anticipation would be an artefact.  
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Because follow up was over the entire lifetime of the hypothetical subjects in 
both generations, and the complete lifetime risk was applied to each subject, 
follow up (ascertainment) bias will not cause the false appearance of genetic 
anticipation in this model.  
The model generated an equal number of men and women in the first 
generation, and allocated gender at random (with a 50:50 chance) to the 
second generation individuals. 
Age of diagnosis of first CRC was randomly assigned according to the 
(gender-specific) observed distribution of age of first CRC diagnosis from the 
ACCFR cohort. The number of offspring born to each first generation carrier 
was randomly assigned according to the observed (gender-specific) 
distribution of lifetime fertility according to the age of diagnosis of CRC as 
calculated above.  Each second generation individual was given a 50% chance 
of inheriting the MMR gene mutation. For each mutation-carrying child, age 
of diagnosis of first CRC was allocated in the same way as for their parents.  
The simulation was run for 1000 first generation subjects. Ages of diagnoses 
of CRC were compared between the simulated parents and their affected 
children.  
The code for the model (written in Microsoft Visual Basic for Applications) 
forms appendix III. 
 3.5.3.2 Model validation: observed apparent anticipation in the ACCFR 
cohort 
The appearance of genetic anticipation in the ACCFR cohort was sought by 
comparing the age of diagnosis of first CRC between parents with their 
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affected children (‘parent- child pairs’). Parent- child pairs were identified if 
both the parent and child had been diagnosed with CRC. Subjects were 
included if they were proven mutation carriers, or if their mutation status was 
unknown but their family was known to carry a MMR gene mutation. This 
analysis was repeated using only parent- child pairs in whom the children 
were born more than 80 years ago. This minimizes the chance of incomplete 
follow up of the children falsely lowering the apparent age of diagnosis of 
CRC relative to their parents (follow up bias), and is in keeping with the 
methodology used by Nilbert et al [149]to correct for the birth cohort effect 
that can falsely create the appearance of anticipation. 
 3.5.3.3 Statistical analysis 
Mean age of diagnosis of first CRC was compared using the Student’s t- test.  
A P - value of 0.05 was regarded as statistically significant. Correlation was 
determined using Spearman’s rank method. Statistical analysis was done 
using MedCalc for Windows (MedCalc Software, Ostend, Belgium). All 
results are stated as mean ± standard error of the mean unless otherwise 
specified. 
 3.5.3.4 Ethics 
Ethical approval for the study was granted by the University of Melbourne 
Ethics Committee. 
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 3.5.4 Results 
 3.5.4.1 Age of onset of colorectal cancer in the ACCFR  
The ACCFR database contained complete data for 9350 members of 295 
families known to carry Lynch syndrome mutations. Of these, 1088 patients 
(568 men and 520 women) have been diagnosed with CRC. The mean age of 
diagnosis of CRC was 46.8±14.3 years (46.3±13.3 for the men, and 47.3±15.4 
for the women, P = 0.24). The ages of onset of CRC are illustrated below 
(Figure 26). 
 
Figure 26 Histogram of age (in years) of first CRC diagnosis in subjects 
from the ACCFR. 
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 3.5.4.2 Cohort fertility in the ACCFR 
A total of 981 (512 male and 469 female) patients with CRC were born before 
1963, and the cohort fertility rates were calculated from this group. Cohort 
fertility grouped by age of diagnosis of CRC is illustrated in below (Figure 
27). Total lifetime (cohort) fertility was related to age of diagnosis of CRC in 
men (correlation coefficient 0.143, P=0.0012), women (correlation coefficient 
0.104, P= 0.04) and overall (correlation coefficient 0.13, P=0.0001). 
Figure 27 Cohort (lifetime) fertility rates vs. age (in years) of diagnosis of 
CRC 
 3.5.4.3  Simulation 
Using the above parameters, the simulation was run for 1000 first generation 
mutation carriers. This generated 1169 simulated offspring who were 
mutation carriers. The mean difference in age of diagnosis of first CRC 
between simulated parents and their mutation positive offspring (apparent 
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anticipation) was 1.8 ± 0.54 years (P=0.0044). Apparent anticipation was 
similar for male (1.1 ± 0.77) and female (1.9 ± 0.72) simulated parents 
(P=0.44). 
 3.5.4.4 Apparent anticipation in the ACCFR cohort 
A total of 461 parent- child pairs with CRC were identified within the 
ACCFR study cohort. The mean age of diagnosis of first CRC was 51.1 ± 
0.63 years in the parent group, and 42.3 ± 0.56 years in their children 
(P<0.0001). When only those parent child pairs with a potential follow up of 
over 80 years (i.e. only subjects born before 1933) were included, 120 parent- 
child pairs were identified. In this group, the mean age of diagnosis of first 
CRC was 53.9 ± 0.68 years in the parent group, and 49.1 ± 0.67 years in their 
children (apparent anticipation 4.8 ±1.73 years, P=0.0064). There was no 
significant difference in apparent anticipation between the simulated (1.8 
years) and observed (4.8 years) parent-child pairs (P=0.89). 
 3.5.5 Discussion 
This simulation demonstrates that the appearance of genetic anticipation in 
Lynch syndrome can be created due to changes in lifetime fertility in MMR 
gene mutation carriers with CRC.  The apparent anticipation predicted by the 
model was not significantly different from the observed appearance of 
anticipation in the AFCCS families with Lynch syndrome, and was in keeping 
with the observed anticipation in large studies of the Danish HNPCC registry 
of between three and nine years (as reported by Larson et al [148]and 
Boonstra et al [150]).  
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There was a marked decrease in lifetime fertility in mutation carriers with 
early diagnosis of CRC compared with those who developed CRC later in 
life. For example, women diagnosed with CRC between ages 20 and 24 years 
gave birth to a mean of 1.2 children in their lifetime compared with women 
diagnosed with CRC after age 50 years who gave birth to a mean of 2.8 
children in their lifetime. The reasons for the reduction in fertility after CRC 
in these patient groups have not been studied here, but cancer-related 
morbidity, the effects of surgery, chemotherapy and radiotherapy, and 
personal choice can all be expected to play a role. It may also simply reflect 
the reduced lifespan of patients who develop CRC at a young age. No 
previous studies have documented fertility rates after CRC in Lynch 
syndrome although reduced fertility is well recognized in patients who receive 
certain types of chemotherapy or radiotherapy, and suspected to occur after 
surgery for CRC [153]. It is this reduction in fertility that contributed to 
apparent anticipation in our model. 
A potential cause for apparent genetic anticipation is follow- up bias[151]. 
This can be corrected for by including only subjects who were born 
sufficiently long ago that they have completed their period at risk[149] (in this 
case by including only subjects (from both generations) who were born at 
least 80 years ago). This type of bias cannot fully explain the observed 
appearance of anticipation in parent-child pairs from the ACCFR as it still 
existed when only mutation carriers with more than 80 years of potential 
follow up (i.e. born before 1933) were included. This is in keeping with the 
findings of Nilbert et al [149], whereas Tsai et al [142] found no difference in 
 156
age of diagnosis of CRC between parents and their children when the birth 
cohort effect was taken into account.  
Subjects with CRC who were not proven MMR gene mutation carriers (but 
were from families known to carry MMR gene mutations) as well as those 
who were confirmed to carry mutations in the MMR genes were included, in 
keeping with the methodology of previous authors[142, 149]. This was to 
allow inclusion of a sufficient number of patients with adequate potential 
follow up. One would expect the great majority of subjects with CRC born 
before 1933 to have died before mutation analysis became available. In the 
ACCFR database, there were 2128 individuals born before 1933, of whom 
433 (20.3%) were diagnosed with CRC. Of these 433, only 59 (13.6%) have 
undergone genetic testing.  
In conclusion, fecundity bias can falsely create the appearance of genetic 
anticipation in Lynch syndrome. This highlights the statistical complexity of 
studying genetic anticipation and the on- going uncertainty as to whether the 
phenomenon occurs in this disease.  
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 3.6 PAPER VI: Fertility after young- onset colorectal 
cancer in Lynch syndrome [6]. 
 3.6.1 Abstract 
 3.6.1.1 Introduction 
Potential infertility is a significant concern for young colorectal cancer (CRC) 
survivors, but this risk is not well quantified. Mismatch repair (MMR) 
mutation carriers are a useful cohort for studying fertility after CRC as they 
commonly develop CRC at a young age, and unaffected family members 
provide demographically similar controls.  The aim of this study was to 
determine the effect of CRC on fertility in a large cohort of MMR mutation 
carriers. 
 3.6.1.2 Methods 
MMR mutation carriers identified from the Australasian Colorectal Cancer 
Family Registry were included. For each year of life within the fertile age 
range (15 to 49), the number of living subjects and the number of children 
born to them were determined. Subjects were grouped by whether they had a 
CRC diagnosis by that age or not. Age- specific and total fertility rates were 
calculated.  
 3.6.1.3 Results 
1068 subjects (611 women and 457 men) were identified, of whom 467 were 
diagnosed with CRC. There were 1,192 births during 18674 person- years of 
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follow up to the women, and 814 births during 14013 person- years of follow 
up to the men.  
Total fertility rate (TFR) was decreased in women with a CRC diagnosis 
compared to those without (1.3 vs. 2.2, P=0.0011), but age- specific fertility 
was only reduced in the 20-24 year age group. In men TFR was similar for 
both groups (2.0 vs. 1.8, P=0.27). 
 3.6.1.4 Conclusion 
Age- specific fertility was decreased in female CRC survivors aged 20-24 
years, but not in older women or in men. 
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 3.6.2  Introduction 
In chapter 3.5 it was found that there was a reduction in the total (lifetime) 
number of children born to subjects from the ACCFR cohort who were 
diagnosed with CRC at a young age [5], but it was not known whether this 
was due to a true reduction in fertility among survivors, or if it was simply 
due to decreased survival. 
Although CRC predominantly affects older patients, approximately 4% of 
cases occur in individuals who are under 45 years of age[154]. Among young 
CRC survivors, potential infertility is known to be a significant concern [155]. 
The American Society of Clinical Oncology (ASCO) has published guidelines 
recommending that oncologists discuss the possibility of infertility with their 
patients, while acknowledging that in many cases there are insufficient data 
available to accurately assess this risk[156].  
In two recent reviews, Spanos et al[157] and O’Neill et al[153] both noted 
that there was no evidence that colon cancer surgery or 5-fluorouracil 
chemotherapy affected fertility, but expressed concerns about the effects of 
rectal surgery and radiotherapy, as well as newer chemotherapy agents. The 
authors of both papers emphasised the importance of adequate pre- treatment 
fertility counselling and discussed the merits of fertility preservation options 
that a CRC survivor could be offered. These include embryo preservation and 
oocyte vitrification. Kumar et al [158] reported that fertility discussion 
occurred in only one third of CRC patients under the age of 40 years at their 
institution. They concluded that it was important to educate health care 
professionals about the importance of fertility risk discussion, while 
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acknowledging the lack of direct evidence for fertility risk due to colon 
surgery or chemotherapy.  
The only previously published study directly comparing fertility rates for 
women with or without gastrointestinal cancer was by Hartman et al [159]. 
They reported a 10% reduction in fertility for women less than 45 years of age 
compared with the Swedish general population. In this study, age- specific 
fertility rates in cancer survivors (for a number of different tumors, including 
gastro- intestinal) were compared with those of the general Swedish 
population using the technique of indirect standardisation. This involves 
determining age- specific birth rates for the reference population, and 
applying these to the study population to calculate the expected number of 
events for that population. The authors calculated a standardised birth rate 
(SBR, an indirectly standardised rate) for gastrointestinal cancer survivors of 
0.90 (95% C.I. 0.83 to 0.97), but did not quote age- specific birth rates for the 
study population. Indirectly standardised rates can give misleading results, 
however, in any situation where the age profiles of the study and reference 
populations are not similar[160] 
No previously published studies have documented age- specific fertility rates 
for female CRC survivors, and fertility rates in male CRC survivors have not 
been reported. 
Lynch syndrome families provide a useful cohort for studying the effect of 
CRC on fertility, as CRC in this population commonly occurs in subjects who 
are within the potentially fertile age group, and unaffected family members 
can be used as demographically similar controls. 
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 3.6.3 Aim 
The aim of this study was to determine the effect of CRC on age- specific 
fertility rates in a large cohort of subjects who carry MMR gene mutations.  
 3.6.4 Methods 
The Australasian Colorectal Cancer Family Registry (ACCFR) is a registry of 
more than 11,500 subjects from 1800 families in Australia and New 
Zealand[152]. This registry contains CRC families recruited through the 
Victorian Cancer Registry and from family cancer clinics throughout 
Australia and New Zealand. Personal and family history of cancer and 
reproductive history were collected by questionnaire.  Attempts were made to 
verify all reports of CRC diagnoses and date of death by medical records, 
pathology reports, death certificates and linkage to national cancer registry 
and death registry databases.  
Subjects identified from the ACCFR with proven germline mismatch repair 
gene mutations were included in this study. Methods for screening and testing 
for MMR gene mutations have been described in detail elsewhere [161]. 
The period of potential fertility was considered to be between the ages of 15 
to 49 years, in keeping with the World Health Organisation[162] and the 
Australian Bureau of Statistics[163] norms for describing population fertility 
rates. For each year of life within this age range, the total number of subjects 
known to be alive at that age and the number of children born to them were 
determined. Subjects in each year of life were grouped according to whether 
they had been diagnosed with CRC by that age or not (so a subject who, for 
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example was diagnosed with CRC at age 29 years would be counted in the 
‘no CRC diagnosis’ group from ages 15 to 28 years, and in the ’after CRC 
diagnosis’ group for each year of life from age 29 years until age 49 years, 
death or last follow up).  
Fertility rates were compared between those subjects who had been diagnosed 
with CRC and those who had not. Female fertility rates were also compared 
with the known fertility rates of the Australian female general population 
(1975 to 2010) as reported by the Australian Bureau of Statistics[163] (male 
fertility rates for the general population are not recorded). 
 3.6.4.1  Age- specific fertility rates 
Age- specific fertility rate (ASFR) is the number of children born per person 
per year at risk within a given age group. It is usually expressed as births per 
1000 population per year. It is calculated as: 
    
Where:  is the number of births observed in age group i. 
  is population- years at risk in age group i. 
Total fertility rate (TFR) is the average number of children a hypothetical 
cohort of women would bear if they had children at the population age- 
specific rates during their whole lives, and survived to the end of their fertile 
period. It is usually expressed as children per women, and is calculated as the 
sum of age specific fertility rates for the ages 15 to 49 years [162].  
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Fertility rates are usually calculated for entire populations (rather than 
samples of populations), and so the current literature does not describe any 
standard statistical methods for estimating confidence intervals for TFR or 
comparing TFR between population samples. Statistical methods designed for 
comparing standardised rates can, however, be applied to fertility rates. This 
is described in detail below. 
 3.6.4.2 Indirect standardisation 
The process of indirect standardisation involves determining stratum- specific 
event rates for the reference population, and applying these to the study 
population to calculate the expected number of events for that population. In 
this case, the events are births, and the populations are stratified by age. The 
‘population’ here is person- years, so a rate of births/person/year is calculated, 
rather than a ratio. 
The indirectly standardized rate (ISR) is the ratio of observed (in the study 
population) to expected events. In other words it is the ratio of actual births in 
the study population to the number of births that would be expected to occur 
if the study population had the same age distribution as the reference 
population (and age- specific birth rates were similar for the two populations). 
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The indirectly standardised rate (ISR) is calculated as follows: 
   

  


Where: O is the total number of observed events in the study population 
E is the total number of expected events 
Oi is the observed number of events in the study population in age- 
group i 
Ei is the number of expected events in age- group i 
ni is the number of individuals in age group i in the study population 
λi is the age- specific event rate for age group i in the reference  
population 
Note that the indirectly standardised rate can be calculated without knowing 
the age- specific event rates in the study population. The total number of 
events needs to be known, as well as the age distribution of the study 
population. The age- specific event rates for the reference population must 
also be known, but the population age distribution of the reference population 
is not required. 
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 3.6.4.3 Indirect standardisation: example 
This is illustrated in the example below, comparing age- specific fertility rates 
between women from the ACCFR with or without a CRC diagnosis. Here the 
‘study population’ is women- years with a CRC diagnosis and the ‘reference 
population’ is women- years without a CRC diagnosis. 
Strata 
(age 
groups) 
i 
Events 
(Study 
Population) 
Oi 
Study 
Population 
ni 
Events 
 (Reference 
Population) 
Reference 
Population 
Reference 
Rates 
λi 
Expected 
Events 
Ei = λini 
15-19 0 8 86 3045 0.028 0.2 
20-24 0 36 382 2992 0.128 4.6 
25-29 14 113 399 2813 0.142 16.0 
30-34 16 165 228 2579 0.088 14.6 
35-39 11 281 104 2263 0.046 12.9 
40-44 1 437 8 1864 0.004 1.9 
45-49 0 581 0 1497 0.000 0.0 
∑Oi = 42 ∑Ei = 50 
Here the indirectly standardised rate (ISR) = 42/50 = 0.84. 
 3.6.4.4 Study population distribution and the interpretation of indirectly 
standardised rates 
A problem with using indirectly standardised rates in this setting is that the 
weighting used to determine the ISR is determined by the study population 
distribution. This means that, for example, even if the stratum- specific rates 
of two study populations were identical, and they were being compared with 
the same reference population, the ISR can be quite different if the age 
distributions of the study populations are different. The ISR can also be 
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misleading if the study and reference populations have different age 
distributions[160]. 
This can be illustrated with the hypothetical data set below. In this 
hypothetical population, the age- specific fertility rates are identical to those 
of the actual ACCFR women with a CRC diagnosis, but the age distribution 
of the sample population is reversed. 
If one was to compare the age- specific fertility rates of this hypothetical 
population with the same reference population as above (ACCFR women with 
a CRC diagnosis) by indirect standardisation, the results would be as follows: 
Strata 
(age groups) 
i 
Events 
(Study 
Population) 
Oi 
Study 
Population 
ni 
Events 
 (Reference 
Population) 
Reference 
Population 
Reference 
Rates 
λi 
Expected 
Events 
Ei = λini 
15-19 0 581 86 3045 0.028 16.4 
20-24 0 437 382 2992 0.128 55.8 
25-29 35 281 399 2813 0.142 39.9 
30-34 16 165 228 2579 0.088 14.6 
35-39 4 113 104 2263 0.046 5.2 
40-44 0 36 8 1864 0.004 0.2 
45-49 0 8 0 1497 0.000 0.0 
∑Oi = 55 ∑Ei= 132 
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Here the indirectly standardised rate (ISR) = 55/132 = 0.42, which is half 
the ISR for the actual population, despite the two study populations having 
identical age- specific fertility rates, and using the same reference population. 
This illustrates that the ISR is dependent on the age distribution of the study 
population, and therefore cannot be meaningfully interpreted in situations 
where the study and reference populations’ age distributions differ 
significantly. 
In this study, the groups with or without a CRC diagnosis (unsurprisingly) 
have markedly different age distributions (illustrated below (Figure 28), and 
so ISR is not useful. 
Figure 28 Age distribution of subjects with or without a CRC diagnosis. 
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 3.6.4.5 Direct standardisation 
In the direct method of standardisation, the stratum- specific event rates from 
the study population are applied to an arbitrarily chosen reference population 
to calculate the expected number of events in the reference population if it 
had the same stratum- specific event rate as the study population. This is in 
contrast to the indirect method, where stratum- specific rates for the reference 
population are used to calculate the expected number of events for the study 
population. 
The directly standardised rate (DSR) is calculated as follows:  
    

  
 
  
  
  
Where: O is the total number of observed events in the study population 
 E is the total number of expected events in the reference population 
 P is the total reference population 
 Ei is the number of expected events in age- group i 
 Pi is the population of age group i in the reference population 
 ri is the age- specific event rate in age group i of the study group 
 Oi is the observed number of events in the study population in age- 
group i 
 ni is the number of individuals in age group i in the study population 
Commonly used reference populations are the World Health Organisation 
(WHO) world standard population[164] and USA 2000[165], but in principle 
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any population can be used according to the purpose of the comparison. The 
main advantage to using the DSR rather than ISR is that the DSR is 
independent of the age distribution of the study population (it is a weighted 
average determined by the age distribution of the reference population). This 
means that the DSR of multiple study populations can be meaningfully 
compared with each other, as long as the same reference population is used. 
Using the above hypothetical example, the directly standardised age- specific 
rates are similar for each age group, and the DSR for both populations is 692 / 
17053 X 1000 = 41 per thousand women overall.  
This is illustrated below (note that fertility rate is given as births/ 1000 
population). 
ACCFR women post CRC Hypothetical population 
Age 
groups 
Reference 
population 
Births Population Fertility 
rate 
Births Population Fertility 
rate 
Pi ri riPi ri riPi 
15-19 3045 0 8 0 0 0 581 0 0 
20-24 2992 0 36 0.0 0 0 437 0.0 0 
25-29 2813 14 113 124 349 35 281 124 349 
30-34 2579 16 165 97 250 16 165 97 250 
35-39 2263 11 281 39 89 4 113 39 89 
40-44 1864 1 437 2.3 4 0 36 2.3 4 
45-49 1497 0 581 0 0 0 8 0 0 
∑ 17053 692 692 
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 3.6.4.6 Total fertility rate is a form of direct standardisation 
Total fertility rate (TFR) is calculated as follows: 
   

 
Where:  is the age- specific fertility rate for ages a from 15 to 49. 
Or as 
   

 
For five- year age groups I from 15-19 to 45-49. 
So: 
   
 
Where: oi is the number of births in population ni for age group i. 
So: 
  
  
  
when    and the population strata are all of equal size (i.e. when  
    for each i, and q is the number of age strata). In the usual reporting 
of ASR,    (the number of five- year age groups from 15 to 49). 
So total fertility rate (TFR) can be considered a special case of a direct 
standardisation in which the standard population is one and the population is 
evenly distributed across the seven age groups. We can, therefore, use 
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statistical tools designed for the analysis of directly standardised rates in order 
to calculate confidence intervals for total fertility rates. 
 3.6.4.7  Confidence intervals for age- specific rates 
For each age- specific rate, the confidence interval  can be calculated using 
Byars method as described by Breslow et al [166]. Using this method, the 
100(1-α)% confidence interval limits   and   for the number of 
observed events are calculated as follows: 
   

 

 

      

    

   

Where: O is the total number of observed events in the study population 
Z is the 100(1-α/2)th percentile value from the standard normal 
distribution (for example, for a 95% C.I. α = 0.05 and z = 1.96 
(which is the 97.5th percentile value from the standard normal 
distribution). 
The confidence interval limits for the rate are then calculated as: 
 


 


 Where: n is the number of person- years. 
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 3.6.4.8  Confidence intervals for directly standardised rate (DSR) 
A directly standardised rate (DSR) is a weighted sum of the age- specific 
rates, so the variance of the DSR is the weighted sum of the variances of those 
rates[167]. A widely accepted method [160] for calculating the confidence 
interval for a DSR(when  the rates are assumed to be independent and to 
follow a Poisson distribution) is that described by Dobson et al [167] as 
follows: 
    
 
     
    

    
The confidence limits   and   of the crude (total) number of 
observed events are calculated using Bryar’s method as above and the 
variances of the observed (crude) count, and the DSR are estimated as 
follows: 
   

 
    


 


 
 3.6.4.9 Direct standardisation and total fertility rate: example 
In this example, the age- specific birth rates are for women from the ACCFR 
without a CRC diagnosis. These can be directly standardised against a 
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reference population of 1 with seven equal age groups (Pi = 1/7 ≈ 0.1429) as 
follows: 
Age groups Births 
Oi 
Study population 
ni 
Reference population 
Pi 

  


15-19 86 3045 0.1429 0.0040 1.89E-07 
20-24 382 2992 0.1429 0.0182 8.71E-07 
25-29 399 2813 0.1429 0.0203 1.03E-06 
30-34 228 2579 0.1429 0.0126 7.00E-07 
35-39 104 2263 0.1429 0.0066 4.15E-07 
40-44 8 1864 0.1429 0.0006 4.70E-08 
45-49 0 1497 0.1429 0 0 
Total O = 1207 17053 1 0.062 3.3E-06 
Here: 


  
 
  
   
     

 
    


 


  


  
The 95% C.I. for the observed births O is as follows: 
   

 

 

   

 

  
      

    

   

    

 

  
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The 95% C.I. for the DSR is: 
    
 
     
  

      
    

    
  

      
The TFR and the C.I. for the TFR can now be calculated by multiplying the 
DSR and the confidence limits of the DSR by 35 (as there are seven age strata, 
each of which is a 5- year age group). So in this example: 
Total fertility rate = 2.2 births/ woman (95% C.I. 2.1 to 2.3) 
 
 3.6.4.10 Comparing two directly standardised rates 
Comparing the directly standardised rates between two cohorts which have 
been standardised against the same reference population, the standard error of 
the ratio of the two rates can be calculated as follows (Breslow and Day[166] 
recommend transformation to a log scale to correct the skewness of the 
distribution of the ratio): 
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 

 


 
 


 

One can then test the null hypothesis (that DSR2/DSR1 = 1) using standard 
normal distribution tables. 
 3.6.4.11 Comparing two total fertility rates: example 
Using the example of women from the ACCFR with or without CRC: 
After CRC diagnosis No CRC diagnosis 
Age 
group 
Reference 
population 
(Pi) 
Births 
O1i 
Population 
n1 
Standardised 
rate1 
Births 
O2i 
Population 
n2 
Standardised 
rate2
15-19 0.1429 0 8 0.0000 86 3045 0.0040 
20-24 0.1429 0 36 0.0000 382 2992 0.0182 
25-29 0.1429 14 113 0.0177 399 2813 0.0203 
30-34 0.1429 16 165 0.0139 228 2579 0.0126 
35-39 0.1429 11 281 0.0056 104 2263 0.0066 
40-44 0.1429 1 437 0.0003 8 1864 0.0006 
45-49 0.1429 0 581 0.0000 0 1497 0.0000 
DSR 0.037 0.062 
Here the TFR for women with a CRC diagnosis is 0.037 X 5 X 7 = 1.3 births/ 
woman, and the TFR for women without a CRC diagnosis is 0.062 X 5 X 7 
=2.2 births/ woman. The ratio of the two TFR’s (which is the same as the 
ratio of the two DSR’s) is 1.7 


   
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 

 


 
 


 
   
 
To test the null hypothesis:     
Which is equivalent to:      
 
 
  
  
   
In all cases where TFR’s  were compared between groups, the P- values 
calculated as above were consistent with the simpler but less precise 
estimation of significant difference by determining whether the confidence 
intervals overlap.  
 3.6.4.12 Statistics summary 
Age- specific fertility rates were compared using the Chi square test. 
Confidence intervals (CI) for  age- specific fertility rates and total fertility rate 
were calculated using Byar’s method for direct standardisation as described 
by Breslow and Day [166]. Confidence intervals for total fertility rates were 
calculate using the widely accepted method [160, 166] described by Dobson 
et al [167] as described above. A P- value of <0.05 was regarded as showing 
significant difference. Statistical analysis was done using Microsoft Excel 
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2010 (Redmond, Washington) and Medcalc® 2008 (Mariakerke, Belgium) 
software.  
 3.6.4.13 Ethics 
Ethical approval for the study was given by the University of Melbourne 
Research Ethics Committee. 
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 3.6.5 Results 
A total of 1068 subjects (611 women and 457 men) with proven germline 
MMR mutations were identified, of whom 467 were diagnosed with CRC. 
There were 417 subjects diagnosed with colon cancer, and 82 with rectal 
cancer (32 subjects were diagnosed with metachronous cancers at both sites). 
Among subjects under the age of fifty years, there were a total of 322 CRC 
diagnosed (285 colon and 45 rectum). They were followed up to a median age 
of 55 (range 18 to 96) years.  
For subjects aged 15 to 49 years, there were a total of 1,192 children born 
during 18674 person- years of follow up for the women, and 814 births during 
14013 person- years of follow up for men. No births occurred in subjects 
under 15 years of age. No women in this cohort gave birth over the age of 49 
years. Four children were fathered by men over 49 years of age. 
Age- specific fertility rates for all women from the study cohort (regardless of 
CRC diagnosis) and from the Australian general population are presented 
below (Table 22 and Figure 29). Age- specific fertility rate was higher in the 
study group than the Australian general population for women in the 15-19, 
20-24 and 25-29 year age groups, but not in other age groups. Total fertility 
rate for women in the study group was 2.2 (95% C.I 2.0 to 2.3), which was 
higher than for women in the Australian general population (TFR 1.87).  
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Table 22 Age- specific fertility rates for women from the entire study 
group and from the Australian general population.  
No confidence intervals are given for the Australian population as these 
are from population census figures, not a sampled population. Age 
specific fertility rates for the study cohort which are significantly 
difference from the general population rate are in bold type. 
Study cohort Australian 
population 
Age 
groups 
Births Person- 
years 
Fertility 
rate 
95% C.I. Fertility rate 
15-19 86 3053 28 23-35 22 
20-24 382 3028 126 114-139 79 
25-29 413 2926 141 128-155 125 
30-34 244 2744 89 78-101 99 
35-39 115 2544 45 37-54 41 
40-44 9 2301 3.9 1.8-7.4 7.3 
45-49 0 2078 0 0-1.8 0.4 
TFR 2.2 2.0-2.3 1.9 
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Figure 29 Age- specific fertility rates for women from the study cohort vs. 
the Australian general population.  
Age- specific fertility rates are given as births/ 1000 person- years. Error 
bars are 95% confidence interval (C.I.). No C.I. are presented for the 
general population data as these are population census figures, not from 
a sampled population. 
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The age- specific fertility rates for study subjects with or without a CRC 
diagnosis are presented below (Results for women are presented in Table 23 
and Figure 30; results for men are in Table 24 and Figure 31). 
For women in the 20- 24 year age group, age specific fertility was lower in 
those with a CRC diagnosis  (0 births/1000 person- years in those who had 
been diagnosed with CRC vs. 128 births/1000 person- years in subjects who 
had not been diagnosed with CRC, P=0.019). There was no statistically 
significant difference in age- specific fertility rates between women with or 
without a CRC diagnosis in any other age group. There was no statistically 
significant difference in age- specific fertility rates between men who had 
been diagnosed with CRC compared with those without a CRC diagnosis in 
any age group.  
Overall, total fertility rate was lower in women with a CRC diagnosis 
compared to those without a CRC diagnosis (1.3 (95% C.I 0.90 to 1.8) vs. 2.2 
(95% C.I. 2.1 to 2.3) P=0.0011. In men, there was no significant difference in 
TFR between the two groups (2.0 (95% C.I. 1.8 to 2.1) for men without a 
CRC diagnosis vs. 1.8 (95% C.I. 1.1 to 2.7) for those with a CRC diagnosis 
(P=0.27). 
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Figure 30 Age- specific fertility rates for women from the study cohort 
with or without a CRC diagnosis.  
Age- specific fertility rates are given as births/ 1000 person- years. Error 
bars are 95% C.I. The upper C.I. for subjects with CRC in age group 25-
29 has been truncated. 
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Figure 31 Age- specific fertility rates for men with or without a CRC 
diagnosis.   
Age- specific fertility rates are given as births/ 1000 person- years. Error 
bars are 95% C.I. The upper C.I. for subjects with CRC in age groups 
20-24 and 25-29 have been truncated 
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Subjects diagnosed with colon or rectal cancers were also analysed separately, 
and these results are shown in Table 25 (There were no men who developed 
rectal CA under the age of 20, so the age- specific fertility rate for the 15-19 
year old subjects in this group could not be calculated. The sample sizes were 
too small to calculate meaningful confidence intervals for age- specific 
fertility rates for a number of groups). For women with a colon cancer 
diagnosis, the results were similar to the findings for CRC overall.  Age- 
specific fertility rate for women with a colon cancer diagnosis in the 20-24 
year age group was reduced, with 0 births/ 1000 person- years compared with 
128 births/ 1000 person years  for women without a CRC diagnosis(P=0.017). 
Age- specific fertility rates for women with a colon cancer diagnosis for all 
other age groups were similar to those for women without a CRC diagnosis. 
Total fertility rate for women with a colon cancer diagnosis was reduced 
compared to women without a CRC diagnosis (1.5 (95% C.I. 1.1-2.1) vs. 2.2 
(95% C.I 2.1-2.3), P=0.016). For women who were diagnosed with rectal 
cancer, there was no significant difference in any of the age- specific fertility 
rates compared with women without a CRC diagnosis, but there was an 
overall reduction in total fertility rate (0.72 (95% C.I 0.2-1.7) vs. 2.2 (95% 
C.I. 2.1-2.3), P=0.015). There were no significant differences in age- specific 
fertility rates for men with colon or rectal cancer diagnoses compared with 
subjects without a CRC diagnosis. Total fertility rate for men after colon 
cancer was similar to that for men without a CRC diagnosis (1.7 (95% C.I. 
1.0 to 2.5) vs. 1.8 (95% C.I. 1.1-2.7), P= 0.72). TFR for men after a rectal 
cancer diagnosis was also similar to men without a CRC diagnosis (1.84 (95% 
C.I. 0.39-5.0) vs. 1.8 (95% C.I. 1.1-2.7), P=0.38.  
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Table 25 Age- specific fertility rates for subjects after a CRC diagnosis, 
grouped by site of tumor (colon vs. rectum).  
Age- specific fertility rates are given as births/ 1000 person- years. Total 
fertility rate (TFR) is given as births/ person. 
Age 
groups 
Births Person- 
years 
Fertility 
rate 
95% 
C.I.
Births Person- 
years 
Fertility 
rate 
95% 
C.I.
After Colon CA diagnosis (women) After Rectal CA diagnosis (women) 
15-19 0 8 0 N/A 0 3 0 N/A 
20-24 0 34 0 0-108 0 8 0 N/A 
25-29 14 90 156 85-261 4 28 143 38-366
30-34 16 151 106 61-172 0 29 0 0-126
35-39 10 251 40 19-73 1 53 20 0.25-105 
40-44 1 401 2.5 0.03-14 0 71 0 0-52
45-49 0 532 0 0-6.9 0 91 0 0-40
TFR 1.5 1.1-2.1 0.72 0.2-1.7 
After Colon CA diagnosis (men) After Rectal CA diagnosis (men) 
15-19 0 1 0 N/A 0 0 N/A N/A 
20-24 0 15 0 0-245 1 7 143 N/A 
25-29 8 44 182 78-358 1 10 100 N/A 
30-34 11 131 84 42-150 1 12 83 N/A 
35-39 12 242 50 26-87 1 42 24 0.3-132 
40-44 5 358 14 4.5-33 0 61 0 0-60
45-49 1 462 2.2 0-12 0 87 0 0-42
TFR 1.7 1.0-2.5 1.84 0.39-5.0 
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 3.6.6 Discussion 
In this cohort of people with germline MMR mutations, total fertility rate for 
women was decreased by approximately 40% after a diagnosis of CRC. The 
reduction in age- specific fertility rates could only be detected in younger 
women (age 20 to 24), and was not apparent in other age groups. A CRC 
diagnosis did not adversely affect age- specific fertility in men. Both colonic 
and rectal cancer diagnoses were associated with decreased TFR in women, 
but no difference was detected for men with cancers in either site. 
In chapter 3.5 it was found that there was a reduction in the total (lifetime) 
number of children born to subjects from the ACCFR cohort who are 
diagnosed with CRC at a young age [5], but it was not known whether this 
was due to a reduction in fertility among survivors, or if it was simply due to 
decreased survival. 
The only previously published study directly comparing fertility rates for 
women with or without gastrointestinal cancer was by Hartman et al [159]. 
They reported a ten per cent reduction in fertility for women less than 45 
years of age compared with the Swedish general population. In this study, 
age- specific fertility rates in cancer survivors (for a number of different 
tumors, including gastro- intestinal) were compared with those of the general 
Swedish population using the technique of indirect standardisation. This 
involves determining age- specific birth rates for the reference population, 
and applying these to the study population to calculate the expected number 
of events for that population. The authors calculated a standardised birth rate 
(SBR, an indirectly standardised rate) for gastrointestinal cancer survivors of 
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0.90 (95% C.I. 0.83 to 0.97), but did not quote age- specific birth rates for the 
study population. Indirectly standardised rates can give misleading results, 
however, in any situation where the age profiles of the study and reference 
populations are not similar[160]. In this study, we found the age distributions 
of subjects with or without a CRC diagnosis were markedly different. For this 
reason the TFR (which is calculated by the process of direct standardisation) 
was used in this study,  in which the age distribution of the sample 
populations do not affect the calculation, and so groups with disparate age 
distributions[160] can be compared.  
A surprising finding in this study was that TFR for women with Lynch 
syndrome from the ACCFR was higher than that of the Australian population 
generally (fertility rates for men in the general population are not reported). 
The probable reason for this is selection bias, as larger families are more 
likely to be recruited by family cancer clinics. This highlights the kind of 
sampling bias that can cause misleading interpretation of fertility rates in an 
affected population when compared with the general population. 
The decision to have children is influenced by numerous psychological and 
social factors, which may bias studies of fertility between groups. Subjects 
were recruited from a large familial cancer database, so that unaffected family 
members could act as a control group (that would be as demographically and 
socially similar as possible to the affected individuals) and because of the 
high number of young CRC patients in this cohort. Only proven germline 
MMR mutation carriers were included (as controls as well as patients post 
CRC) as individuals with Lynch syndrome may modify their reproductive 
behaviour to avoid passing on their mutation. They may decide not to have 
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children, or even consider techniques such as pre- implantation genetic 
testing.  For this study, no attempt was made to collect information from 
subjects as to whether they had chosen to have children or not and what the 
reasons were for the decision. The data presented here cannot determine 
whether the observed changes in fertility were related to CRC or to 
reproductive decisions made following the genetic diagnosis of Lynch 
syndrome (which often occurs after the CRC is diagnosed). Although MMR 
proteins are essential in DNA replication, there is no evidence in the current 
literature that Lynch syndrome directly affects fertility, and the high fertility 
rate in this cohort does not suggest that this occurs. 
It is uncertain whether these findings are generalizable to patients with 
sporadic cancers. Colorectal cancers that display microsatellite instability (as 
in Lynch syndrome) are  known to have a better prognosis than sporadic CRC 
and may be unresponsive to 5-fluorouracil based chemotherapy regimens 
[168]. In addition, CRC detected in subjects with Lynch syndrome, who are 
offered intensive surveillance, may be detected at an earlier stage than 
sporadic tumors. 
It is expected that rectal cancer would have a greater impact on fertility than 
colon cancer (as a greater number receive radiotherapy, and pelvic surgery 
may be more likely to have a deleterious effect on fertility). In Lynch 
syndrome, rectal cancers are less common (as a percentage of CRC overall), 
and in this cohort there were only 82 subjects with rectal cancer (of whom 45 
were diagnosed under the age of 50), so this study was not powered to detect 
differences in age- specific fertility rates in subjects with rectal cancer.  These 
results of this should therefore be interpreted with caution in patients with 
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rectal cancer, and may only be applicable to those with tumours of the colon. 
Another limitation of this study is the small numbers of subjects with CRC in 
the age groups under 20, and our data are underpowered to detect differences 
in fertility (if they exist) in this age group. Such patients are rare, and so it 
would be difficult to recruit large numbers of these subjects in any setting.   
In conclusion, age- specific fertility was decreased in women with Lynch 
syndrome in the 20 to 24 year age group after CRC diagnosis. Subjects of 
both genders who survived into their late twenties and beyond had no 
detectable reduction in age- specific fertility, which may be reassuring to 
colon cancer survivors who hope to have children. 
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4 CONCLUSION 
A large cohort of subjects with Lynch syndrome who all carry the same 
predisposing mutation is a rarity, and provides an important vehicle for 
research aimed at understanding the role of genes and environment in cancer 
risk and in order to improve surveillance strategies. 
In PAPER I it was found that carriers of the C1528T (Exon 13) mutation in the 
hMLH1 gene developed colorectal cancer (CRC) at a young age (median 44 
years), and frequently developed synchronous or metachronous CRC. This 
mutation has a high penetrance, with 92% of subjects developing CRC by age 
65 years. Although gynaecological malignancies are common in women with 
Lynch syndrome generally, this was not the case in carriers of the C1528T 
(Exon 13) mutation in the hMLH1 gene. Only 3 of 98 (3%) women developed 
endometrial carcinoma and no case of ovarian cancer was detected.in this 
cohort of women. This information has allowed accurate risk prediction and 
genetic counselling to members of this family and supports the current policy 
of not offering routine gynaecological screening or prophylactic hysterectomy 
and oophorectomy to women who carry this mutation.  
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PAPER II showed that surveillance colonoscopy improved survival and 
delayed the onset of CRC in carriers of the C1528T (Exon 13) mutation in the 
hMLH1 gene, compared with those subjects who declined surveillance. 
Colorectal cancer- free survival from birth was increased by 26 years, and 
overall survival was increased by 23 years. This was achieved despite the 
logistic difficulty in providing a colonoscopy service to these subjects, and 
despite their variable compliance with the surveillance programme. This was 
a uniquely controlled study of surveillance in Lynch syndrome as the 
intervention and control groups all carried the same mutation.  It was not 
considered ethical to conduct a randomized trial of surveillance colonoscopy 
in this group of patients and it is unlikely that such a trial would ever be 
performed. 
PAPER III confirmed the high long- term risk of developing metachronous 
CRC after segmental colectomy for CRC in Lynch syndrome. This 
information assists these patients in making an informed choice of operation 
for primary colon cancer (total vs. segmental colectomy), and emphasizes the 
importance of life- long surveillance after surgery (of the colon and rectum if 
segmental colectomy was performed, or of the rectum if a total colectomy 
was performed).  
PAPER IV found no evidence of genetic anticipation in a single family who 
carried the C1528T (Exon 13) mutation in the hMLH1 gene once results were 
corrected for follow up bias.  
PAPER V Demonstrated by computer simulation that changes in lifetime 
(cohort) fertility can falsely create the appearance of genetic anticipation in 
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Lynch syndrome (fecundity bias).  This is the first study to demonstrate this 
in the setting of Lynch syndrome (or any other inherited condition). 
The results of PAPER IV and PAPER V illustrate the statistical complexity of 
studying genetic anticipation and the on- going uncertainty as to whether the 
phenomenon occurs in Lynch syndrome. 
PAPER VI described the effect on young- onset CRC on fertility in Lynch 
syndrome. Age- specific fertility was decreased in women with Lynch 
syndrome in the 20 to 24 year age group after CRC diagnosis. Subjects of 
both genders who survived into their late twenties and beyond had no 
detectable reduction in age- specific fertility. This information allows accurate 
counselling regarding future fertility in young Lynch syndrome patients with 
CRC. Further research is warranted to determine the cause(s) for decreased 
fertility in these women, and to determine whether these findings are 
generalizable to patients with young- onset CRC who do not have Lynch 
syndrome. 
Appendix IV lists the peer- reviewed journal articles that have cited the 
papers included in this thesis. They  have been cited a total of 49 times. 
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 5.2 Appendix II: Statements of authorship 
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 5.3 Appendix III: Code (Visual Basic for Applications) of the 
model used for simulating Lynch syndrome parent- child 
pairs with CRC 
Option Explicit 
Sub ParentChildPairs() 
Dim AffectedChildren(1 To 15000) As Integer, NumberOfParents As Integer 
Dim ChildGender(1 To 15000, 1 To 20) As Integer,Dim Counter As Integer 
Dim i As Integer, n As Integer, AgeCRCParent(1 To 15000) As Integer, 
AgeCRCChild(1 To 15000, 1 To 20) As Integer, Dim Mendel As Double 
Dim NumberOfChildren(1 To 15000) As Integer 
Dim CRC_age_group(1 To 15000) As Integer 
'AgeCRCChild (parent identifier,child number of that parent) 
'Will use odd numbers for mothers, even numbers for fathers 
Worksheets("results sheet").Columns("A:CA").Clear 
Worksheets("parent child pairs").Columns("A:AA").Clear 
Worksheets("children").Columns("A:AA").Clear 
NumberOfParents = Worksheets("Variable Input").Range("G7") 
For i = 1 To NumberOfParents Step 2 'assigns age of first CRC for mothers 
    n = Int(1000 * Rnd) + 1 
    AgeCRCParent(i) = Worksheets("1000 first cancers female").Cells(n + 1, 2) 
    Worksheets("Results sheet").Cells(i, 2) = AgeCRCParent(i) 
 If AgeCRCParent(i) > 50 Then CRC_age_group(i) = 1 Else If 
AgeCRCParent(i) > 45 Then CRC_age_group(i) = 2 Else If AgeCRCParent(i) > 40 
Then CRC_age_group(i) = 3 Else: If AgeCRCParent(i) > 35 Then CRC_age_group(i) = 
4 Else: If AgeCRCParent(i) > 30 Then CRC_age_group(i) = 5 Else: If 
AgeCRCParent(i) > 25 Then CRC_age_group(i) = 6 Else: If AgeCRCParent(i) > 20 
Then CRC_age_group(i) = 7 Else: CRC_age_group(i) = 8 
    Worksheets("Results sheet").Cells(i, 3) = CRC_age_group(i) 
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Next i 
 
For i = 2 To NumberOfParents Step 2 'assigns age of first CRC for fathers 
    n = Int(1000 * Rnd) + 1 
    AgeCRCParent(i) = Worksheets("1000 first cancers male").Cells(n + 1, 2) 
    Worksheets("Results sheet").Cells(i, 2) = AgeCRCParent(i) 
If AgeCRCParent(i) > 50 Then CRC_age_group(i) = 1 Else If AgeCRCParent(i) > 45 
Then CRC_age_group(i) = 2 Else If AgeCRCParent(i) > 40 Then CRC_age_group(i) = 
3 Else: If AgeCRCParent(i) > 35 Then CRC_age_group(i) = 4 Else: If 
AgeCRCParent(i) > 30 Then CRC_age_group(i) = 5 Else: If AgeCRCParent(i) > 25 
Then CRC_age_group(i) = 6 Else: If AgeCRCParent(i) > 20 Then CRC_age_group(i) = 
7 Else: CRC_age_group(i) = 8 
    Worksheets("Results sheet").Cells(i, 3) = CRC_age_group(i) 
Next i 
 
For i = 1 To NumberOfParents Step 2 'assigns number of children for mothers 
    n = Int(500 * Rnd) + 1 
    NumberOfChildren(i) = Worksheets("Female fertility vs age of CA").Cells(n + 1, 
CRC_age_group(i)) 
    Worksheets("Results sheet").Cells(i, 4) = NumberOfChildren(i) 
    Next i 
 
For i = 2 To NumberOfParents Step 2 'assigns number of children for fathers 
    n = Int(500 * Rnd) + 1 
    NumberOfChildren(i) = Worksheets("Male fertility vs age of CA").Cells(n + 1, 
CRC_age_group(i)) 
    Worksheets("Results sheet").Cells(i, 4) = NumberOfChildren(i) 
Next i 
 
For i = 1 To NumberOfParents 'Assigns number of mutation positive children 
    AffectedChildren(i) = 0 
    For n = 1 To NumberOfChildren(i) 
        Mendel = Rnd 
        If Mendel > 0.5 Then AffectedChildren(i) = AffectedChildren(i) + 1 
    Next n 
    Worksheets("Results sheet").Cells(i, 5) = AffectedChildren(i) 
Next i 
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For i = 1 To NumberOfParents 'Assigns gender to mutation positive children 
    For n = 1 To AffectedChildren(i) 
        ChildGender(i, n) = 1 'male 
        Mendel = Rnd 
        If Mendel > 0.5 Then ChildGender(i, n) = 2 'female 
        Worksheets("Children").Cells(i, n) = ChildGender(i, n) 
    Next n 
Next i 
For i = 1 To NumberOfParents 'Assigns age of first CRC to mutation positive children 
    For n = 1 To AffectedChildren(i) 
        Mendel = Int(Rnd * 1000) + 1 
        If ChildGender(i, n) = 1 Then AgeCRCChild(i, n) = Worksheets("1000 first 
cancers male").Cells(Mendel + 1, 2) 
        If ChildGender(i, n) = 2 Then AgeCRCChild(i, n) = Worksheets("1000 first 
cancers male").Cells(Mendel + 1, 2) 
        Worksheets("Children").Cells(i, n + 15) = AgeCRCChild(i, n) 
    Next n 
Next i 
Counter = 1 
For i = 1 To NumberOfParents 
    If AffectedChildren(i) > 0 Then 
       For n = 1 To AffectedChildren(i) 
        Counter = Counter + 1 
           Worksheets("Parent child pairs").Cells(Counter, 1) = AgeCRCParent(i) 
           Worksheets("Parent child pairs").Cells(Counter, 3) = AgeCRCChild(i, n) 
           Worksheets("Parent child pairs").Cells(Counter, 4) = AgeCRCParent(i) - 
AgeCRCChild(i, n) 
           If i / 2 <> Int(i / 2) Then 'mothers 
Worksheets("Parent child pairs").Cells(Counter, 14) = AgeCRCParent(i) 
Worksheets("Parent child pairs").Cells(Counter, 15) = AgeCRCChild(i, n) 
Worksheets("Parent child pairs").Cells(Counter, 16) = AgeCRCParent(i) - 
AgeCRCChild(i, n) 
            Else 'fathers 
Worksheets("Parent child pairs").Cells(Counter, 11) = AgeCRCParent(i) 
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                Worksheets("Parent child pairs").Cells(Counter, 12) = AgeCRCChild(i, n) 
                Worksheets("Parent child pairs").Cells(Counter, 13) = AgeCRCParent(i) - 
AgeCRCChild(i, n) 
            End If 
       Next n 
    End If 
Next i 
 
End Sub 
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